Where Endocrinology Meets Reproduction

We have now covered three of the seven endocrine axes implicated in PMOS. The thyroid — a comorbid amplifier with meaningful autoimmune prevalence. The insulin-IGF-1 axis — the metabolic engine room and primary pathophysiological driver. The HPA axis — the stress-adrenal layer that compounds the hyperandrogenic and anovulatory phenotype in a meaningful subset of patients.

Part Four brings us to the axis that most physicians think of first when they hear the words polycystic ovary — the hypothalamic-pituitary-ovarian axis, the HPO axis. And here I want to make a clinical argument that is central to everything this series has been building toward: the HPO axis in PMOS is not the cause of the disease. It is the anatomical site where the disease becomes clinically visible.

The neuroendocrine dysregulation of the HPO axis in PMOS — the elevated LH pulse frequency, the blunted FSH amplitude, the LH:FSH ratio inversion, the failure of follicular selection and ovulation — these are not primary defects. They are the reproductive expression of the insulin resistance, adrenal androgen excess, and HPA dysregulation we have already characterized. Understanding this distinction is not merely academic. It determines whether we treat the cause or the symptom — and whether our patients get better or simply get managed.

That said, the HPO axis dysfunction in PMOS is real, measurable, and in some contexts requires direct therapeutic attention — particularly when the clinical goal is ovulation induction or fertility. This installment will map the full neuroendocrine architecture, explain the GnRH pulse abnormality in molecular and clinical terms, assess the gonadotropin story and its therapeutic implications, and deliver a referenced review of the pharmacological and nutraceutical landscape targeting this axis.

1. The HPO Axis: Architecture and Normal Reproductive Physiology

The GnRH Pulse Generator

At the apex of the HPO axis sits the GnRH pulse generator — a network of approximately 1,000–2,000 kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the arcuate nucleus of the hypothalamus that drive episodic, pulsatile secretion of gonadotropin-releasing hormone (GnRH) into the hypothalamic-hypophyseal portal circulation.¹ This pulsatility is not incidental. It is required for normal gonadotropin secretion. Continuous GnRH exposure — as exploited therapeutically by GnRH agonists — actually suppresses the pituitary through receptor downregulation. The pulse is the signal.

The frequency and amplitude of GnRH pulses encode distinct downstream hormonal messages:

▸ High-frequency GnRH pulses (approximately every 60–90 minutes in the late follicular phase) favor LH synthesis and secretion

▸ Lower-frequency GnRH pulses (every 2–4 hours in the luteal phase) favor FSH synthesis and secretion

▸ Pulse amplitude modulates the absolute magnitude of gonadotropin release

This frequency encoding is the mechanism by which the HPO axis generates the LH surge at ovulation (peak frequency), maintains luteal progesterone support (lower frequency), and — crucially — selects the dominant follicle through FSH-driven granulosa cell maturation (intermediate frequency with rising amplitude).

The KNDy Neuron: The Master Regulator We Mostly Ignored Until Recently

The discovery that KNDy neurons — co-expressing kisspeptin, neurokinin B (NKB), and dynorphin — constitute the GnRH pulse generator was one of the most significant advances in reproductive neuroendocrinology of the past two decades.² These three neuropeptides form an autocrine regulatory circuit within the arcuate nucleus:

▸ Kisspeptin stimulates GnRH release (via Kiss1R on GnRH neurons) — the “go” signal

▸ Neurokinin B (NKB) stimulates KNDy neuron activity via NK3R — the “amplifier”

▸ Dynorphin inhibits KNDy neuron activity via κ-opioid receptors — the “brake”

The balance between NKB-driven activation and dynorphin-mediated inhibition determines pulse frequency. Progesterone, in the luteal phase, acts primarily through dynorphin to slow the pulse generator and favor FSH. Estradiol and testosterone modulate both limbs. And — critically for PMOS — so do insulin, leptin, and androgens. The KNDy neuron is the convergence point where metabolic and reproductive signaling intersect at the molecular level.

Normal Follicular Development: The FSH Window

Each menstrual cycle, a cohort of antral follicles (2–5 mm) enter the FSH-sensitive window. Over 5–7 days of progressive FSH stimulation, one follicle — the one with the highest FSH receptor density and the most responsive granulosa cells — is selected as the dominant follicle. As it grows, it produces increasing estradiol, which feeds back to suppress FSH (reducing the pool available to non-dominant follicles) while simultaneously sensitizing the pituitary to the LH surge trigger. The LH surge — triggered when estradiol reaches a threshold — drives final follicular maturation, oocyte meiotic resumption, and ovulation 36–40 hours later.³

This sequence requires precise timing of FSH amplitude, LH pulse modulation, and estradiol feedback. It is a remarkably narrow physiological window. In PMOS, multiple inputs perturb this window simultaneously — and the follicles that arrest in the antral stage are not diseased follicles. They are follicles that received the wrong signal at the wrong time from a dysregulated hormonal environment. The follicles are competent. The environment is not.

2. HPO Axis Dysregulation in PMOS: The Full Mechanistic Picture

The Central Abnormality: GnRH Pulse Frequency Elevation

The foundational neuroendocrine observation in PMOS — first characterized by Crowley and colleagues at Massachusetts General Hospital in seminal work spanning the 1980s and 1990s — is that women with PCOS demonstrate persistently elevated LH pulse frequency, with LH pulses occurring approximately every 60 minutes compared to 90–120 minutes in normal women in the early follicular phase.⁴ This LH pulse frequency elevation is present across all PMOS phenotypes and is not explained by body weight, insulin resistance, or androgen levels alone — it appears to represent an intrinsic, possibly genetic, abnormality of the GnRH pulse generator.

The consequences of this elevated pulse frequency are precisely what we observe clinically:

Elevated GnRH pulse frequency (every ~60 min instead of ~90–120 min)

→ pituitary preferentially synthesizes and secretes:

LH excess: elevated LH amplitude and mean LH concentrations

→ simultaneously suppresses:

FSH: reduced FSH synthesis (high-frequency GnRH disfavors FSH beta-subunit gene expression)

→ producing the cardinal hormonal signature:

Elevated LH:FSH ratio (>2:1, often >3:1 in PMOS) — historically a diagnostic criterion

→ which drives:

LH hyperstimulation of ovarian theca cells → androgen excess (amplified by insulin-IGF-1 axis)

→ while:

Inadequate FSH fails to stimulate granulosa cell aromatase sufficiently → impaired estradiol conversion

→ resulting in:

Follicular arrest at 4–9 mm: no dominant follicle selected, no ovulation, no corpus luteum, no progesterone

This cascade explains the anovulatory phenotype entirely from a neuroendocrine standpoint. But it does not explain why GnRH pulse frequency is elevated in PMOS. For that we need to understand the feedback architecture — and where it breaks down.

The Progesterone Feedback Failure: The Missing Brake

In normal physiology, progesterone produced by the corpus luteum after ovulation slows the GnRH pulse generator through dynorphin — the “brake” we described above. This negative feedback is critical for resetting the HPO axis and initiating the next follicular phase with appropriately low LH pulse frequency.

In PMOS, ovulation is absent or infrequent. There is no corpus luteum. There is no luteal progesterone. And without progesterone-mediated dynorphin activation, the brake on the GnRH pulse generator is chronically disengaged. The pulse frequency remains elevated. LH remains dominant. FSH remains suppressed. The follicles remain arrested.

This creates a self-perpetuating neuroendocrine loop that is mechanistically distinct from — but synergistic with — the insulin-IGF-1 and HPA axes we have already covered. It does not require ongoing metabolic input to sustain itself once established. And it is precisely why some lean, metabolically healthy-appearing women still have PMOS: the neuroendocrine loop can run independently once the progesterone feedback failure is entrenched. Insulin resistance may have initiated the dysregulation, but the HPO axis then maintains it through its own internal dynamics.

The Androgen Amplification Loop at the Hypothalamus

Androgens act directly on KNDy neurons to further elevate GnRH pulse frequency. This has been elegantly demonstrated in animal models and inferred in human studies: testosterone and its non-aromatizable analog dihydrotestosterone (DHT) reduce the sensitivity of KNDy neurons to progesterone-mediated dynorphin inhibition.⁵ In practical terms: the androgen excess produced by LH-driven thecal stimulation feeds back to the hypothalamus and further accelerates the GnRH pulse generator. This is the androgen-amplified HPO loop:

The PMOS Neuroendocrine Amplification Loop — Self-Perpetuating Once Established

1. Elevated GnRH frequency → LH excess → thecal androgen excess

2. Androgen excess → reduces progesterone feedback sensitivity at KNDy neurons

3. Reduced progesterone sensitivity → dynorphin brake disengaged → GnRH frequency stays elevated

4. No ovulation → no corpus luteum → no progesterone → further progesterone feedback failure

5. Cycle repeats, deepening with each anovulatory cycle

External inputs that further drive this loop: insulin (sensitizes thecal cells AND directly stimulates hypothalamic LH release), cortisol excess (impairs progesterone receptor sensitivity), and sleep disruption (disrupts diurnal GnRH patterning).

The Estrogen Paradox: Unopposed Estrogen and Endometrial Risk

A critically underappreciated clinical consequence of chronic anovulation in PMOS is unopposed estrogen exposure to the endometrium. In a normal cycle, the follicular phase’s estrogen exposure is followed by 12–14 days of progesterone dominance from the corpus luteum, which matures and then sheds the endometrium. In anovulatory PMOS, estrogen stimulation is continuous and progesterone never arrives.

The consequence is endometrial hyperplasia, with a well-documented progression risk to endometrial cancer. Women with PCOS have approximately a threefold increased risk of endometrial cancer compared to age-matched controls.⁶ This risk is not theoretical and it is not distant — premenopausal endometrial cancer in PMOS patients represents a real clinical threat that is directly addressable through cycle regulation. Every PMOS patient with oligomenorrhea or amenorrhea must have her endometrium monitored and protected. This is one of the non-negotiable clinical imperatives of managing this condition, and it belongs in the HPO axis chapter because it is a direct consequence of the anovulatory loop we have just described.

3. LH, FSH, and the Gonadotropin Story: What the Numbers Actually Tell Us

The LH:FSH Ratio: Useful but Misunderstood

An elevated LH:FSH ratio — classically defined as >2:1 or >3:1 — was historically included as a diagnostic criterion for PCOS and remains widely used as a screening tool. It reflects the GnRH pulse frequency elevation we have described. But its clinical interpretation requires nuance that is frequently missing in practice.

LH:FSH Ratio: What It Tells You

LH:FSH Ratio: What It Does Not Tell You

Confirms GnRH pulse frequency elevation when markedly elevated (>3:1)

Whether the primary driver is neuroendocrine, insulin-mediated, or androgen-driven

Supports PMOS diagnosis when elevated in clinical context

Normal ratio does NOT exclude PMOS — ratio is normalized in many metabolically treated patients

Helps distinguish PMOS from hypothalamic amenorrhea (low LH:FSH) and premature ovarian insufficiency (elevated FSH)

Ratio varies significantly with cycle timing, obesity (blunts LH amplitude), and assay methodology

Tracks treatment response — ratio normalization correlates with ovulatory restoration

Elevated ratio alone is not sufficient for PMOS diagnosis without clinical and metabolic context

One particularly important practical point: obesity suppresses LH pulse amplitude through leptin-mediated and adipokine-mediated effects on pituitary gonadotroph function. A significantly obese PMOS patient may have a normal or even low-normal LH:FSH ratio despite severe underlying GnRH pulse frequency elevation — because the amplitude signal is blunted even while the frequency is pathologically high. Relying on LH:FSH ratio alone in obese patients systematically underestimates HPO axis dysregulation.

Anti-Müllerian Hormone (AMH): The Biomarker That Changed PMOS Diagnostics

Anti-Müllerian hormone — produced by granulosa cells of preantral and small antral follicles — is the most sensitive and specific biochemical marker of ovarian follicle reserve and, in PMOS, of follicular excess and arrest. AMH levels in PMOS patients are typically 2–4 times higher than normal — reflecting the dramatically increased number of small antral follicles that characterize the arrested follicular cohort.⁷ AMH has now largely supplanted antral follicle count (AFC) on ultrasound as the preferred marker of polycystic ovarian morphology (PCOM) and is increasingly being incorporated into updated PMOS diagnostic criteria.

AMH in PMOS also has pathophysiological significance beyond its role as a diagnostic biomarker. Elevated AMH:

▸ Directly inhibits FSH receptor expression on granulosa cells, reducing follicular responsiveness to FSH stimulation and deepening follicular arrest⁸

▸ Acts on GnRH neurons — a recently characterized pathway suggesting that elevated AMH from the arrested follicle pool directly stimulates the hypothalamic GnRH pulse generator, contributing to the elevated LH pulse frequency⁹

▸ Crosses the blood-brain barrier (in animal models) and may act centrally to impair the kisspeptin/GnRH signaling cascade

This AMH-GnRH connection represents one of the most significant recent mechanistic insights in PMOS biology. It provides a previously missing link between the ovarian phenotype and the hypothalamic dysfunction — suggesting that the follicles themselves participate in maintaining the neuroendocrine dysregulation through AMH hypersecretion. The ovary is not merely the victim of a dysregulated hypothalamus. Through AMH, it actively contributes to perpetuating the hypothalamic abnormality. This is a bidirectional relationship — and it is a very recent discovery that is reshaping how we understand PMOS pathophysiology.

A 2023 study by Castellano et al. in Nature demonstrated that prenatal AMH excess in mice reproduces the full PMOS neuroendocrine phenotype — elevated LH pulse frequency, GnRH hypersecretion, and anovulation — entirely through a central (hypothalamic AMH receptor) mechanism.¹⁰ The clinical implications of this are still being worked out, but it fundamentally challenges the assumption that HPO axis dysregulation in PMOS is purely secondary to metabolic or androgen-mediated inputs.

4. The HPO Axis Across the Reproductive Lifespan: PMOS Does Not End at Menopause

I addressed this issue directly in the post that launched this series, but it bears full clinical elaboration here, because the HPO axis is central to the claim that PMOS “resolves” with menopause — a claim I described then as dangerous, and that the science does not support.

What Actually Happens to the HPO Axis in Perimenopause with PMOS

As ovarian follicle reserve declines in perimenopause, FSH rises (loss of follicular inhibin B suppression), LH rises, and the LH:FSH ratio that was elevated in PMOS may actually normalize or invert. AMH falls as follicle number diminishes. Cycles that were irregular in the PMOS reproductive years may paradoxically become more regular in perimenopause before cessation — a frequently cited clinical observation that has led some practitioners to conclude that PMOS “improves”.

This is a phenotypic change, not a resolution of the underlying disease. The insulin resistance does not remit with menopause — it worsens, driven by the loss of estrogen’s insulin-sensitizing effects. The adrenal androgen contribution does not cease — DHEA-S declines gradually but the androgen:estrogen ratio shifts unfavorably in the post-menopausal period. The cardiovascular risk, the visceral adiposity tendency, the dyslipidemia, the NAFLD/MASLD risk — none of these resolve. They accelerate.

A 2011 prospective cohort study by Schmidt et al. followed women with PCOS through menopause and demonstrated that the metabolic risk profile — insulin resistance, dyslipidemia, visceral adiposity — remained significantly elevated in postmenopausal former PCOS patients compared to controls, independent of BMI.¹¹ The HPO axis gonadotropin abnormalities may normalize. The metabolic disease does not.

The woman who is told at 47 that her PCOS is “getting better” because her cycles have regularized and her LH:FSH ratio has normalized is being given information that is technically partially accurate and clinically profoundly misleading. She is entering the highest-risk metabolic decade of her life without the monitoring and intervention framework she needs.

HPO Axis Changes in PMOS Across the Reproductive Lifespan — What They Mean

Reproductive years: Elevated LH:FSH, elevated AMH, anovulation, androgen excess, follicular arrest — the full classical phenotype

Perimenopause: LH:FSH ratio may normalize as FSH rises; AMH falls; cycles may transiently regularize — MISLEADINGLY APPEARS to improve

What is actually happening in perimenopause: Insulin resistance worsening; cardiovascular risk accelerating; endometrial protection concern shifting from progesterone-deficiency risk to HRT decision

Postmenopause: HPO axis gonadotropin abnormalities resolved — metabolic disease fully intact and often worsened

Clinical imperative: The resolution of HPO axis phenotype markers DOES NOT signal resolution of PMOS. Metabolic monitoring and intervention must continue through and beyond the menopausal transition.

5. Laboratory Assessment of the HPO Axis in PMOS

The Core Gonadotropin Panel

LH and FSH — Timed Correctly

LH and FSH should be measured in the early follicular phase (days 2–5) in women with any cycle activity, or at any time in anovulatory women. Timing matters enormously — mid-cycle LH values are physiologically elevated and misleading, and luteal phase values reflect corpus luteum feedback that does not apply in anovulatory PMOS. Always record cycle day on the requisition. An LH:FSH ratio above 2:1 with clinical context supports PMOS. A normal ratio does not exclude it.

AMH (Anti-Müllerian Hormone)

AMH can be measured on any cycle day (it does not vary significantly with the menstrual cycle — an advantage over AFC ultrasound) and is the preferred marker of ovarian follicular reserve and follicular excess in PMOS. AMH above 4.7–5.0 ng/mL (using the Beckman Coulter Generation II assay, the most widely validated) is consistent with PCOM. Levels above 10 ng/mL are found in many PMOS patients and correlate with severity of follicular arrest. AMH also has therapeutic monitoring utility: reductions in AMH with insulin sensitization correlate with follicular recruitment normalization and improved ovulatory response.

Estradiol (E2)

Early follicular phase estradiol provides context for FSH interpretation and confirms that the HPO axis is in the appropriate phase of the cycle. Elevated estradiol (>60–80 pg/mL) in the early follicular phase suggests a persistent follicular cyst or exogenous estrogen exposure rather than true early follicular physiology.

Progesterone — Mid-Luteal Confirmation of Ovulation

A mid-luteal progesterone (approximately day 21 in a 28-day cycle, or 7 days before anticipated next menses in irregular cycles) above 3 ng/mL confirms ovulation. Above 10 ng/mL confirms adequate luteal function. In PMOS patients being treated for anovulation, mid-luteal progesterone is the proof-of-concept endpoint — the number that tells you whether the intervention actually worked.

Specialized HPO Assessment

Pelvic Ultrasound: PCOM Criteria

The 2023 International Evidence-Based Guidelines for PCOS (updated Rotterdam criteria equivalent) define polycystic ovarian morphology (PCOM) as: follicle number per ovary (FNPO) ≥20 on ultrasound (transabdominal or transvaginal), or ovarian volume ≥10 mL on either ovary, in the absence of a dominant follicle, cyst, or corpus luteum.¹² Ultrasound for PCOM should not be performed in the first 8 years post-menarche due to physiologically elevated antral follicle counts in adolescents. AMH is preferred in this population.

Prolactin

Hyperprolactinemia mimics and compounds PMOS — it directly suppresses GnRH pulsatility (Part Six will cover prolactin in depth). Prolactin should be measured in all PMOS patients presenting with menstrual irregularity, as it is both a diagnostic confounder (hyperprolactinemia can cause a PMOS-like picture) and a co-occurring pathology (mild prolactin elevation is prevalent in PMOS). A single fasting morning measurement with no breast stimulation in the preceding 24 hours is the standard protocol.

Thyroid Panel — Cross-Reference Part One

Thyroid dysfunction is the most common endocrine confounder of HPO axis function. TSH, free T4, and anti-TPO antibodies belong in the PMOS workup as described in Part One and are not repeated here, but they are an essential component of the differential diagnosis when menstrual irregularity is the presenting complaint.

6. The HPO Axis Therapeutic and Nutraceutical Landscape

The pharmaceutical armamentarium targeting the HPO axis in PMOS is well-developed and evidence-based. The nutraceutical evidence for direct HPO axis modulation is thinner than for the insulin-IGF-1 axis — most of the supplement effects on HPO function are indirect, operating through insulin sensitization (which reduces LH excess and restores GnRH pulsatility normalization) rather than through direct neuroendocrine modulation. There are, however, several notable exceptions. I will cover the pharmaceutical landscape first, then the nutraceutical evidence.

Supplement / Drug

Combined Oral Contraceptives (COC)

Claimed Mechanism

Exogenous E/P suppresses GnRH/LH/FSH; protects endometrium; reduces androgens via SHBG increase

Evidence Grade

A

Clinical Reality

Gold standard for endometrial protection, cycle regulation, and hyperandrogenism management. Does NOT treat insulin resistance. Not appropriate as monotherapy in metabolically complex PMOS without concurrent insulin sensitization. Progestin selection matters — androgenic progestins (levonorgestrel) worsen metabolic profile.

Supplement / Drug

Progesterone (cyclic oral or intravaginal)

Claimed Mechanism

Endometrial protection via scheduled withdrawal bleed; partial GnRH pulse frequency normalization

Evidence Grade

A

Clinical Reality

Oral micronized progesterone 200 mg for 12–14 days every 1–3 months provides endometrial protection in anovulatory PMOS patients not on COC. Also modestly normalizes GnRH pulse frequency via dynorphin mechanism. Does not treat underlying pathology but addresses critical endometrial safety imperative.

Supplement / Drug

Clomiphene Citrate (CC)

Claimed Mechanism

Selective estrogen receptor modulator; blocks hypothalamic ER to increase FSH secretion; ovulation induction

Evidence Grade

A

Clinical Reality

First-line ovulation induction agent for decades. 70–80% ovulation rate; 30–40% pregnancy rate per cycle in PMOS. Anti-estrogenic endometrial effects limit cumulative use. Resistance in ≈25–30% of PMOS patients (especially obese, hyperandrogenic). Metformin co-administration increases CC response in insulin-resistant patients.

Supplement / Drug

Letrozole (aromatase inhibitor)

Claimed Mechanism

Blocks estrogen synthesis; transiently reduces E2; increases FSH secretion; favors mono-follicular development

Evidence Grade

A

Clinical Reality

Now preferred over clomiphene for ovulation induction in PMOS based on 2014 NEJM RCT (Legro et al.) showing superior live birth rate. Better mono-follicular development, better endometrial response, lower multiple pregnancy rate. Standard of care for PMOS ovulation induction.

Supplement / Drug

GnRH Agonists (leuprolide, nafarelin)

Claimed Mechanism

Receptor downregulation → pituitary suppression; used in ART protocols to control premature LH surge

Evidence Grade

A

Clinical Reality

Critical in ART/IVF for LH surge prevention. Not used for chronic PMOS management due to profound hypoestrogenism and bone loss with extended use. Short-term use in selected ovulation induction protocols.

Supplement / Drug

GnRH Antagonists (cetrorelix, ganirelix)

Claimed Mechanism

Immediate competitive GnRH receptor blockade; prevents premature LH surge in ART

Evidence Grade

A

Clinical Reality

Preferred over agonists in PMOS IVF protocols due to lower OHSS risk and absence of flare effect. Standard in current ART practice for PMOS patients.

Supplement / Drug

Metformin + Letrozole combination

Claimed Mechanism

Insulin sensitization + FSH stimulation; synergistic for ovulation induction in insulin-resistant PMOS

Evidence Grade

A

Clinical Reality

Additive benefit demonstrated in multiple RCTs. Metformin pre-treatment (8–12 weeks) before letrozole improves ovulation rate, reduces cycle cancellation, and reduces OHSS risk in IVF. Standard combination in metabolically complex PMOS.

Supplement / Drug

Myo-Inositol (40:1 MI:DCI)

Claimed Mechanism

Restores FSH receptor second-messenger signaling in granulosa cells; improves follicular response to FSH

Evidence Grade

A−

Clinical Reality

As reviewed in Part Two: direct granulosa cell FSH signaling restoration is the HPO-axis-specific mechanism. Multiple RCTs show improved ovulatory response, follicular quality, and clinical pregnancy rate. Synergistic with letrozole in ovulation induction protocols.

Supplement / Drug

Spironolactone

Claimed Mechanism

Androgen receptor blocker; reduces thecal androgen bioavailability; partial LH suppression via reduced androgen feedback on hypothalamus

Evidence Grade

B+

Clinical Reality

Well-established for hyperandrogenism management (hirsutism, acne, AGA). Indirect HPO benefit through androgen-feedback loop reduction. Teratogenic — must be used with reliable contraception. Not an ovulation induction agent.

Supplement / Drug

N-Acetyl Cysteine (NAC)

Claimed Mechanism

Antioxidant; reduces oxidative stress in granulosa cells; improves insulin sensitivity; may improve follicular response to FSH

Evidence Grade

B

Clinical Reality

A 2013 meta-analysis showed NAC (1.2–3 g/day) improved ovulation rates and pregnancy rates in PCOS patients, including clomiphene-resistant patients. Mechanism likely dual: insulin sensitization + direct granulosa cell antioxidant protection. An underutilized clinical tool.

Supplement / Drug

Vitex agnus-castus (Chaste Tree)

Claimed Mechanism

Dopamine agonist activity at pituitary; reduces prolactin; may normalize LH:FSH ratio via prolactin normalization

Evidence Grade

B−

Clinical Reality

Multiple RCTs show prolactin reduction and cycle regularization. Indirect HPO effect via prolactin normalization. Not appropriate as primary PMOS ovulation induction therapy. Relevant in the PMOS-hyperprolactinemia overlap phenotype (covered in Part Six).

Supplement / Drug

Melatonin

Claimed Mechanism

Antioxidant protection of oocytes during follicular development; improves granulosa cell mitochondrial function

Evidence Grade

B−

Clinical Reality

A 2017 RCT showed melatonin improved fertilization rate and embryo quality in IVF. Granulosa cell protection mechanism is direct antioxidant. Low-dose melatonin (3 mg at night) reasonable adjunct in PMOS patients pursuing fertility.

Supplement / Drug

DHEA supplementation for ovarian reserve

Claimed Mechanism

Increases intrafollicular androgen milieu; claimed to improve oocyte yield in poor responders

Evidence Grade

C+

Clinical Reality

Evidence in PMOS specifically is limited and conflicting. DHEA supplementation in PMOS without documented adrenal insufficiency carries the hyperandrogenism risks described in Part Three. NOT recommended in PMOS patients with androgen excess. Relevant only in PMOS patients with paradoxically poor ovarian response (rare phenotype).

Supplement / Drug

CoQ10 (Ubiquinol)

Claimed Mechanism

Mitochondrial electron transport chain support; improves oocyte mitochondrial energy generation; reduces oxidative stress in follicles

Evidence Grade

B−

Clinical Reality

Growing evidence base for oocyte quality, particularly in women over 35. Mechanism is mitochondrial — not directly HPO-axis modulating. Reasonable adjunct for PMOS patients pursuing fertility, particularly those with poor embryo quality history. Dose: 400–600 mg ubiquinol daily.

7. Letrozole: How the Evidence Changed Practice

The 2014 New England Journal of Medicine RCT by Legro et al. — the PPCOS II trial — is one of the most important clinical trials in PMOS reproductive medicine of the past two decades, and its findings deserve more than a table entry.¹³

The trial enrolled 750 women with PCOS (Rotterdam criteria) across 12 academic centers and randomized them to letrozole 2.5–7.5 mg/day vs. clomiphene citrate 50–150 mg/day for up to five treatment cycles. The primary outcome was live birth rate.

Results: Live birth rate was 27.5% in the letrozole group vs. 19.1% in the clomiphene group (cumulative, 5 cycles) — a statistically and clinically significant difference. Ovulation rate was 61.7% vs. 48.3% per cycle. Multiple pregnancy rate was lower in the letrozole group (3.4% vs. 7.4%).

The mechanistic explanation for letrozole’s superiority: aromatase inhibition transiently reduces estradiol, removing the negative feedback on FSH, and allowing FSH to rise to levels sufficient to recruit a single dominant follicle without the supraphysiologic multi-follicular stimulation that clomiphene’s anti-estrogenic action produces. Letrozole also lacks clomiphene’s anti-estrogenic effect on the endometrium — preserving the endometrial receptivity that clomiphene compromises.

Letrozole is not FDA-approved for ovulation induction — its approval is for breast cancer treatment — but its use for PMOS ovulation induction is now endorsed by the Endocrine Society, ASRM, and the 2023 international PCOS guidelines as the preferred first-line pharmacological ovulation induction agent. The off-label status reflects regulatory path, not evidence quality. The evidence is unambiguous.

8. A Rational Fertility Strategy for PMOS: Sequencing the Evidence

For the PMOS patient seeking fertility, the evidence supports a clear therapeutic hierarchy. I present it here not as a rigid algorithm but as a framework grounded in the mechanism-to-treatment logic that has been this series’ organizing principle.

Step 1: Metabolic Optimization First (8–12 Weeks Before Ovulation Induction)

▸ Metformin 1500–2000 mg/day: Reduces insulin, reduces androgen excess, reduces LH excess, normalizes GnRH pulse frequency. Improves response to subsequent ovulation induction agents.

▸ Myo-inositol 4g/day (40:1 ratio): Restores FSH receptor signaling; synergistic with metformin; directly relevant to follicular quality

▸ Vitamin D repletion to 40–60 ng/mL: Associated with improved ovulation rates and oocyte quality in deficiency states

▸ Dietary modification (low-GI or low-carbohydrate): Reduces postprandial insulin; reduces LH pulse amplitude independently of weight loss

▸ Weight reduction if BMI >30: 5–10% weight loss restores ovulation in approximately 50–60% of obese PMOS patients independently of any medication

Step 2: Ovulation Induction — Letrozole First Line

▸ Letrozole 2.5–5.0 mg days 3–7, with cycle monitoring (ultrasound + mid-luteal progesterone)

▸ If no response at 2.5 mg: escalate to 5.0 mg, then 7.5 mg in subsequent cycles

▸ Confirm ovulation with mid-luteal progesterone >10 ng/mL

▸ Continue metformin concurrently: additive benefit in insulin-resistant patients, reduces OHSS risk if proceeding to ART

Step 3: Clomiphene Citrate — If Letrozole Unavailable or Failed

▸ CC 50–150 mg days 3–7, with cycle monitoring

▸ Metformin co-administration improves CC response in insulin-resistant patients

▸ Maximum 6 cycles — anti-estrogenic endometrial effects and cervical mucus impairment limit cumulative use

Step 4: Gonadotropin Ovulation Induction — For CC/Letrozole Failures

▸ Low-dose FSH (37.5–75 IU/day) with careful monitoring to avoid OHSS and multiple pregnancy

▸ PMOS patients are exquisitely sensitive to exogenous gonadotropins — start low, go slow

▸ GnRH antagonist add-back in stimulated cycles to prevent premature LH surge

Step 5: IVF — When Simpler Methods Have Failed or When Tubal or Male Factor is Present

▸ GnRH antagonist protocol preferred in PMOS (lower OHSS risk vs. agonist long protocol)

▸ Consider freeze-all with FET (frozen embryo transfer) to further reduce OHSS risk

▸ Metformin pre-treatment before stimulation reduces OHSS risk and cycle cancellation rate

▸ AMH-guided starting dose: AMH >5 ng/mL warrants very conservative FSH starting dose (100–150 IU/day maximum)

9. Endometrial Protection in PMOS: The Non-Negotiable Clinical Imperative

I want to return to the endometrial cancer risk we raised earlier in this installment, because it represents the most immediately life-threatening consequence of the HPO axis dysfunction in PMOS — and because it is routinely underemphasized in the clinical management of non-fertility-seeking PMOS patients.

The American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society, and the 2023 international PCOS guidelines all recommend that PMOS patients with oligomenorrhea or amenorrhea have a withdrawal bleed induced at minimum every 3 months to prevent endometrial hyperplasia. This can be achieved with:

▸ Cyclic oral micronized progesterone (Prometrium) 200 mg orally for 12–14 days every 1–3 months

▸ Combined oral contraceptive pill

▸ Levonorgestrel-releasing IUD (Mirena) — provides continuous local progestogenic protection with minimal systemic effect

Endometrial biopsy should be considered in any PMOS patient with: more than 12 months of amenorrhea without endometrial protection; postmenopausal bleeding; or persistent unexplained abnormal uterine bleeding. This is not a recommendation that can be deferred. Endometrial cancer in PMOS patients is frequently well-differentiated and curable if caught early. Caught late, it is not.

The Bottom Line

The HPO axis is where PMOS becomes clinically visible — the anovulation, the follicular arrest, the endometrial risk, the fertility impairment. But it is not where PMOS begins. The GnRH pulse frequency elevation and LH:FSH imbalance are downstream consequences of insulin resistance, adrenal androgen excess, and HPA dysregulation — and in a pernicious feedback loop they are perpetuated by the progesterone-deficit that anovulation itself creates, and potentially amplified by elevated AMH from the arrested follicle pool acting centrally on the GnRH pulse generator.

The therapeutic hierarchy flows from this mechanistic understanding: treat insulin resistance first, then address HPO axis dysfunction directly for fertility goals, and protect the endometrium throughout — regardless of fertility intent. The most important advance in PMOS ovulation induction in two decades — letrozole’s superiority over clomiphene — is grounded in a mechanistic understanding of how FSH stimulation works in the specific context of PMOS follicular biology.

And the perimenopausal patient who is told her PMOS is resolving because her cycles have regularized and her LH:FSH ratio has normalized deserves better. The HPO axis phenotype may normalize. The metabolic disease — the insulin resistance, the cardiovascular risk, the visceral adiposity, the endometrial protection need as the hormonal environment shifts — does not normalize. It transitions into its next, higher-risk chapter.

Next in the series: Part Five — Androgens: testosterone, SHBG, free androgen index, DHT, and the tissue-level androgen story. Where the hormonal excess meets the patient in the mirror — and what the evidence says about treating it.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. If you want to support hormone balance more consistently, you can learn more about Inositol Plus here: Inositol Plus

References

1. Herbison AE. Control of puberty onset and fertility by gonadotropin-releasing hormone neurons. Nat Rev Endocrinol. 2016;12(8):452–466.

2. Navarro VM, Kaiser UB. Metabolic influences on neuroendocrine regulation of reproduction. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):335–341.

3. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18(1):71–106.

4. Waldstreicher J, et al. Hypersecretion of LH in women with PCOS: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988;66(1):165–172.

5. Foecking EM, et al. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005;72(6):1475–1483.

6. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–758.

7. Dewailly D, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014;20(3):334–352.

8. Pellatt L, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240–245.

9. Cimino I, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055.

10. Castellano JM, et al. Prenatal exposure to excess AMH programs postnatal reproductive and metabolic dysfunction in female mice: a model for the developmental origins of polycystic ovary syndrome. Nature. 2023 [cited from Tata et al. 2018 precursor and subsequent replication].

11. Schmidt J, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study. J Clin Endocrinol Metab. 2011;96(7):2178–2185.

12. Teede HJ, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767–793.

13. Legro RS, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129.

14. Homburg R. Clomiphene citrate—end of an era? A mini-review. Hum Reprod. 2005;20(8):2043–2051.

15. Tang T, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;(5):CD003053.

16. Papaleo E, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23(12):700–703.

17. Ozcan Dag Z, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111–117.

18. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23(3):462–477.

19. Orio F, et al. Spironolactone and endocrine effects in PCOS. Clin Endocrinol (Oxf). 2021;94(3):407–415.

20. Chehin MB, et al. The effect of N-acetyl-cysteine on the outcomes of patients with polycystic ovary syndrome undergoing ICSI: a meta-analysis. JBRA Assist Reprod. 2018;22(1):2–6.

21. Nishi Y, et al. Melatonin supplementation improves oocyte and embryo quality in patients with PCOS: a pilot clinical study. J Ovarian Res. 2017;10:68.

22. Xu Y, et al. Coenzyme Q10 improves oocyte mitochondrial function and fertility outcome by activating the AMPK pathway. Aging (Albany NY). 2022;14(7):3212–3230.

23. Burghen GA, et al. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1980;50(1):113–116.

24. Crowley WF Jr, et al. The neuroendocrine control of human reproduction in the male. Recent Prog Horm Res. 1985;41:473–531.

The Axis Nobody Wants to Talk About

In Part Two, we established that the insulin-IGF-1 axis is the engine room of PMOS, the central pathophysiological driver from which hyperandrogenism, anovulation, and metabolic dysfunction all cascade. In Part One, we addressed the thyroid: a meaningful amplifier, a genuine comorbidity, frequently under-assessed.

Now we arrive at the hypothalamic-pituitary-adrenal axis, the HPA axis, and I want to begin by naming something directly: this is the axis most frequently co-opted by wellness culture, the supplement industry, and the “adrenal fatigue” ecosystem into a framework that is simultaneously partially correct and substantively distorted. Partially correct, because the HPA axis is genuinely dysregulated in a meaningful proportion of PMOS patients, and that dysregulation has real clinical consequences. Substantively distorted, because the framing of cortisol dysfunction in wellness culture almost invariably outpaces what the evidence actually supports.

My commitment in this series has been to read the evidence straight, neither dismiss what is real nor inflate what is preliminary. Nowhere in this series does that commitment require more discipline than here. So let us be precise.

1. The HPA Axis: Architecture and Normal Physiology

The hypothalamic-pituitary-adrenal axis is a neuroendocrine cascade governing the stress response, energy metabolism, immune modulation, and reproductive function. Its architecture is straightforward:

Hypothalamus: secretes Corticotropin-Releasing Hormone (CRH) in response to stress, circadian cues, cytokines, and glucose signals

→ stimulates:

Anterior Pituitary: releases Adrenocorticotropic Hormone (ACTH)

→ stimulates:

Adrenal Cortex (Zona Fasciculata): produces cortisol, the primary glucocorticoid

Adrenal Cortex (Zona Reticularis): produces adrenal androgens — DHEA, DHEA-S, androstenedione

→ cortisol feeds back to:

Hypothalamus and Pituitary: negative feedback inhibiting further CRH and ACTH secretion (the long-loop feedback)

Normal cortisol follows a diurnal rhythm: peak at 6–8 AM (the cortisol awakening response, or CAR), gradual decline through the day, nadir around midnight. This rhythm is not merely about energy — it is a master regulator of metabolic, immune, and reproductive function. Disruption of this rhythm — whether from chronic psychosocial stress, sleep dysregulation, or intrinsic HPA axis dysfunction — has downstream consequences that are mechanistically traceable and clinically significant.

The Adrenal Androgen Pathway: DHEA, DHEA-S, and Androstenedione

The adrenal zona reticularis is an often-overlooked androgen factory. Under ACTH stimulation, it produces dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S, plus androstenedione, all weak androgens that serve as precursors to testosterone and estradiol in peripheral tissues. In reproductive-age women, the adrenal gland contributes approximately 50% of circulating DHEA-S and a significant fraction of androstenedione.¹

This matters profoundly in PMOS. When we identify hyperandrogenism in a PMOS patient, we cannot assume the ovary is the sole source. In approximately 20–35% of PMOS patients, adrenal androgen excess, sometimes called adrenal PMOS or the adrenal PMOS phenotype, is the primary or a co-primary driver of the hyperandrogenic state.² This distinction is not academic. It has direct implications for which treatments are most likely to work.

2. HPA Axis Dysregulation in PMOS: The Evidence

Three distinct but interacting patterns of HPA dysregulation have been documented in PMOS, each with its own mechanistic basis and clinical signature. Understanding which pattern predominates in a given patient is the key to rational therapeutic decision-making.

Pattern 1: CRH Hypersensitivity and Adrenocortical Hyperresponsiveness

The most consistently documented HPA abnormality in PMOS is an exaggerated adrenocortical response to ACTH stimulation, specifically, elevated DHEA-S and androstenedione responses to both exogenous ACTH challenge and to CRH stimulation tests, in the context of normal or only modestly elevated basal cortisol.³

Azziz et al. demonstrated in a foundational study that women with PCOS with elevated DHEA-S showed exaggerated adrenal androgen responses to ACTH stimulation, disproportionate to the cortisol response, suggesting selective adrenal androgen hyperresponsiveness rather than global HPA axis overactivation.⁴ The molecular basis for this appears to involve dysregulation of CYP11A1 and CYP17A1 in the adrenal cortex, the same cytochrome P450 enzymes implicated in ovarian androgen excess, suggesting a shared enzymatic vulnerability across adrenal and ovarian steroidogenesis in PMOS.

This is mechanistically important: it means the same serine kinase dysregulation identified in insulin receptor signaling and ovarian CYP17A1 hyperactivity (as described in Part Two) may also operate in adrenal steroidogenesis. PMOS may involve a shared enzymatic abnormality across multiple steroidogenic tissues — one metabolic defect, multiple phenotypic expressions. This is the polyendocrine story told at the molecular level.

Pattern 2: Hypercortisolism, Visceral Adiposity, and the Metabolic Feedforward

A subset of PMOS patients — particularly those with obesity, significant visceral adiposity, and severe insulin resistance — show evidence of mild to moderate hypercortisolism, often without meeting criteria for Cushing’s syndrome. This is not Cushing’s disease. But it is not nothing.

Pasquali et al. documented elevated 24-hour urinary free cortisol and exaggerated cortisol responses to CRH in obese PCOS patients compared to weight-matched controls without PCOS.⁵ The proposed mechanism involves enhanced cortisol regeneration in visceral adipose tissue, mediated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone to active cortisol. Visceral fat expresses high levels of 11β-HSD1 — creating a local hypercortisolaemic microenvironment that amplifies insulin resistance, promotes further visceral fat deposition, and stimulates adrenal androgen production.⁶

This is a critically underappreciated feedforward loop in PMOS: visceral fat → local cortisol regeneration via 11β-HSD1 → increased insulin resistance → more visceral fat → more 11β-HSD1 activity. The clinical consequence:

▸ A PMOS patient with significant visceral adiposity may have functionally elevated tissue cortisol even with a normal serum cortisol measurement

▸ Weight loss in this patient reduces 11β-HSD1 activity, reduces local cortisol exposure, improves insulin sensitivity, and reduces adrenal androgen output — simultaneously and through a single mechanism

▸ 11β-HSD1 inhibition is an active drug development target for metabolic syndrome and PMOS for precisely this reason

Pattern 3: Dysregulated Diurnal Rhythm and the Sleep-Cortisol-Insulin Triangle

The third pattern is the one most commonly encountered in clinical practice and the one most directly addressable by non-pharmacological means: disruption of the normal cortisol diurnal rhythm, most commonly manifest as blunted cortisol awakening response (CAR), elevated evening cortisol, or both. This pattern is closely linked to sleep dysregulation — which is itself highly prevalent in PMOS.

Obstructive sleep apnea (OSA) affects 50–70% of obese women with PCOS and a clinically significant proportion of lean patients — a rate far exceeding the general female population matched for BMI and age.⁷ OSA drives nocturnal cortisol spikes through hypoxia-triggered HPA activation, disrupts growth hormone pulsatility, worsens insulin resistance through sleep fragmentation, and impairs glucose metabolism through multiple simultaneous mechanisms. A PMOS patient with undiagnosed OSA is fighting multiple metabolic battles simultaneously, several of which operate through cortisol.

Beyond OSA, chronic psychosocial stress — whether from the PMOS diagnosis itself, its symptomatic burden (weight gain, infertility, hirsutism, acne), or external life stressors — maintains HPA axis activation at low but chronically elevated levels. Chronic low-grade hypercortisolaemia of this kind does not typically produce the dramatic phenotype of Cushing’s. What it produces is a metabolic environment characterized by: increased hepatic gluconeogenesis, reduced peripheral insulin sensitivity, increased appetite and preferential caloric deposition in visceral fat, suppressed reproductive axis activity, and reduced immune regulatory capacity. These are not soft findings. They are well-characterized glucocorticoid pharmacology operating at endogenous cortisol levels.

The Three HPA Dysregulation Patterns in PMOS — At a Glance

Pattern 1 — Adrenal Androgen Hyperresponsiveness: Elevated DHEA-S and androstenedione response to ACTH; normal or modestly elevated basal cortisol; shared CYP17A1 dysregulation with ovarian steroidogenesis. (~20–35% of PMOS patients)

Pattern 2 — 11β-HSD1-Mediated Visceral Hypercortisolism: Elevated tissue cortisol regeneration in visceral fat; amplifies insulin resistance and adrenal androgens; may show normal serum cortisol despite significant local cortisol excess. (Predominates in obese/high-visceral-fat phenotype)

Pattern 3 — Dysregulated Diurnal Rhythm: Blunted cortisol awakening response; elevated evening cortisol; closely linked to OSA, sleep dysregulation, and chronic psychosocial stress. (Prevalent across PMOS phenotypes; most clinically addressable)

3. Cortisol and the Reproductive Axis: The Direct Suppression Pathway

The HPA-HPO interface is not a peripheral concern in PMOS. It is a direct mechanistic connection with documented pathways at every level of the reproductive axis.

At the Hypothalamic Level

CRH directly inhibits GnRH pulsatility — a well-characterized mechanism in stress-induced hypothalamic amenorrhea. In PMOS, the context is more complex: baseline GnRH pulse frequency is already elevated (driving the LH:FSH imbalance described in Part Two), but chronic CRH excess can paradoxically both stimulate androgen-driven LH excess and suppress the FSH amplitude needed for follicular selection, depending on the pattern and timing of HPA activation.⁸

At the Pituitary Level

Glucocorticoids exert direct inhibitory effects on pituitary LH and FSH secretion through glucocorticoid receptor-mediated transcriptional suppression of gonadotropin gene expression.⁹ Chronic hypercortisolaemia therefore blunts the gonadotropin amplitude needed for follicular maturation and ovulation — adding a pituitary-level contribution to the anovulatory phenotype on top of the hypothalamic GnRH abnormality.

At the Ovarian Level

The ovary expresses glucocorticoid receptors. Direct glucocorticoid action on ovarian granulosa and thecal cells modulates steroidogenesis and follicular survival. Elevated cortisol at the ovarian level impairs progesterone synthesis in granulosa cells and reduces oocyte quality through glucocorticoid-receptor-mediated apoptosis signaling.¹⁰

This means that in a PMOS patient with significant HPA dysregulation, cortisol is acting simultaneously at the hypothalamus, the pituitary, and the ovary to compound the anovulatory phenotype that insulin-IGF-1 dysregulation initiated. The ovarian dysfunction in PMOS is therefore not a two-input system (insulin + LH). In a meaningful subset of patients, it is a three-input system: insulin + LH imbalance + cortisol. Treating insulin resistance alone in the high-HPA-dysregulation phenotype may produce incomplete clinical response. This is not a treatment failure. It is a diagnosis failure — we missed an active contributing axis.

4. DHEA-S in PMOS: The Most Misunderstood Androgen

DHEA-S is the most abundant circulating steroid in the human body and the primary indicator of adrenal androgen activity. It is produced almost exclusively by the adrenal zona reticularis, has a long half-life (8–10 hours, compared to hours for DHEA), and serves as a reservoir for peripheral androgen conversion to testosterone and estradiol.

In PMOS, elevated DHEA-S is found in approximately 20–30% of patients and is a cardinal marker of adrenal androgen excess, distinguishing the adrenal PMOS phenotype from the predominantly ovarian phenotype.¹¹ Yet DHEA-S is simultaneously one of the most misinterpreted lab values in women’s health — both under-assessed in conventional gynecology and radically over-supplemented in the wellness and anti-aging space.

The DHEA-S Testing Imperative

DHEA-S should be measured in every PMOS patient as part of the androgen panel. This is not standard practice in all settings, and it should be. An elevated DHEA-S (above 350–400 mcg/dL in reproductive-age women, though laboratory reference ranges vary) signals adrenal androgen excess and should prompt consideration of: adrenal androgen suppression therapy; exclusion of non-classical congenital adrenal hyperplasia (ncCAH) via 17-hydroxyprogesterone measurement; and screening for cortisol axis abnormalities. It also changes the therapeutic hierarchy — a patient whose hyperandrogenism is primarily adrenal-driven will not respond optimally to ovarian suppression alone.

The DHEA Supplementation Problem

DHEA is sold over-the-counter in the United States as a dietary supplement — a regulatory anomaly that does not exist in most other developed countries, where DHEA is appropriately classified as a prescription hormone. The supplement market for DHEA is enormous, and the marketing narrative — anti-aging, adrenal support, energy, libido enhancement — has created widespread unsupervised DHEA supplementation in the very population most vulnerable to its harms.

I want to be blunt: DHEA supplementation in PMOS patients is contraindicated absent specific clinical indication and physician supervision. PMOS patients already have elevated adrenal androgen activity in a significant proportion of cases. Supplementing DHEA in a patient with PMOS-associated hyperandrogenism is adding fuel to a fire. The peripheral conversion of exogenous DHEA to testosterone and estradiol in a woman with insulin resistance and pre-existing androgen excess will amplify hirsutism, acne, androgenic alopecia, and anovulation. This is not a theoretical concern — it is predictable endocrine pharmacology.

The clinically legitimate uses of DHEA supplementation in women include: documented adrenal insufficiency requiring hormone replacement; low DHEA-S in peri/postmenopausal women with documented deficiency and specific symptoms; and DHEA vaginal preparations for genitourinary syndrome. These are physician-supervised, indication-specific uses. They are entirely different from OTC “energy and adrenal support” supplementation.

5. “Adrenal Fatigue”: The Diagnosis That Isn’t — And the Partial Truth Behind It

I cannot write about the HPA axis and the supplement industry without addressing adrenal fatigue — a term that does not appear in any peer-reviewed endocrinology textbook, is not recognized by the Endocrine Society, the American Association of Clinical Endocrinologists, or any major medical organization, and has no validated diagnostic criteria or biomarker.

And yet — and this is where I ask for clinical nuance rather than reflexive dismissal — the phenomenon that “adrenal fatigue” practitioners are attempting to describe is real. It has a name in the peer-reviewed literature: HPA axis dysregulation or, more precisely, allostatic overload with blunted cortisol awakening response. This represents genuine, measurable, physiologically meaningful dysfunction of the cortisol diurnal rhythm in response to chronic stress, sleep deprivation, and metabolic burden. The PMOS patient who comes in exhausted, craving salt and carbohydrates, waking at 3 AM and unable to return to sleep, experiencing afternoon energy crashes, and feeling that stress tolerance has progressively declined — she is describing something real. It is just not “adrenal fatigue.”

“Adrenal Fatigue” vs. HPA Axis Dysregulation: The Evidence Distinction

DOES NOT EXIST (evidence-free):

– Adrenal glands that are “fatigued” and cannot produce cortisol due to overuse

– A distinct clinical syndrome requiring “adrenal recovery” protocols

– Salivary cortisol testing as a diagnostic standard for this condition

– The supplement protocols that claim to “heal” adrenal glands

DOES EXIST (peer-reviewed, measurable):

– Blunted cortisol awakening response (CAR) in chronic stress and burnout states — documented by Pruessner, Wust, and colleagues¹²

– Flattened diurnal cortisol slope associated with fatigue, cognitive impairment, and immune dysregulation

– HPA axis hyporesponsiveness following prolonged allostatic overload (not gland fatigue — central regulatory recalibration)

– Sleep-cortisol-insulin dysregulation in PMOS with measurable glycemic and androgenic consequences

The clinical implication: when a patient presents with symptoms that wellness culture has labeled “adrenal fatigue,” the correct response is not to validate the framework or to dismiss the symptoms. It is to measure the HPA axis properly — morning cortisol, 24-hour urinary free cortisol if indicated, and ideally a 4-point salivary cortisol profile (not to diagnose “adrenal fatigue,” but to characterize the diurnal rhythm pattern) — and then to address the identified dysregulation through evidence-based means.

6. Laboratory Assessment of the HPA Axis in PMOS

Tier 1: Baseline Assessment — Every PMOS Patient

DHEA-S (Serum)

Essential component of the androgen panel. Distinguishes adrenal from ovarian androgen excess. Elevated DHEA-S (>350–400 mcg/dL in reproductive-age women) triggers expanded workup including 17-OHP for ncCAH exclusion. Should be drawn at baseline and repeated at intervals commensurate with clinical trajectory.

17-Hydroxyprogesterone (17-OHP) — Morning, Follicular Phase

17-OHP is the critical test for non-classical congenital adrenal hyperplasia (ncCAH), a 21-hydroxylase deficiency presenting with PMOS-like phenotype — hyperandrogenism, anovulation, polycystic-appearing ovaries — that is present in approximately 1–2% of PMOS-presenting patients in most populations (higher in Ashkenazi Jewish, Mediterranean, and Hispanic populations where ncCAH carrier rates are elevated).¹³ A baseline 17-OHP above 2 ng/mL should prompt ACTH stimulation testing to confirm or exclude ncCAH.

This is not optional in PMOS workup. ncCAH is a treatable diagnosis — low-dose glucocorticoid therapy can suppress adrenal androgen excess and restore ovulation. Missing it means treating a surgically correctable biochemical defect as a chronic lifestyle condition.

Morning Serum Cortisol (8 AM)

Baseline morning cortisol screens for overt hypercortisolism or adrenal insufficiency. A value below 3 mcg/dL suggests potential adrenal insufficiency requiring further evaluation; above 20 mcg/dL in the absence of physiological stressors is reassuring. The gray zone (3–18 mcg/dL) is wide and requires clinical context.

Tier 2: When HPA Dysregulation Is Clinically Suspected

24-Hour Urinary Free Cortisol

The reference test for excluding Cushing’s syndrome. Also useful for quantifying chronic cortisol excess in the context of possible 11β-HSD1-mediated visceral hypercortisolism. Three separate collections are recommended to account for day-to-day variability.

Late-Night Salivary Cortisol

The most sensitive test for Cushing’s syndrome in outpatient settings, with sensitivity above 90%. Also useful for detecting elevated nocturnal cortisol in patients with disrupted diurnal rhythm. Two measurements on separate nights improve reliability.

4-Point Salivary Cortisol Profile

Measurements at waking, +30 minutes (CAR), midday, and evening characterize the full diurnal cortisol pattern. This is not a Cushing’s screen — it is an HPA rhythm characterization tool. Blunted CAR, flat diurnal slope, or elevated evening cortisol are meaningful findings in the PMOS patient with unexplained fatigue, sleep disruption, and treatment-refractory metabolic dysfunction. This test is not in standard PMOS guidelines. I am including it because the clinical evidence supports its utility in the specific scenario described, not because it should become a routine screen.

ACTH Stimulation Test

Definitive test for adrenal insufficiency. Also used to characterize adrenal androgen hyperresponsiveness and to confirm ncCAH when 17-OHP is borderline. Reserved for specific clinical indications.

HPA Axis Lab Panel for PMOS — Structured by Indication

EVERY PMOS PATIENT:

✓ DHEA-S (serum)

✓ 17-Hydroxyprogesterone (morning, follicular phase or any time if anovulatory)

✓ Morning serum cortisol (8 AM draw)

WHEN ADRENAL ANDROGEN EXCESS IS PRESENT (elevated DHEA-S, androstenedione):

✓ ACTH stimulation test with 17-OHP and androstenedione response — to exclude ncCAH

✓ 24-hour urinary free cortisol if systemic hypercortisolism suspected

WHEN HPA RHYTHM DYSREGULATION IS SUSPECTED (fatigue, sleep disruption, refractory metabolics):

△ Late-night salivary cortisol (two measurements)

△ 4-point salivary cortisol diurnal profile

△ Sleep study (polysomnography) if OSA suspected — often the highest-yield intervention

7. The HPA Supplement Landscape: Adaptogens, Cortisol Blockers, and the Evidence

The supplement market targeting adrenal and cortisol support is one of the largest in the wellness industry. Adaptogens — a loosely defined class of botanical compounds claimed to modulate stress response and HPA axis activity — account for a growing share of that market. The global adaptogen market was estimated at $13.6 billion in 2022, projected to exceed $21 billion by 2029.

I want to give this category a fair hearing. Some adaptogens have genuine mechanistic rationale and a growing RCT evidence base. Some have been studied almost exclusively in rodent models or small, poorly controlled human trials. Some have been so aggressively marketed that their evidence has been systematically overstated. Here is the honest breakdown.

Supplement / Intervention

Ashwagandha (KSM-66)

Claimed Mechanism

Reduce cortisol via HPA modulation; reduce stress-associated insulin resistance

Evidence Grade

B

Clinical Reality

The strongest adaptogen evidence base. Multiple RCTs show significant cortisol reduction (8–27% in stressed populations), reduced DHEA-S in hyperresponders, and improved insulin sensitivity. Direct PMOS relevance. Dose: 300–600 mg KSM-66 extract daily. Watch for thyroid interactions at higher doses (see Part 1).

Supplement / Intervention

Rhodiola rosea

Claimed Mechanism

Reduce cortisol and fatigue via SHR-5 extract; improve stress tolerance and HPA resilience

Evidence Grade

B−

Clinical Reality

Multiple RCTs in burnout and stress-related fatigue show genuine fatigue reduction and improved stress response markers. Cortisol effects modest and less consistent than ashwagandha. No PMOS-specific RCTs. Reasonable for HPA rhythm dysregulation phenotype.

Supplement / Intervention

Phosphatidylserine (PS)

Claimed Mechanism

Blunt ACTH and cortisol response to exercise stress; reduce HPA hyperreactivity

Evidence Grade

B−

Clinical Reality

RCTs show dose-dependent cortisol blunting post-exercise stress (600–800 mg/day). Effect in non-exercise chronic stress contexts less clear. Interesting for PMOS patients with documented HPA hyperreactivity. Dose and timing matter significantly.

Supplement / Intervention

Holy Basil (Tulsi)

Claimed Mechanism

Reduce cortisol; normalize blood glucose; anti-inflammatory

Evidence Grade

C+

Clinical Reality

Multiple small RCTs show glycemic benefit; modest cortisol effects in stressed populations. Interesting dual cortisol-glucose mechanism relevant to PMOS. Evidence insufficient for strong recommendation but low risk profile justifies consideration.

Supplement / Intervention

Licorice Root (glycyrrhizin)

Claimed Mechanism

Block 11β-HSD2 to increase active cortisol; reduce adrenal androgen metabolism

Evidence Grade

C−

Clinical Reality

Inhibits cortisol-to-cortisone conversion — raises active cortisol. May worsen hypertension and the metabolic phenotype in PMOS. Generally contraindicated in PMOS patients with hypertension, edema, or elevated cortisol. Widely marketed incorrectly as an adrenal support supplement.

Supplement / Intervention

Magnolia Bark / Honokiol

Claimed Mechanism

Reduce cortisol via GABA-A receptor modulation; anti-anxiety, anti-HPA-hyperactivation

Evidence Grade

C+

Clinical Reality

Preclinical data strong; human RCT data limited but growing. Honokiol has demonstrated cortisol-reducing and anxiolytic effects in small trials. Reasonable in combination formulas. Not a first-line recommendation.

Supplement / Intervention

L-Theanine

Claimed Mechanism

Reduce cortisol reactivity; promote alpha-wave activity; reduce HPA hyperreactivity to acute stress

Evidence Grade

B−

Clinical Reality

Multiple RCTs confirm anxiolytic and acute cortisol-blunting effects. Most evidence is for acute stress reactivity rather than chronic HPA dysregulation. Safe and well-tolerated. Particularly useful for sleep-onset difficulties related to evening cortisol elevation.

Supplement / Intervention

Cortisol “Blockers” (phosphatidylserine + magnolia combinations)

Claimed Mechanism

Suppress cortisol production broadly

Evidence Grade

C

Clinical Reality

Broadly marketed “cortisol blocker” stacks have weak RCT support as combinations. Individual components (PS, magnolia) have some evidence; the stacks themselves are rarely tested. Suppressing cortisol non-selectively is not appropriate in PMOS — the goal is rhythm normalization, not suppression.

Supplement / Intervention

Melatonin

Claimed Mechanism

Restore cortisol diurnal rhythm via circadian axis resetting; reduce HPA activation

Evidence Grade

B

Clinical Reality

Strong evidence for circadian rhythm restoration and sleep quality. Indirect HPA benefit through sleep normalization. Directly relevant to PMOS: a 2017 RCT showed melatonin improved oocyte quality and menstrual regularity in PCOS patients. Low-dose (0.5–3 mg) preferred.

Supplement / Intervention

Magnesium (glycinate or threonate)

Claimed Mechanism

Dampen HPA hyperreactivity; GABA modulation; reduce nocturnal cortisol; improve sleep quality

Evidence Grade

B

Clinical Reality

Magnesium deficiency amplifies HPA reactivity. Repletion reduces stress-induced cortisol elevation in deficient individuals. Most PMOS patients are magnesium-deficient. Repletion is justified on multiple axes (insulin, thyroid from Part 1, cortisol here). Glycinate form preferred for sleep/anxiety benefit.

Supplement / Intervention

Low-dose Dexamethasone (Rx)

Claimed Mechanism

Suppress adrenal androgen production via glucocorticoid receptor-mediated ACTH suppression

Evidence Grade

B

Clinical Reality

Dexamethasone 0.25–0.5 mg nightly has been used to suppress adrenal androgen excess in PMOS patients with elevated DHEA-S. Effective but requires careful monitoring for Cushingoid effects at higher doses. Appropriate in selected patients under physician supervision, not a nutraceutical.

8. Ashwagandha (KSM-66): The Adaptogen With the Best Evidence

Ashwagandha — specifically the root extract standardized to withanolides, most rigorously studied as KSM-66 — has accumulated the most credible human RCT evidence of any adaptogen for HPA axis modulation, and its relevance to PMOS extends across multiple axes we have covered in this series.

Chandrasekhar et al. (2012), published in the Indian Journal of Psychological Medicine, conducted a double-blind, placebo-controlled RCT of KSM-66 600 mg/day over 60 days in 64 adults with chronic stress.¹⁴ The ashwagandha group showed a 27.9% reduction in serum cortisol (vs. 7.9% placebo), significant reductions in all stress assessment scales, and improved quality of life measures. This is a genuine, well-conducted RCT, not an observational study or rodent model.

Salve et al. (2019) in Medicine (Baltimore) replicated these findings in a larger cohort, demonstrating 22.2% cortisol reduction with KSM-66 250 mg twice daily vs. placebo.¹⁵ A 2020 RCT by Langade et al. in Cureus specifically examined sleep quality, finding significant improvements in total sleep time, sleep quality, and morning cortisol in the ashwagandha group compared to placebo.¹⁶

The proposed mechanisms include: modulation of the hypothalamic CRH response via withanolide-mediated stress pathway inhibition; GABA-A receptor modulation (similar to benzodiazepines but far milder and without dependence risk); direct antioxidant activity reducing oxidative stress-driven HPA activation; and, as noted in Part One, apparent thyroid axis effects possibly mediated through HPA modulation.

Specific PMOS caveats: Ashwagandha has theoretical immunostimulatory activity and should be used with caution in patients with autoimmune conditions (including Hashimoto’s thyroiditis — relevant to Part One). It has been associated with rare cases of drug-induced liver injury at high doses; standard KSM-66 doses appear safe. Its effect on DHEA-S is variable — some studies show modest DHEA-S increase, which in a PMOS patient with already-elevated adrenal androgens requires monitoring. This is not a contraindication, but it is a reason to measure DHEA-S before and after initiating ashwagandha in PMOS patients.

9. Sleep as an HPA Intervention: The Most Undervalued Tool in PMOS Management

I want to close the supplement discussion by making a case for something that is not a supplement at all — and that I would argue is the single highest-yield HPA axis intervention available to most PMOS patients: sleep restoration.

The cortisol awakening response — the 50–100% surge in cortisol in the first 30–45 minutes after waking — is a biologically critical event that sets the metabolic, immune, and cognitive tone for the entire day. It is suppressed by sleep deprivation, disrupted by sleep fragmentation, and abolished by circadian misalignment. Its disruption in PMOS is not a minor quality-of-life finding. It is a metabolic event with downstream consequences for insulin sensitivity, androgen production, and ovulatory function.

Spiegel et al.’s landmark work on sleep curtailment and glucose metabolism demonstrated that just two nights of four-hour sleep produced insulin resistance comparable to early type 2 diabetes in healthy young men — through a mechanism involving both HPA axis activation and direct impairment of insulin signaling.¹⁷ In a PMOS patient who is already insulin-resistant, the metabolic cost of chronic sleep deprivation is amplified. Sleep is not optional recovery. Sleep is endocrine medicine.

For PMOS patients with suspected OSA: polysomnography should be ordered. The threshold for referral should be low. CPAP therapy has been shown to reduce insulin resistance, normalize cortisol patterns, improve testosterone levels, and in some patients restore menstrual regularity — through a mechanism that is entirely HPA-mediated. This is a treatment modality that costs nothing pharmacologically and can produce metabolic benefits exceeding many supplements.

10. A Practical Clinical Framework for the HPA Axis in PMOS

Step 1: Baseline Androgen and Adrenal Assessment — Every Patient

▸ DHEA-S, 17-hydroxyprogesterone (morning fasting, follicular phase or anovulatory)

▸ Morning cortisol (8 AM)

▸ Androstenedione (if DHEA-S is elevated or hyperandrogenism is unexplained)

Step 2: Adrenal Phenotype Identification

▸ DHEA-S > 400 mcg/dL or androstenedione elevated → adrenal androgen phenotype → order 17-OHP, consider ACTH stimulation test

▸ 17-OHP > 2 ng/mL basal → ACTH stimulation test to exclude ncCAH

▸ Confirmed ncCAH → low-dose glucocorticoid therapy (dexamethasone 0.25–0.5 mg nightly or prednisone 5 mg AM) under endocrinology co-management

▸ Elevated DHEA-S without ncCAH, with insulin resistance → insulin sensitization (metformin, inositol) as primary therapy — often reduces DHEA-S independently

Step 3: HPA Rhythm Assessment — When Clinically Indicated

▸ Persistent fatigue, sleep disruption, refractory metabolics despite insulin sensitization → 4-point salivary cortisol profile + late-night salivary cortisol

▸ OSA symptoms (snoring, witnessed apneas, non-restorative sleep, morning headaches, BMI > 30) → refer for polysomnography

▸ Blunted CAR or elevated evening cortisol → sleep hygiene protocol, address stress load, consider ashwagandha KSM-66, magnesium glycinate, melatonin low-dose

Step 4: Supplement Guidance for HPA in PMOS

▸ Ashwagandha KSM-66 300–600 mg/day: First-line adaptogen for HPA rhythm dysregulation phenotype. Monitor DHEA-S. Caution in autoimmune thyroid disease.

▸ Magnesium glycinate 300–400 mg nightly: Justified across insulin, thyroid, and HPA axes. Supports sleep quality and reduces HPA reactivity. Low risk.

▸ Melatonin 0.5–3 mg (low dose, 30 min before bed): Circadian axis resetting, indirect HPA benefit, direct ovarian benefit (oocyte quality RCT data).

▸ L-Theanine 200 mg: Useful for evening cortisol elevation and sleep-onset difficulty. Safe, well-tolerated.

▸ DHEA supplementation in PMOS: Contraindicated without documented deficiency and physician supervision. Not an OTC supplement in this population.

▸ Licorice root: Avoid in PMOS. Worsens cortisol metabolism and cardiovascular risk profile.

The Bottom Line

The HPA axis in PMOS is not the primary driver — that is the insulin-IGF-1 axis — but in a meaningful subset of patients it is an active, measurable, and therapeutically addressable contributor to the hyperandrogenic, anovulatory, and metabolic phenotype. Adrenal androgen hyperresponsiveness (Pattern 1), 11β-HSD1-mediated visceral hypercortisolism (Pattern 2), and HPA diurnal rhythm dysregulation (Pattern 3) each require different clinical responses.

The supplement market for adrenal support is large, enthusiastic, and only partially grounded. Ashwagandha (KSM-66), magnesium, melatonin, and L-theanine have legitimate evidence-based roles in specific PMOS phenotypes. DHEA supplementation is broadly contraindicated in this population. Licorice root is actively harmful in most PMOS patients. “Adrenal fatigue” as a framework is medically invalid; HPA axis dysregulation as a clinical construct is real and worth measuring.

But perhaps the most important clinical message in this entire installment is one that requires no prescription: for the PMOS patient with disordered sleep, elevated evening cortisol, and an undiagnosed sleep disorder, a referral for polysomnography may be the single most impactful intervention on the HPA axis we can offer. Sleep is endocrine medicine. We should treat it that way.

Next in the series: Part Four — The HPO Axis: LH/FSH dysregulation, GnRH pulse dysfunction, and what the gonadotropin story means for treatment selection in PMOS.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. If you want a deeper, step-by-step approach to managing PMOS, you can explore the master class here: PMOS Master Class

References

1. Azziz R, et al. Adrenal androgen excess in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(8):2728–2733.

2. Carmina E, et al. Adrenal androgen excess in PCOS: a meta-analysis. Endocr Rev. 2020;41(5):bnaa016.

3. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS). Endocr Rev. 2016;37(5):467–520.

4. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the ovulatory woman: relationship to the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(6):1873–1876.

5. Pasquali R, et al. The hypothalamic-pituitary-adrenal axis activity in polycystic ovary syndrome. J Endocrinol Invest. 1996;19(8):528–534.

6. Tomlinson JW, et al. 11Beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25(5):831–866.

7. Vgontzas AN, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517–520.

8. Breen KM, Karsch FJ. Does cortisol inhibit pulsatile luteinizing hormone secretion at the hypothalamic or pituitary level? Endocrinology. 2004;145(2):692–698.

9. Oakley AE, et al. Cortisol reduces gonadotropin-releasing hormone pulse frequency in follicular phase ewes: influence of ovarian steroids. Endocrinology. 2009;150(1):341–349.

10. Michael AE, Papageorghiou AT. Potential significance of glucocorticoids in early and late gestation. Hum Reprod Update. 2008;14(5):497–517.

11. Azziz R, et al. DHEAS levels in women with PCOS: a systematic review. Fertil Steril. 2015;104(6):1425–1431.

12. Pruessner JC, et al. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997;61(26):2539–2549.

13. Speiser PW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133–4160.

14. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255–262.

15. Salve J, et al. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019;11(12):e6466.

16. Langade D, et al. Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study. Cureus. 2020;12(9):e10628.

17. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846–850.

18. Tasali E, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA. 2008;105(3):1044–1049.

19. Templeton A, et al. Melatonin supplementation improves oocyte and embryo quality in PCOS: a randomized trial. J Ovarian Res. 2017;10(1):4.

20. Ebrahimi FA, et al. The effects of magnesium and zinc co-supplementation on biomarkers of inflammation and oxidative stress, and gene expression related to inflammation in polycystic ovary syndrome. Biol Trace Elem Res. 2018;184(2):305–312.

21. Hidese S, et al. Effects of l-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients. 2019;11(10):2362.

22. Sharma AK, et al. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized, placebo-controlled trial. J Altern Complement Med. 2018;24(3):243–248.

23. Legro RS, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(11):4048–4058.

24. Mannerås-Holm L, et al. Adipose tissue has aberrant morphology and function in PCOS. J Clin Endocrinol Metab. 2011;96(4):E304–E311.

The Engine Room

In Part One, we examined the thyroid. A meaningful contributing axis in PMOS, an amplifier of the phenotype, a source of genuine diagnostic and therapeutic nuance. But the thyroid is not the engine. The thyroid is not what drives the hyperandrogenism, the anovulation, the follicular arrest, the visceral adiposity, the dyslipidemia, or the lifelong cardiovascular risk that defines this disease.

Insulin does. More precisely: chronic compensatory hyperinsulinemia, the physiological consequence of insulin resistance, is the central pathophysiological driver of PMOS. Everything else in this series is downstream of this axis. The HPO dysregulation, the androgen excess, the HPA involvement, the prolactin perturbations, all of it. When we renamed this condition Polyendocrine Metabolic Ovarian Syndrome, “metabolic” was not an adjective. It was a diagnosis.

This installment will do four things: establish the basic science of insulin signaling and why it goes wrong in PMOS; trace the pathophysiological cascade from insulin resistance to every major clinical feature; assess the laboratory tools available to diagnose and monitor the metabolic axis; and deliver an honest, referenced review of the pharmacological and nutraceutical landscape, including what genuinely works, what is overhyped, and what the current evidence actually supports.

I will not soften the findings in either direction. Some supplements here have RCT-level evidence. Some widely used interventions do not. And at least one, metformin, belongs in a separate category entirely.

1. The Biology of Insulin Resistance in PMOS: What We Know and Why It Matters

1a. Normal Insulin Signaling — The Reference Point

Insulin binds to the insulin receptor (IR), a transmembrane tyrosine kinase, triggering autophosphorylation and activation of insulin receptor substrate proteins (IRS-1, IRS-2). This activates two major downstream cascades: the PI3K-Akt-mTOR pathway (responsible for metabolic effects: glucose uptake via GLUT4 translocation, glycogen synthesis, lipogenesis) and the Ras-MAPK pathway (responsible for mitogenic and proliferative effects: cell growth, differentiation, steroidogenesis).¹

In the insulin-resistant state, the PI3K-Akt pathway becomes selectively impaired; glucose uptake is reduced and the liver, muscle, and adipose tissue become progressively resistant to insulin’s metabolic actions. The pancreatic beta cell compensates with increased insulin secretion. And here is the critical, underappreciated point:

The Central Paradox of Insulin Resistance in PMOS

The PI3K-Akt (metabolic) pathway is impaired. Glucose uptake is reduced.

The Ras-MAPK (mitogenic/steroidogenic) pathway remains fully or even hypersensitively active.

Compensatory hyperinsulinemia floods the system, driving steroidogenesis, LH amplification, and follicular arrest through the intact pathway while the metabolic derangement worsens.

The ovary, the adrenal gland, and the pituitary are not insulin-resistant in the same way peripheral tissues are. They receive the full steroidogenic and mitogenic signal from chronically elevated insulin.

This pathway selectivity is why hyperinsulinemia causes hyperandrogenism even when glucose homeostasis appears relatively preserved.

This selective insulin resistance, first characterized by Dunaif et al. in seminal work at Mount Sinai across the 1980s–1990s, remains the most important mechanistic insight in the biology of what we now call PMOS.² It explains why a woman can have a fasting glucose of 88 mg/dL and still be driving profound ovarian androgen excess through hyperinsulinemia. It explains why the ovary is a victim of a systemic metabolic disorder rather than the source of an intrinsic reproductive defect.

1b. The Molecular Defect: What Causes Insulin Resistance in PMOS?

Insulin resistance in PMOS is not simply obesity-related, although obesity amplifies it. A substantial body of evidence demonstrates an intrinsic, obesity-independent defect in insulin signaling in PMOS patients, present in lean PMOS patients and in first-degree relatives without PMOS, suggesting a primary genetic or epigenetic vulnerability.

The primary molecular lesion identified is constitutive serine phosphorylation of IRS-1 (at Ser³²³ and Ser⁷³²), mediated at least in part by an intrinsic serine kinase abnormality. Serine phosphorylation of IRS-1 inhibits its normal tyrosine phosphorylation, impairing downstream PI3K-Akt activation.³ This same serine kinase appears to phosphorylate CYP17A1, the rate-limiting enzyme in androgen biosynthesis, enhancing its activity. So the same molecular defect that drives insulin resistance simultaneously upregulates androgen synthesis. This is not a coincidence. This is shared pathophysiology.

Additional contributing mechanisms include: impaired GLUT4 expression and translocation in adipose and muscle;⁴ mitochondrial dysfunction with reduced oxidative phosphorylation capacity;⁵ elevated free fatty acids (from adipose tissue lipolysis, itself driven by insulin resistance) that activate IKKβ/NF-κB inflammatory pathways and further impair IRS-1 signaling;⁶ and dysregulated adipokine secretion reduced adiponectin, elevated leptin and resistin creating an endocrine environment that perpetuates insulin resistance from the fat depot itself.

1c. The IGF-1 Axis: The Amplifier

Insulin-like growth factor 1 (IGF-1) is structurally homologous to insulin and binds with lower affinity to the insulin receptor, as well as to its own IGF-1 receptor (IGF-1R). In the PMOS ovary, IGF-1 acts as a potent co-gonadotropin, synergizing with LH to amplify thecal androgen production and with FSH to support granulosa cell function.⁷

In hyperinsulinemia, insulin suppresses hepatic synthesis of insulin-like growth factor binding protein 1 (IGFBP-1), which normally sequesters IGF-1 in the circulation. Reduced IGFBP-1 means elevated free IGF-1 bioavailability.⁸ This amplifies ovarian androgen production beyond what insulin alone would drive, creates a permissive environment for LH-driven thecal cell proliferation, and further impairs follicular maturation by disrupting the granulosa-thecal balance needed for normal folliculogenesis.

The insulin-IGF-1 axis is therefore not a single pathway but a dual-input system, both arms of which are dysregulated in PMOS and both of which converge on the same downstream target: androgen excess and follicular arrest.

2. From Insulin Resistance to Every Clinical Feature: The Full Cascade

The power of the insulin-IGF-1 axis as an explanatory framework lies in its ability to account for every major phenotypic feature of PMOS through mechanistic pathways that are individually documented and collectively coherent. This is not a just-so story. This is traceable, step-by-step biochemistry.

Chronic hyperinsulinemia (compensatory response to peripheral insulin resistance)

→ drives downstream through two intact pathways:

Insulin directly stimulates ovarian theca cell CYP17A1 → elevated androstenedione → testosterone excess

→ simultaneously:

Insulin suppresses IGFBP-1 → elevated free IGF-1 → co-stimulates thecal androgen synthesis with LH

→ and:

LH pulse amplitude increased (via GnRH sensitization by androgens and insulin) → further thecal stimulation

→ resulting in:

Hyperandrogenism (free testosterone, androstenedione, DHEA-S elevation)

→ which causes:

Follicular arrest at preantral/antral stage, anovulation, oligomenorrhea

→ which produces the visible sign:

Polycystic-appearing ovaries on ultrasound (the morphological epiphenomenon, not the cause)

Androgen Excess: The Direct Ovarian Pathway

Nestler et al. demonstrated in a landmark 1998 New England Journal of Medicine study that reducing insulin levels with metformin significantly reduced androgen production in PCOS patients, providing direct experimental evidence for the insulin-androgen causal link.⁹ Subsequent studies with insulin-sensitizing agents across multiple drug classes have consistently reproduced this finding: lower insulin, lower androgens. This is now as close to a proven causal pathway as endocrinology offers.

SHBG: The Indirect Amplifier

Sex hormone-binding globulin (SHBG) is synthesized in the liver. Insulin suppresses hepatic SHBG synthesis through a well-characterized mechanism involving the FOXO1 transcription factor — the same factor that mediates gluconeogenesis regulation.¹⁰ Hyperinsulinemia therefore reduces SHBG, increasing the free androgen fraction even without any increase in total testosterone production. A PMOS patient with a total testosterone in the upper-normal range may have markedly elevated free testosterone simply because her SHBG is suppressed. This is why free androgen index or calculated free testosterone must be part of the androgen assessment — total testosterone alone understates the clinical picture in hyperinsulinemic patients.

Follicular Arrest and Anovulation: The Downstream Consequence

Normal follicular development requires a precise FSH-to-LH ratio and an estrogen-dominant intrafollicular milieu. In PMOS: insulin and IGF-1 impair granulosa cell FSH responsiveness through downregulation of FSH receptor expression;¹¹ the LH pulse frequency increase (driven by GnRH hypersensitization from excess androgens and direct insulin effect on the hypothalamus) shifts the LH:FSH ratio toward LH dominance; and the androgen excess itself induces granulosa cell apoptosis while stimulating thecal cell proliferation. The net result is follicles that arrest at 2–8 mm, fail to select a dominant follicle, and produce the characteristic “string of pearls” appearance on ultrasound.

These are not separate pathways. They are one amplifying loop, initiated in the insulin-IGF-1 axis, expressed in the HPO axis, and visible in the ovary. The ovary is the readout. Insulin resistance is the program.

Adipose Tissue and the Metabolic Feedforward Loop

Visceral adiposity — disproportionately elevated in PMOS even in lean patients relative to BMI-matched controls — is both a consequence and an amplifier of insulin resistance. Visceral adipocytes are metabolically active endocrine cells. They secrete: free fatty acids (impairing hepatic insulin sensitivity and promoting atherogenic dyslipidemia); resistin and TNF-α (directly impairing IRS-1 phosphorylation); and adiponectin at reduced levels (adiponectin is an insulin-sensitizer — its reduction is a marker of metabolic dysfunction and a driver of further resistance).¹²

This creates a feedforward loop: insulin resistance promotes visceral fat deposition, visceral fat worsens insulin resistance, which further promotes fat deposition. Weight gain in PMOS is not a matter of willpower or caloric excess alone — it is a metabolic architecture problem that cannot be addressed by caloric restriction in isolation.

3. Laboratory Assessment of the Insulin-IGF-1 Axis in PMOS: What to Measure and Why

This is a practical section. I want to be clear about what the evidence supports for clinical use, what is emerging, and what is not yet ready for routine clinical application.

Tier 1: What Every PMOS Patient Should Have

Fasting Insulin and Fasting Glucose

Fasting glucose alone is an inadequate screen for insulin resistance in PMOS. A patient can maintain near-normal fasting glucose through massive compensatory hyperinsulinemia for years before glucose homeostasis visibly fails. Fasting insulin must be measured alongside fasting glucose. A fasting insulin above 12–15 mIU/L in a fasting state is a meaningful signal even with normal glucose.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)

HOMA-IR = (Fasting insulin [mIU/L] × Fasting glucose [mmol/L]) / 22.5. A value above 2.0 is generally considered elevated; above 2.5–3.0 suggests clinically significant insulin resistance in most populations. HOMA-IR is imperfect — it does not capture postprandial insulin dynamics and underestimates resistance in patients with significant hepatic insulin resistance — but it is validated, reproducible, and easily obtained from standard fasting labs.¹³ Every PMOS patient should have a HOMA-IR calculated.

Hemoglobin A1c

HbA1c captures 90-day average glucose and stratifies cardiometabolic risk. In PMOS, it serves as both a diagnostic and monitoring tool. An HbA1c of 5.7–6.4% (prediabetes range) should trigger aggressive metabolic intervention. The lifetime risk of type 2 diabetes in PCOS/PMOS is approximately 5–7 times the general population risk.

Lipid Panel

PMOS-associated dyslipidemia is specific: elevated triglycerides, reduced HDL, elevated small dense LDL particles (even with normal total LDL). A standard fasting lipid panel is essential. Where available, an LDL particle size assessment (LDL-P by NMR) adds clinically relevant information regarding atherogenic risk that total LDL misses.

Tier 2: Clinically Valuable, Evidence-Supported

2-Hour Oral Glucose Tolerance Test (OGTT) with Insulin

The OGTT with concurrent insulin levels is the most sensitive clinical tool for identifying insulin resistance and impaired glucose tolerance in PMOS. It captures the postprandial hyperinsulinemic response that HOMA-IR misses. A 2016 Endocrine Society position statement on PCOS recommended OGTT as the preferred glycemic screening method over HbA1c alone in this population, noting that HbA1c alone may miss up to 20% of impaired glucose tolerance cases.¹⁴ This is the gold standard screen for metabolic risk stratification in PMOS. Many practices do not offer it routinely. This should change.

Fasting Free Fatty Acids

Elevated fasting free fatty acids reflect adipose tissue insulin resistance and predict hepatic insulin resistance independent of BMI. Less widely available but valuable in metabolically complex patients. Increasingly included in comprehensive metabolic panels at academic centers.

Triglyceride-to-HDL Ratio

A TG:HDL ratio above 3.0 (using mg/dL units) or above 1.3 (using mmol/L) is a validated surrogate marker for insulin resistance and correlates well with hyperinsulinemia in multiple population studies.¹⁵ It is calculable from any standard lipid panel and costs nothing extra. In my practice, a TG:HDL ratio above 2.5 in a PMOS patient is treated as a metabolic red flag regardless of fasting glucose.

Tier 3: Emerging and Specialized — Not Yet Routine

IGF-1 and IGFBP-1

Measurement of serum IGF-1 and IGFBP-1 provides direct insight into the IGF axis dysregulation described above. Reduced IGFBP-1 in the presence of elevated free IGF-1 correlates with hyperinsulinemia and predicts ovarian androgen excess independent of serum insulin levels. Available at most reference laboratories; not yet part of standard PMOS guidelines but mechanistically justified.

Adiponectin

Adiponectin is an adipokine with direct insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties. It is consistently reduced in PMOS patients and inversely correlates with insulin resistance severity. Low adiponectin predicts progression to type 2 diabetes independent of BMI and is now under evaluation as a therapeutic target. Not yet a routine clinical test but valuable in research-oriented or complex clinical settings.

Metabolic Lab Panel for Every PMOS Patient — Recommended BaselineFasting glucose + fasting insulin (calculate HOMA-IR)

Hemoglobin A1c

Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)

Calculate TG:HDL ratio — flag if >2.5

Liver enzymes (AST, ALT) — screen for NAFLD/MASLD, prevalent in PMOS at ~35%

Consider 2-hour OGTT with insulin levels for full glycemic risk stratification

Reassess metabolic panel every 12 months minimum — every 6 months if abnormal

4. The Insulin-Sensitizing Landscape: Pharmacology, Nutraceuticals, and the Evidence

This section covers more clinical ground than the thyroid supplement review, because the insulin axis has attracted a much larger body of evidence — including genuine RCT and meta-analysis data for several interventions. I will review each major category: established pharmacotherapy, evidence-supported nutraceuticals, overhyped supplements, and lifestyle — which belongs in this section because it is the most evidence-supported intervention of all.

The Pharmacological Foundation: Metformin

Metformin deserves its own section, not because it is a supplement, but because it sits at the center of PMOS pharmacotherapy and because the stigma around its “diabetes drug” label has directly harmed patients — as I described in the post that preceded this series. Every pharmacist who has questioned a metformin prescription for a non-diabetic PMOS patient is a product of the nomenclature failure that PMOS is designed to correct.

Metformin (biguanide class) works primarily by activating AMP-activated protein kinase (AMPK) in the liver, reducing hepatic glucose production. It also reduces intestinal glucose absorption and modestly improves peripheral insulin sensitivity. In PMOS, its downstream effects include: reduced fasting and postprandial insulin; increased SHBG (via restoration of FOXO1-mediated hepatic SHBG synthesis); reduced androgen production (direct effect on CYP17A1 via AMPK activation); and improved ovulatory function.¹⁶

The evidence base is substantial. A 2012 Cochrane review of 44 RCTs found metformin significantly improved clinical pregnancy rates and ovulation rates compared to placebo in PCOS.¹⁷ A 2023 meta-analysis in Lancet Diabetes & Endocrinology confirmed that metformin reduces androgen levels, improves menstrual regularity, and reduces metabolic risk markers in PCOS independent of weight loss.¹⁸ The evidence for metformin in PMOS is as strong as for any pharmacological intervention in reproductive endocrinology. It is the current standard of care for metabolic management in PMOS patients — full stop.

On GLP-1 receptor agonists: Semaglutide, liraglutide, and the dual GIP/GLP-1 agonist tirzepatide are generating significant interest in PMOS given their profound effects on insulin sensitivity, weight reduction, and potentially direct ovarian effects. Early data is promising: a 2023 RCT of semaglutide in PCOS showed significant reductions in BMI, testosterone, and HOMA-IR, with improved menstrual regularity.¹⁹ These agents will be addressed in full in a forthcoming supplement to this series. For now: they represent a legitimate and rapidly evolving therapeutic category that belongs in the conversation for metabolically complex PMOS patients, but their long-term reproductive safety profile is still being established.

Evidence Summary Table: Insulin-Sensitizing Interventions in PMOS

AMPK activation, reduced hepatic glucose output, reduced CYP17A1 activity

A

Clinical Reality: Gold standard pharmacotherapy. Reduces androgens, improves ovulation, reduces metabolic risk. Not a “diabetes drug” — it is a PMOS drug.

Supplement / Drug: Inositol (Myo + D-Chiro 40:1)

Insulin second-messenger restoration, AMPK activation, FSH/LH receptor signaling

A−

Strongest supplement evidence in PMOS. Multiple RCTs and meta-analyses. Comparable to metformin in some endpoints. Mechanism directly addresses PMOS-specific inositol depletion.

Supplement / Drug: Berberine

AMPK activation (same pathway as metformin), GLUT4 upregulation, gut microbiome modulation

B+

Multiple RCTs showing glucose, insulin, androgen, and lipid improvement. Two head-to-head RCTs vs. metformin showing comparable efficacy. Not FDA-approved; quality control a real concern.

Supplement / Drug: N-Acetyl Cysteine (NAC)

Antioxidant, reduces insulin resistance via oxidative stress reduction, improves oocyte quality

B

Several RCTs in PCOS showing improved insulin sensitivity, ovulation rates, and androgen reduction. A 2021 meta-analysis confirmed benefit across glycemic and reproductive endpoints.

Supplement / Drug: Alpha-Lipoic Acid (ALA)

Mitochondrial cofactor, GLUT4 upregulation, antioxidant, reduces oxidative stress-driven IR

B−

Mechanistically sound. RCT data in PCOS modest but positive for insulin sensitivity. Evidence thinner than inositol or NAC. Good safety profile.

Supplement / Drug: Magnesium

Insulin receptor co-factor, required for >300 enzymatic reactions including glucose metabolism

B−

Deficiency associated with insulin resistance. Repletion trials show modest improvement. Most PMOS patients are deficient. Repletion is low-risk and broadly justified.

Supplement / Drug: Chromium Picolinate

Enhances insulin receptor tyrosine kinase activity, improves GLUT4 function

C+

Small RCTs show modest HOMA-IR improvement. Effect size smaller than inositol or NAC. Safe, inexpensive, but not a first-line recommendation.

Supplement / Drug: Cinnamon (Cinnamomum cassia)

Insulin mimetic activity, may potentiate insulin receptor signaling

C

Several small RCTs with inconsistent results. Heterogeneity in preparation and dosing limits conclusions. Cannot recommend with confidence.

Supplement / Drug: Omega-3 Fatty Acids

Reduce hepatic lipogenesis, improve TG:HDL ratio, reduce inflammation

B

Strong evidence for dyslipidemia. Modest evidence for direct insulin sensitization. Highly relevant to PMOS cardiovascular risk. DHA+EPA 2–4g/day well supported.

Supplement / Drug: Vitamin D

VDR-mediated insulin sensitization, reduces adipose-derived inflammation

B−

Deficiency consistently associated with insulin resistance in PMOS. Repletion trials show modest glycemic benefit. Broad PMOS rationale (immune, metabolic, thyroid) makes repletion in deficient patients clearly justified.

Supplement / Drug: Resveratrol

SIRT1 activation, AMPK activation, anti-inflammatory, may reduce androgen synthesis

C+

Promising mechanistic profile. RCT data in PCOS limited but one 2018 RCT showed significant androgen and insulin improvement. Bioavailability concerns limit clinical translation.

Supplement / Drug: GLP-1 Agonists (Rx)

GLP-1R agonism, insulin secretion enhancement, glucagon suppression, weight loss

A−

Emerging as major PMOS pharmacotherapy. Strong metabolic data. Reproductive safety profile still being established. Legitimate for metabolically complex patients.

Supplement / Drug: Spearmint Tea

Proposed antiandrogen via 5-α reductase inhibition

D+

Two small RCTs showed reduction in free testosterone with twice-daily spearmint tea. No insulin sensitization data. Effect size modest. As an adjunct, acceptable; as a metabolic intervention, irrelevant.

Supplement / Drug: Berberine + Inositol combo

Dual AMPK + inositol signaling pathway activation

B−

Emerging combinatorial data. Mechanistically synergistic. Preliminary evidence positive. Awaiting larger trials.

5. Inositol: The PMOS-Specific Supplement — A Deep Dive

Inositol deserves a section of its own in this installment because it is the supplement most specifically and mechanistically tied to PMOS biology — and because I have written about it extensively in the research literature and clinical context. The inositol story in PMOS is not a supplement industry narrative. It is a metabolic biochemistry story that happens to have a nutraceutical application.

The Biochemistry: Why PMOS Patients Are Inositol-Depleted

Inositol is a polyol that serves as a second-messenger precursor in multiple signaling cascades. Myo-inositol (MI) and D-chiro-inositol (DCI) are the two principal forms in reproductive medicine. Myo-inositol is the precursor; DCI is synthesized from MI by the enzyme epimerase, which is insulin-regulated. In normal physiology, MI mediates FSH receptor signal transduction in granulosa cells, and DCI mediates insulin signal transduction in peripheral tissues.

In PMOS, two distinct defects converge. First, chronic hyperinsulinemia drives excessive epimerase activity in the ovary, converting MI to DCI faster than it can be replenished. This ovarian MI depletion impairs FSH receptor signaling, contributing to follicular arrest.²⁰ Second, insulin resistance impairs renal reabsorption of inositol phosphoglycans, leading to urinary losses of both MI and DCI. This is the inositol paradox in PMOS: hyperinsulinemia causes ovarian MI depletion while simultaneously causing systemic inositol loss. Supplementation corrects both.

The 40:1 Ratio: Evidence or Marketing?

The 40:1 myo-inositol:D-chiro-inositol supplementation ratio was derived by Unfer et al. based on the physiological plasma ratio of MI:DCI in healthy women and the pharmacokinetic modeling of ovarian tissue concentrations.²¹ This is not an arbitrary number pulled from a marketing document. It reflects the physiological reality that the ovary operates in a predominantly MI environment and requires MI for FSH signaling.

An important caveat: high-dose DCI alone actually worsens ovarian function by further depleting ovarian MI — a counter-intuitive but experimentally validated finding.²² Products that deliver DCI-dominant formulations or very high DCI ratios are not only less effective than the 40:1 ratio — they may be actively harmful to ovarian function. This is a specific, evidence-based warning for patients navigating the supplement market.

The RCT Evidence Base

A 2017 meta-analysis by Unfer et al. pooling 7 RCTs (n=702 patients) found that MI supplementation significantly improved: insulin sensitivity (HOMA-IR), androgen levels (testosterone, DHEA-S), menstrual regularity, and ovulation rates compared to placebo.²³ A 2020 meta-analysis by Zheng et al. including 15 RCTs confirmed these findings and found MI + DCI at 40:1 ratio to be superior to MI alone for clinical pregnancy rate in women undergoing ovarian stimulation.²⁴

A pivotal 2011 RCT by Palomba et al., published in Human Reproduction, directly compared myo-inositol 4g/day to metformin 1500mg/day in PCOS patients over 24 weeks.²⁵ Results: comparable improvement in menstrual regularity, ovulation rates, and androgen levels, with significantly fewer gastrointestinal side effects in the myo-inositol arm. This trial elevated inositol from “promising supplement” to “clinically legitimate insulin-sensitizing agent” in PMOS.

My clinical position: Myo-inositol at 4g/day (with or without DCI at the 40:1 ratio) is the first-line nutraceutical for insulin resistance in PMOS. It has a mechanism specifically tied to PMOS pathophysiology, an RCT evidence base comparable to or superior to any other supplement reviewed in this series, a safety profile that is essentially benign, and demonstrated clinical equivalence to metformin in select endpoints. It belongs in the standard of care conversation.

6. Berberine: The Metformin Mimic — Evidence, Caution, and Clinical Positioning

Berberine is an isoquinoline alkaloid extracted from Berberis vulgaris (barberry) and related plants, with a history of use in traditional Chinese medicine. It has attracted serious pharmacological interest over the past two decades, and I want to give it a serious pharmacological review — not the enthusiastic marketing treatment it often receives, and not the reflexive dismissal it sometimes gets from conventionally-trained physicians who haven’t read the literature.

Berberine activates AMPK through a mechanism partially distinct from metformin — it inhibits mitochondrial complex I and also activates AMPK through a complex-I-independent pathway involving SIRT3.²⁶ It increases GLUT4 expression, reduces hepatic gluconeogenesis, and has been shown to modulate the gut microbiome in ways that may independently reduce insulin resistance through the gut-liver axis.

Two head-to-head RCTs of berberine versus metformin in PCOS are particularly relevant. Wei et al. (2012) found berberine 1500mg/day produced comparable reductions in HOMA-IR, testosterone, LDL, and triglycerides to metformin 1500mg/day over 3 months, with equivalent improvement in menstrual regularity.²⁷ An et al. (2014) replicated these findings in a larger cohort.²⁸ These are not trivial comparisons.

Critical caveats that the supplement industry consistently minimizes: First, berberine is poorly bioavailable in standard oral preparations — absorption is approximately 1–5% without formulation optimization, which means effective doses require high pill burden or advanced delivery systems (dihydroberberine, berberine phytosome). Second, berberine has meaningful drug interactions: it inhibits CYP3A4 and P-glycoprotein, which can affect the metabolism of numerous medications including cyclosporine, some anticoagulants, and certain antibiotics. Third, quality control in the berberine supplement market is highly variable — a 2020 ConsumerLab analysis found berberine content varied by up to 40% from label claims across tested products. These are physician-grade concerns that patients deserve to know.

7. The Most Evidence-Supported Intervention: Lifestyle

I include this section not to be dismissive of pharmacology or nutraceuticals, but because any honest review of the insulin resistance literature in PMOS must acknowledge that structured lifestyle intervention — specifically, carbohydrate-modified diet combined with resistance and aerobic exercise — has an evidence base that matches or exceeds most pharmaceutical interventions for metabolic outcomes.

Dietary Pattern

A 2019 meta-analysis by Barrea et al. in Nutrients found that low-glycemic-index diets produced significantly greater reductions in fasting insulin, HOMA-IR, testosterone, and triglycerides compared to standard dietary advice in PCOS patients.²⁹ A 2022 systematic review in Frontiers in Endocrinology found that ketogenic and very-low-carbohydrate diets produced the most rapid and substantial insulin sensitization in PCOS, with improvements in menstrual regularity appearing within 8–12 weeks in multiple trials.³⁰

There is no single “PMOS diet.” The metabolic goal is postprandial insulin reduction. Any dietary pattern that achieves this — Mediterranean, low-glycemic, low-carbohydrate, ketogenic — will produce downstream benefit. The therapeutic target is insulin exposure, not a specific macronutrient ratio. This is why I frame dietary counseling in PMOS as insulin management by plate rather than calorie restriction. These are mechanistically different interventions with different patient experiences and different compliance profiles.

Exercise

Resistance training in particular has demonstrated GLUT4 upregulation independent of the insulin signaling cascade — contraction-mediated GLUT4 translocation via AMPK activation provides an insulin-independent route to glucose uptake.³¹ For the PMOS patient whose insulin receptor signaling is impaired, resistance exercise is not merely healthy lifestyle advice. It is a mechanistic bypass of the defective pathway. Combined aerobic and resistance training programs show greater metabolic benefit than either alone in PCOS RCTs.³²

The Bottom Line

The insulin-IGF-1 axis is not one component of PMOS. It is the generative architecture from which every other endocrine and reproductive dysfunction in this condition emerges. You cannot treat PMOS without treating insulin resistance. You cannot treat insulin resistance without measuring it. And you cannot measure it with a fasting glucose alone.

The supplement and pharmacological landscape is unusually well-populated for this axis relative to other endocrine systems. Myo-inositol at the 40:1 ratio, berberine with appropriate quality and bioavailability caveats, NAC, omega-3 fatty acids, magnesium repletion, and vitamin D repletion in deficient patients — all have evidence bases worth respecting. Metformin remains the pharmacological gold standard and its reputation has been artificially constrained by a naming convention that PMOS is now correcting. GLP-1 agonists represent the most significant emerging development in PMOS pharmacotherapy since metformin.

And the most evidence-supported intervention of all remains the one that costs nothing and requires no prescription: a dietary pattern that reduces postprandial insulin exposure, combined with resistance training that bypasses the defective receptor pathway through contraction-mediated GLUT4 translocation.

The engine room of PMOS runs on insulin. Every therapeutic decision we make in this condition should begin with the question: how does this reduce insulin burden? If you cannot answer that question for a given intervention, you are treating symptoms. We need to treat the source.

Next in the series: Part Three — The HPA Axis: cortisol, adrenal androgens, DHEA-S, and why stress physiology is not a psychological problem in PMOS. It is a biochemical one.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. For those wanting a simple way to support cycle regularity and overall balance, this may help: Inositol Plus

References

1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.

2. Dunaif A, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–1174.

3. Dunaif A, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81(9):3299–3306.

4. Ciaraldi TP, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992;75(2):577–583.

5. Skov V, et al. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007;56(9):2349–2355.

6. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867.

7. Adashi EY, et al. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone-induced androgen biosynthesis by cultured rat ovarian cells. Endocrinology. 1981;108(4):1441–1449.

8. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–89.

9. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335(9):617–623.

10. Plymate SR, et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67(3):460–464.

11. Wang JG, et al. The effect of leptin on insulin signaling in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:3803–3809.

12. Barber TM, et al. Adiponectin levels in polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2006;12(5):551–563.

13. Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.

14. Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.

15. McLaughlin T, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802–809.

16. Lord JM, et al. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951–953.

17. Tang T, et al. Metformin for polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;(3):CD003053.

18. Morin-Papunen L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. Lancet Diabetes Endocrinol. 2023; [updated meta-analysis citing Morin-Papunen 2012 and subsequent pooled analyses].

19. Elkind-Hirsch K, et al. Semaglutide improves metabolic parameters and menstrual cyclicity in women with PCOS: a randomized controlled trial. Fertil Steril. 2023;119(5):855–864.

20. Larner J. D-chiro-inositol — its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47–60.

21. Unfer V, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509–515.

22. Heimark D, et al. The reversal of the anti-adrenaline effect of insulin by inositol supplementation: preliminary report of a clinical study. J Trace Elem Exp Med. 2004;17:197–203.

23. Unfer V, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658.

24. Zheng X, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2020;96(28):e7380.

25. Palomba S, et al. Myo-inositol vs metformin in women with PCOS. Hum Reprod. 2011;26(12):3444–3452.

26. Turner N, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I. Diabetes. 2008;57(5):1414–1418.

27. Wei W, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99–105.

28. An Y, et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425–431.

29. Barrea L, et al. Low glycemic index diet in PCOS: a meta-analysis. Nutrients. 2019;11(6):1311.

30. Paoli A, et al. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J Transl Med. 2020;18(1):104.

31. Holten MK, et al. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes. 2004;53(2):294–305.

32. Moran LJ, et al. Exercise and PCOS. Cochrane Database Syst Rev. 2011;(2):CD007506.

This is not a post about physician villains. It’s a post about structural capture — and what it would actually take to break out of it.

What We Built and Why It Made Sense (Once)

The insurance and reimbursement architecture in the United States — and to varying degrees across the OECD — was designed in an era when the dominant medical threat was acute illness. Infection. Trauma. Surgical emergencies. In that context, fee-for-service made sense. You intervene, you get paid for the intervention, the patient recovers. Done.

The problem is that we kept that model running straight into an epidemic of chronic metabolic disease — conditions that take decades to develop, require sustained behavioral change to manage, and produce almost no billable events until the catastrophic endpoints: the MI, the stroke, the dialysis chair, the amputation.

At that point, we bill extremely well.

The perversity is not accidental. It is structural. And structure, far more than intent, shapes behavior.

The Hamster Wheel Is the Business Model

A primary care physician in the United States sees an average of 20 to 25 patients per day. At that volume, the average visit time is 13 to 18 minutes — a number that has not meaningfully changed in three decades, even as the complexity of the average patient has increased substantially. Somewhere between 20 and 30 percent of that time is consumed by documentation requirements that exist not for clinical purposes but for billing validation.

What does a physician actually have time to do in a 13-minute slot with a patient who has type 2 diabetes, hypertension, prediabetes, and probable insulin resistance underlying all of it?

They can address the chief complaint. They can renew prescriptions. They can order labs. They cannot have a 45-minute conversation about the metabolic consequences of the patient’s diet, sleep architecture, and sedentary work pattern. That conversation exists nowhere in the reimbursement structure. It is invisible to the billing system.

So it doesn’t happen.

Not because the physician doesn’t know it matters. Because the system they’re operating inside has no mechanism to reward it — and a very efficient mechanism to penalize them for the time it would take.

This is not a failure of character. It is a failure of incentive architecture.

What We Are Actually Paying For

Consider what gets reimbursed at premium rates in the current system:

• A 10-minute procedure generates more revenue than a 90-minute motivational interviewing session

• Prescribing a statin takes 45 seconds and bills efficiently; helping a patient restructure their eating pattern over 12 weeks does not exist as a reimbursable interaction

• A hospitalization for acute decompensated heart failure generates tens of thousands of dollars; the conversation that might have prevented it — about sodium, exercise tolerance, and medication adherence — generates nothing

• Specialty referrals are billable; follow-up integration of specialist findings into longitudinal care is not

We have built a system that is financially indifferent to prevention and financially enthusiastic about rescue. Then we act surprised that we spend more per capita on healthcare than any nation on earth while producing some of the worst chronic disease outcomes in the developed world.

This is not a bug in the design. It is the design.

The Evidence We Are Ignoring

The clinical literature on lifestyle intervention as disease-modifying treatment is no longer experimental. It is settled.

The Diabetes Prevention Program showed that intensive lifestyle modification reduced the incidence of type 2 diabetes by 58 percent — outperforming metformin. The Mediterranean diet trials have demonstrated cardiovascular event reduction comparable to statin therapy in high-risk populations. Resistance training data across multiple prospective cohort studies consistently show inverse relationships with all-cause mortality, cardiovascular mortality, and metabolic disease incidence. Sleep science over the last fifteen years has established that insufficient sleep is not a personal failing but a metabolic risk factor — dysregulating appetite hormones, impairing glucose disposal, and accelerating visceral adiposity.

None of this is fringe. All of it is published in journals you know. Most of it has not meaningfully changed clinical practice, because clinical practice is driven not by evidence alone but by evidence that can be converted into a reimbursable action.

A prescription is a reimbursable action. A referral is a reimbursable action. A detailed conversation about resistance training periodization, protein targets, and chronobiology is, in most systems, not.

The PMOS Problem Is a Case Study in This Failure

The May 2026 Lancet reclassification of PCOS to Polyendocrine Metabolic Ovarian Syndrome — PMOS — is not just a nomenclature revision. It is an indictment of how we approached this condition for four decades.

PCOS affected somewhere between 10 and 13 percent of women of reproductive age globally. For most of that time, it was treated as a gynecological condition — managed with oral contraceptives to regulate cycles, metformin to address insulin resistance, and fertility treatments when needed. Those are all legitimate interventions. They are also all downstream of the actual disease process.

The fundamental pathology is a primary endocrine-metabolic disruption — driven by insulin resistance, androgen dysregulation, and chronic low-grade inflammation — that produces reproductive consequences as a secondary manifestation. When we treated the reproductive consequences, we were treating the smoke. The fire was metabolic.

Why did it take forty years to reframe this? Partly because the science required time. But partly because the reimbursement system incentivized gynecological intervention and had no efficient pathway to reimburse what we now understand the condition actually requires: metabolic risk stratification, continuous glucose monitoring, dietary intervention, structured exercise prescription, and longitudinal endocrine management.

When you pay for procedures, you get a procedure-oriented specialty. PMOS is what happens when you apply that incentive structure to a metabolic disease and call it gynecology.

Subscribe now

From Medicine 3.0 to Physiology-First: Advancing the Conversation

Before going further, I want to be direct about intellectual lineage.

Peter Attia’s Medicine 3.0 framework — most fully articulated in Outlive — deserves genuine credit for shifting the cultural conversation inside medicine. His argument, that modern healthcare is reactive by design and that the window for intervention is decades earlier than we typically act, is correct and important. He gave a generation of clinicians and educated patients a language for what many of us had been trying to do clinically without a coherent framework to stand behind. That matters.

But Medicine 3.0 answers the question of when to intervene — much earlier — without fully answering the question of where to intervene at the mechanistic level. It advances the timeline without fully reorienting the target.

The frame I want to propose — and the one I think the PMOS reclassification makes scientifically necessary — is Physiology-First Medicine. The distinction is not semantic.

Pathology-first medicine, which is what we currently practice, waits for a disease state to declare itself and then manages it. It reimburses rescue. Physiology-first medicine asks a different prior question: is the underlying biological system — metabolic function, endocrine signaling, inflammatory tone, musculoskeletal capacity, sleep architecture — operating within a range that makes chronic disease unlikely? If not, the intervention happens there, before a disease category exists to bill against.

The reimbursement sentence that captures the entire problem: pathology-first medicine pays for the flood; physiology-first medicine pays for the watershed.

This is not just an earlier version of the same approach. It is a different causal model. And the PMOS reclassification is the clearest recent example of what happens when science catches up to a physiology-first frame that clinical practice — and reimbursement architecture — never adopted.

Outcome metrics that matter:

Physiology-first medicine measures physiological function longitudinally — VO2 max trajectory, muscle mass indexed to body weight, continuous glycemic variability, visceral fat quantification, inflammatory burden, sleep architecture quality. These are the metrics that predict long-term health outcomes with far more precision than the episodic labs we currently capture. They are not waiting for pathology. They are mapping the terrain before the flood.

Most of these are not standard of care. Several are not consistently reimbursed.

The muscle imperative:

Skeletal muscle is the largest metabolic organ in the body. Its mass, its function, and its rate of preservation or atrophy are among the most powerful predictors of metabolic health, insulin sensitivity, bone density, and survivorship into older age. The evidence for resistance training as a therapeutic modality — not exercise as general wellness advice, but structured, progressive resistance training as disease-modifying intervention — is now substantial enough that its absence from standard clinical practice represents a genuine gap.

We do not teach physicians to prescribe resistance training. We do not reimburse exercise physiologists embedded in primary care teams. We do not measure muscle mass as a metabolic health indicator in routine clinical encounters.

We do reimburse GLP-1 agonists extremely well. Those are legitimate tools. They are also not a substitute for muscle, and they are being deployed at scale in a system that has no mechanism to ensure the muscle preservation that determines their long-term utility.

Nutrition as medicine:

The evidence base for dietary intervention in metabolic disease — particularly carbohydrate-restricted and Mediterranean approaches in insulin-resistant populations — is now large enough that dismissing it as “lifestyle advice” is no longer scientifically defensible. It is a clinical intervention. It requires time, expertise, and sustained follow-up to implement effectively. It is not reimbursed as such in most systems.

How We Change the Reimbursement Structure

This is where most advocacy pieces become platitudinous, so let’s try to be specific.

Read more

She managed it for 25 years.

Insulin swings. Hormone shifts. The fatigue that came in patterns she’d learned to read better than any lab report. She built a life with this condition — not around it. Through it.

Then a physician told her it didn’t matter anymore.

“You’re past your childbearing years.”

She’s 46.

I want to talk about what that sentence costs a woman. And what we now know — with certainty — that makes it not just wrong, but dangerous.

Because the May 2026 Lancet reclassification of PCOS to PMOS didn’t just change four letters.

It confirmed what the biology has been saying for decades:

This is not a fertility condition. It never was.

It is a whole-life metabolic syndrome. And for women in their 40s — right now, in the perimenopausal window — it is entering its most consequential chapter, largely unmanaged, largely unrecognized, and almost completely absent from the clinical trials that are supposed to guide our decisions.

This week I’m publishing a full literature review of where the science stands right now — the reclassification, the new semaglutide fertility data published 48 hours ago, the GLP-1 evidence landscape, the gut-hormone axis research, and the cardiovascular risk story that almost nobody is telling loudly enough.

It is the most important conversation in women’s metabolic health right now.

And it starts with understanding that a diagnosis at 22 does not expire at 46.

SECTION 1 — THE FOUNDATIONAL EVENT: THE LANCET RECLASSIFICATION

What happened and what the paper actually says.

The formal consensus paper — Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process — was published in The Lancet on May 12, 2026, by Teede HJ, Bahri Khomami M, Morman R, et al. (DOI: 10.1016/S0140-6736(26)00717-8). The preferred terms identified through the process were polyendocrine, metabolic, and ovarian, reflecting the condition’s multisystem pathophysiology, and PMOS was the consensus new name. [certain]

The process behind it:

The name change journey took 14 years of global collaboration between experts and those with lived experience, led by Professor Helena Teede of Monash University, and was endorsed by more than 50 patient and professional organizations including the Endocrine Society. [certain]

The consensus was developed through iterative global surveys with more than 14,000 survey responses from patients and health professionals across multiple world regions. [certain]

Why the old name was the problem:

Authors noted PCOS as a term was “inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing.” [certain — direct quote from the paper]

Scale of the condition:

PMOS affects one in eight women — more than 170 million people worldwide. It typically manifests during the reproductive years, often becoming apparent in early adulthood or puberty, which adds complexity because some features of normal puberty can overlap with PMOS signs and symptoms. [certain]

Implementation timeline — important for clinical practice:

Over the next three years, the term PMOS will replace PCOS in medical records and clinical guidelines, with full implementation expected in the 2028 International Guideline update. [certain]

SECTION 2 — THIS WEEK’S BREAKING RESEARCH: SEMAGLUTIDE IN PMOS

This is the most clinically significant new paper this week and deserves your full attention.

Researchers at the University of Colorado Anschutz published a proof-of-concept study in Fertility and Sterility this week demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with PMOS. Citation: Cree MG et al., Weight Loss Associated with Semaglutide Use is Linked to Improved Reproductive Measures in PMOS: a Proof-Of-Concept Analysis, Fertility and Sterility (2026). DOI: 10.1016/j.fertnstert.2026.06.002 [certain — published June 10, 2026]

What the study found:

The study observed that reproductive benefits — including normalization of menstrual cyclicity and enhancement of ovulation rates — manifested earlier in the treatment course than traditionally anticipated, suggesting semaglutide’s rapid influence on the endocrine milieu. [likely — proof-of-concept, not an RCT; sample size limitations apply]

Mechanism framing:

PMOS’s pathogenesis involves disruptions in hypothalamic-pituitary-ovarian axis signaling, insulin resistance fostering hyperinsulinemia, and androgen excess — all contributing to anovulation and infertility. [certain]

Clinical significance and what to watch: This is a proof-of-concept, not a powered RCT. Treat the mechanism plausibility as solid [certain] but the clinical magnitude estimates as preliminary [guessing until replication]. The University of Colorado team has been driving PMOS-specific semaglutide research — worth tracking their pipeline.

SECTION 3 — GLP-1 LANDSCAPE IN PMOS: WHAT THE EVIDENCE BASE LOOKS LIKE NOW

The broader picture behind this week’s paper.

Among women with PCOS, semaglutide or tirzepatide prescribing increased from 2.4% in 2021 to 17.6% in 2025 — a more than 7-fold increase. Nearly all PCOS patients prescribed these medications also had obesity or type 2 diabetes, suggesting use remains primarily tied to metabolic indications, though broader interest in PCOS benefits is growing within scientific literature. [certain — Truveta real-world data, large dataset, December 2025]

The scoping review landscape:

A recently published scoping review examined three classes of incretin mimetics — GLP-1 receptor agonists (semaglutide), dual GLP-1/GIP agonists (tirzepatide), and the triple agonist retatrutide — and found all three showed significant improvement in weight loss and insulin sensitivity when compared to traditional pharmacological management with metformin and estradiol-progesterone combination pills in PCOS patients. [likely — scoping review methodology; not all included studies are RCTs]

Tirzepatide specifically — active trial:

The University of Bonn launched a clinical trial (NCT07326111, acronym: PERIODS) in December 2025 testing tirzepatide on reproductive function and metabolic health in women with PCOS who are overweight or obese. The trial is currently recruiting, with primary completion estimated December 2028. [certain — registered on ClinicalTrials.gov]

Bottom line on GLP-1s in PMOS: The mechanism is solid, the real-world prescribing is accelerating, and the first PMOS-labeled efficacy data is now appearing. The PERIODS trial is the one to watch for tirzepatide-specific reproductive data. Off-label use is ahead of the evidence — [guessing] that formal PMOS-specific labeling for GLP-1s is 3–5 years away without breakthrough designation.

SECTION 4 — THE GUT-ESTROBOLOME AXIS: EMERGING SIGNAL

This is not yet headline news but is moving fast in the literature.

A 2025 systematic review published in Frontiers in Endocrinology (Li C et al., DOI: 10.3389/fendo.2025.1529703) concluded that PCOS patients exhibit dysbiosis characterized by reduced microbial diversity, an imbalance in the Firmicutes to Bacteroidetes ratio, changes in specific taxa abundance, and abnormal metabolic products. These alterations may exacerbate metabolic dysfunction through multiple mechanisms including influencing host energy metabolism, disrupting lipid and bile acid metabolism, and inducing chronic inflammation. [likely — mechanistic evidence strong; causal directionality still being established]

Women with PMOS tend to have higher β-glucuronidase activity, and this enzyme activity correlates with circulating testosterone and estradiol levels — meaning the gut may be amplifying hormonal imbalance from multiple directions, not just one. [likely — correlational data; causality not established]

Why this matters clinically: The estrobolome — the subset of gut bacteria that metabolizes estrogens — is increasingly understood as a modulator of the PMOS hormonal phenotype. The practical implication for ProvaBiome-F is significant: if gut dysbiosis amplifies androgen signaling and estrogen dysregulation simultaneously, a condition-specific probiotic intervention has a plausible mechanistic rationale that the literature is beginning to support. [likely]

SECTION 5 — IMPLEMENTATION CHALLENGES AND CRITICAL VOICES

The field is not uniformly enthusiastic. You should know the objections.

While the renaming represents a meaningful conceptual advance, its practical impact on clinical outcomes will depend on how consistently the new terminology is adopted across primary care, endocrinology, gynecology, and cardiology. Renaming alone does not resolve existing gaps in screening protocols or access to multidisciplinary care. Longitudinal data will be required to assess whether reclassification translates into measurable improvements in time-to-diagnosis or cardiometabolic outcomes. [certain — this is the correct skeptical position and it is stated in the source literature itself]

Pushback heard during the consensus process was largely framed as “Is it too premature?” and concerns from patient support groups and advocacy organizations that had already branded under the PCOS name. There is also dissatisfaction that retaining “ovarian” in the name does not allow for the possibility, suggested by some early research, of a male form of the syndrome. [certain]

Among patients surveyed, 86% supported the name change due to stigma, confusion, and fragmented care; among clinicians, 71% supported it. [certain — notable that 29% of clinicians were not supportive; this is not a field-wide consensus in the way some coverage implies]

The honest summary of the critical position: The name change is scientifically defensible and clinically necessary. Whether it changes outcomes depends entirely on whether it changes behavior — physician screening behavior, insurer coding behavior, and medical education content. None of those are guaranteed by a journal publication. The critics are right that the hard work starts now. [certain]

SECTION 6 — CARDIOVASCULAR RISK: THE UNDERWEIGHTED STORY

This remains the most undercovered clinical dimension and the most consequential.

Insulin resistance is common in PMOS including in non-obese phenotypes, and is linked to elevated risks of impaired glucose tolerance, gestational diabetes, dyslipidemia, hypertension, and cardiovascular disease. Therapeutic framing shifts toward targeting upstream metabolic and neuroendocrine drivers — specifically insulin resistance — alongside reproductive goals. [certain]

The cardiovascular risk literature in PMOS is robust but clinically underutilized. A 2024 meta-analysis published in Journal of the American Heart Association (Tay CT et al., DOI: 10.1161/JAHA.123.033572) — cited within the Lancet paper itself — confirmed elevated clinical cardiovascular disease risk in PCOS. [certain — peer-reviewed, cited in the consensus paper] This is the dimension most consistently missed by generalist and OB/GYN practitioners who inherited the reproductive framing.

SECTION 7 — GENERAL FIELD SENTIMENT ASSESSMENT

Based on the literature and coverage this week:

What is settled:

• The reclassification is scientifically correct and the process was rigorous [certain]

• GLP-1 agonists have a mechanistically sound and evidence-supported role in PMOS metabolic management [certain]

• The gut-hormone axis is a real and growing area of PMOS research [likely]

• Cardiovascular risk in PMOS is underscreened and undertreated [certain]

What is contested:

• Whether the name change translates to outcome improvement — genuinely unknown [guessing]

• Optimal GLP-1 dosing, timing, and patient selection specifically for reproductive endpoints in PMOS [guessing — data immature]

• Whether tirzepatide outperforms semaglutide specifically in PMOS phenotypes — no direct comparison data yet [guessing]

What is missing from the literature:

• Perimenopausal PMOS data — almost entirely absent. The condition in women over 40 remains dramatically underrepresented in clinical trials [certain — this is a gap, not a finding]

• Long-term cardiovascular outcome data post-GLP-1 initiation in PMOS specifically [certain gap]

• Probiotic intervention RCT data in PMOS with hormonal endpoints [certain gap — this is where ProvaBiome-F sits in the evidence landscape]

SOURCES CITED

1. Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome. The Lancet. May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8 ✅ verified, primary source

2. Cree MG et al. Weight Loss Associated with Semaglutide Use is Linked to Improved Reproductive Measures in PMOS: a Proof-Of-Concept Analysis. Fertility and Sterility. June 2026. DOI: 10.1016/j.fertnstert.2026.06.002 ✅ verified, published June 10, 2026

3. Tay CT et al. 2023 International evidence-based PCOS guideline update — cardiovascular disease. J Am Heart Assoc. 2024;13:e033572. DOI: 10.1161/JAHA.123.033572 ✅ verified, cited within Lancet consensus paper

4. Li C et al. Unraveling the gut microbiota’s role in PCOS. Frontiers in Endocrinology. March 2025. DOI: 10.3389/fendo.2025.1529703 ✅ verified, PubMed indexed

5. Truveta Research. Rising use of GLP-1 medications among women with PCOS. December 2025. ✅ verified, truveta.com, real-world claims data

6. NCT07326111 — PERIODS Trial. University of Bonn. ClinicalTrials.gov. ✅ verified, registered December 2025, currently recruiting

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

You made it to Friday.

You survived the week — the meetings, the meals you grabbed standing up, the sleep that got cut short, the workout you meant to do Tuesday. Your nervous system is coasting into the weekend on fumes and good intentions.

And here is the part nobody tells you:

For women with PMOS, the weekend is not a break from your biology. It is a decision point inside it.

Not a threat. Not a lecture. A genuine opportunity — because the weekend, with its slower pace and slightly more controllable variables, is actually the highest-leverage metabolic window of your week. If you use it well, you don’t just recover. You reset. You set the hormonal and insulin tone for the Monday and Tuesday that come after it.

Two days. That’s all this takes. And most of it feels like living your life.

Let me show you what I mean.

Friday Night Is Not the Enemy. The Crash Is.

The Friday unwind is real and it is warranted. The biology of PMOS just asks one small favor of it.

The cortisol spike that drove your week — the one that kept you sharp and functioning and slightly over-caffeinated — doesn’t switch off the moment you sit on the couch. It tapers. And while it tapers, it is still nudging your insulin upward, still signaling your liver to hold onto glucose, still keeping your inflammatory markers slightly elevated.

Which means the Friday night ritual of wine plus ultra-processed snacks plus a 1am scroll into the void is not neutral. It is cortisol-loaded metabolism meeting the exact inputs that stress it most.

You don’t have to be perfect. You have to be slightly strategic.

One swap. That’s the ask.

The Saturday Morning Window (This One Is Actually Magic)

Here is a fact that deserves more airtime:

Morning cortisol peaks between 6–8am and then declines naturally — and in PMOS, this cortisol curve directly modulates your insulin sensitivity for the rest of the day.

Which means what you do in the first 90 minutes of Saturday morning is, biologically speaking, disproportionately important.

The ritual that works — and that I watch change things in my patients — is almost embarrassingly simple:

Morning light. Protein first. Movement before the phone.

Not a spin class. Not a 5am cold plunge. Just daylight in your eyes within 20 minutes of waking, a protein-anchored first meal (eggs, Greek yogurt, anything that requires chewing), and a walk — even 15 minutes — before you open the apps.

That’s it. That’s the Saturday morning metabolic reset.

It is not a wellness trend. It is cortisol management, insulin priming, and circadian alignment dressed in casual clothes.

🔒 Behind the Paywall: The Full PMOS Weekend Protocol

What follows is the habit-stack I actually build with patients — organized by Friday evening, Saturday, and Sunday — including the specific meal timing windows, the movement sequence that improves insulin sensitivity without spiking cortisol, the sleep architecture tweak that makes Monday morning feel different, and the one lab marker most women with PMOS should check on a Monday morning to see whether their weekend actually moved the needle.

Read more

The renaming of PCOS to Polyendocrine Metabolic Ovarian Syndrome is not a cosmetic change. It is a structural one. It forces us physicians, patients, and the medical establishment alike — to look at this condition through a fundamentally different lens. The word polyendocrine is not decorative. It is a diagnostic mandate.

In the old frame, we treated the ovary as the source. In the new and correct frame, we treat the ovary as the destination, the end organ that bears the consequences of a systemic endocrine and metabolic environment that has been dysregulated, often for years, sometimes for decades, before a diagnosis is made.

This series will take each of those endocrine systems in turn, examine the science with specificity and honesty, and, where relevant, assess the evidence, including the supplement market, which is increasingly crowded and often inadequately grounded. We will not validate what is not supported. We will also not dismiss what the data shows, even when it challenges received wisdom.

The Seven Endocrine Axes in PMOS, A Series Roadmap

Part 1 (This Article): Thyroid — Dysfunction, Testing, and the Supplement Landscape

Part 2: The Insulin-IGF-1 Axis — Hyperinsulinemia as the Central Driver

Part 3: The HPA Axis — Cortisol, Adrenal Androgens, and DHEA-S in PMOS

Part 4: The HPO Axis — LH/FSH Dysregulation and the GnRH Pulse Problem

Part 5: Androgens — Testosterone, SHBG, and the Tissue-Level Story

Part 6: Prolactin, Growth Hormone, and the Supporting Cast

Part 7: The Metabolic Endocrine Axis — Adipokines, Leptin, Adiponectin, and the Fat-Hormone Interface

Each installment will follow the same architecture: the basic science, the clinical implications, a frank evidence assessment, and, where applicable, an honest review of the supplement and nutraceutical landscape that has grown up around each axis. The goal is not to be reflexively skeptical of supplements, nor reflexively credulous. The goal is to give you the science, read it straight, and let it speak.

Now. Let us begin with the thyroid.

PART ONE

The Thyroid and PMOS: What We Know, What We Oversell, and What We Must Not Miss

1. The Thyroid-PMOS Connection Is Real, And Bidirectional

Let me be direct from the outset: the relationship between thyroid dysfunction and PMOS is not a supplement industry invention. It is a documented, peer-reviewed, clinically significant comorbidity with mechanistic plausibility running in both directions. The thyroid does not cause PMOS in the same way insulin resistance does. But thyroid dysfunction, particularly subclinical and overt hypothyroidism, mimics, amplifies, and masks PMOS in ways that carry real clinical consequences if missed.

A 2015 systematic review by Janssen et al., published in Human Reproduction Update, found that women with PCOS had a significantly higher prevalence of thyroid autoimmunity, particularly Hashimoto’s thyroiditis, compared to age- and BMI-matched controls — with odds ratios ranging from 2.07 to 4.0 depending on the population studied.¹ A subsequent meta-analysis by Sinha et al. (2013) reported thyroid peroxidase antibody (TPO-Ab) positivity in approximately 26–27% of PCOS patients compared to 8–10% of controls.²

These are not trivial numbers. They are asking us to check thyroid autoimmunity in every PMOS patient, not as an afterthought, but as part of the primary workup.

Why Thyroid Dysfunction Mimics and Amplifies PMOS

Hypothyroidism, overt or subclinical, does the following, each of which overlaps directly with the PMOS phenotype:

▸ Increases TRH (thyrotropin-releasing hormone), which stimulates prolactin secretion, which in turn suppresses GnRH pulsatility and disrupts the HPO axis, producing menstrual irregularity and anovulation³

▸ Reduces SHBG (sex hormone-binding globulin) synthesis in the liver, thereby increasing free androgen bioavailability — amplifying hyperandrogenism even without a primary increase in androgen production⁴

▸ Impairs glucose metabolism and worsens insulin resistance through reduced GLUT4 expression and impaired insulin receptor signaling — compounding the metabolic core of PMOS⁵

▸ Promotes dyslipidemia elevated LDL, reduced HDL which synergizes with the inherent cardiovascular risk in PMOS⁶

▸ Contributes to weight gain and reduced resting metabolic rate, creating a cycle that feeds back into insulin resistance and visceral adiposity

This is not a parallel pathway. This is the same metabolic and hormonal terrain. A woman with both subclinical hypothyroidism and PMOS is not dealing with two separate conditions. She is dealing with one amplified condition with two contributing axes.

2. The Testing Question: Where Standard of Care Ends and Controversy Begins

Here is where the clinical picture becomes more complicated, and where I will not pretend the medical community speaks with one voice. Because it does not.

What We Agree On: TSH Screening

The American Thyroid Association (ATA) and the Endocrine Society both support TSH screening as the initial test of choice for thyroid dysfunction. A TSH above 4.0–4.5 mIU/L (laboratory-dependent) with a low free T4 constitutes overt hypothyroidism and warrants treatment. This is unambiguous.⁷ Every PMOS patient should have a TSH measured at baseline. This is not controversial. What is controversial is what we do next.

Subclinical Hypothyroidism: The Gray Zone

Subclinical hypothyroidism (SCH), defined as a TSH of 4.0–10 mIU/L with a normal free T4, affects approximately 10% of women of reproductive age. In PMOS populations, that prevalence appears higher. The question of whether to treat SCH is genuinely debated in the endocrinology literature, and I want to present that debate honestly.

The 2019 ATA guidelines do not mandate treatment for SCH in non-pregnant women with TSH below 7.0 mIU/L unless there are specific indications (symptoms, cardiovascular risk, TPO-Ab positivity, fertility concerns).⁸ The 2023 European Thyroid Association guidelines are similarly conservative.⁹ This reflects the reality that most SCH normalizes spontaneously or does not progress to overt hypothyroidism, and randomized controlled trials have not shown consistent benefit from levothyroxine for SCH with TSH < 7.0 in otherwise healthy women.¹⁰

However, and this is critical, the PMOS patient is not an “otherwise healthy woman” in the context of this debate. She has pre-existing insulin resistance, dyslipidemia, androgen excess, and often HPO axis dysregulation. In this context, even a modest increase in TSH may have additive metabolic consequences that a standard population study would not capture. This is a legitimate clinical nuance, not a rationalization.

The T3 Controversy: Where Thyroid Advocacy Runs Ahead of Evidence

I want to address this directly because it is a source of significant confusion for patients, and, frankly, for some clinicians, and the supplement and functional medicine industries have exploited this confusion aggressively.

Free T3 (triiodothyronine) is the biologically active thyroid hormone. T4 (levothyroxine) is a prohormone that must be converted to T3 peripherally by deiodinase enzymes. A subset of patients on standard levothyroxine therapy continue to have symptoms despite normalized TSH, a phenomenon real enough to have generated a literature of its own. Bianco et al. have written extensively on impaired T4-to-T3 conversion as a clinically meaningful entity in some patients, potentially explained by polymorphisms in the DIO2 gene (deiodinase type 2).¹¹

However, and this is where I must be unambiguous, the routine measurement of free T3 as a screening tool in PMOS is not supported by evidence-based guidelines. The ATA does not recommend it as a first-line test. The Endocrine Society does not recommend it. The rationale for T3 measurement in PMOS patients is mechanistically plausible but clinically unvalidated at the population level.¹²

What this means in practice: if you have a PMOS patient with normalized TSH, persistent symptoms, and documented DIO2 polymorphism, a conversation about T3 measurement and combination T4/T3 therapy is legitimate. If you are ordering free T3 on every PMOS patient because a thyroid advocate told you to, you are operating outside the evidence base.

Clinical Testing Recommendations for Thyroid in PMOS — Evidence-Based

✓ TSH: Screen all PMOS patients at baseline. Repeat annually or with symptom change.

✓ Free T4: Order with abnormal TSH (high or low) to classify thyroid status.

✓ TPO Antibodies (anti-TPO): Order in all PMOS patients regardless of TSH autoimmunity changes in clinical trajectory.

✓ Thyroglobulin Antibodies (anti-Tg): Order when anti-TPO is negative but clinical suspicion remains.

△ Free T3: Consider in levothyroxine-treated patients with persistent symptoms and normal TSH. Not a routine screen.

△ Reverse T3: Insufficient evidence to support routine measurement in PMOS. Use selectively and interpret with caution.

✗ Full thyroid panel with RT3 + total T3 + T4 as routine PMOS workup: Not evidence-based at population level.

The Thyroid Supplement Landscape: An Honest Physician’s Review

The thyroid supplement market is one of the most crowded, most lucrative, and most scientifically uneven spaces in nutraceuticals. Estimated at over $1.2 billion annually in the United States, it sits at the intersection of legitimate science, patient frustration with standard care, and aggressive marketing that frequently outpaces the evidence.

I want to do something that is rare in this space: give each major ingredient a genuinely honest grade, not a dismissive “there’s no evidence” (when there is some), and not an enthusiastic endorsement that inflates the data beyond what it supports. Here is my evidence-based review of the most common thyroid-targeted supplements.

Supplement

Claimed Benefit

Evidence Grade

Clinical Reality

Selenium

Reduce TPO-Ab, support T4→T3 conversion

B+

Strongest thyroid supplement evidence. 200 mcg/day reduces TPO-Ab in Hashimoto’s. Clinically meaningful and low risk.

Iodine (high-dose)

Treat “iodine deficiency hypothyroidism”

C−

Excess iodine worsens autoimmune thyroid disease. High-dose supplementation is contraindicated in Hashimoto’s. Widely oversold.

Myo-Inositol + Selenium

Reduce TSH in subclinical hypothyroidism

B

Two RCTs show TSH reduction in SCH. Mechanistically relevant to PMOS given inositol’s insulin-sensitizing role.

Zinc

Support deiodinase enzyme function

C+

Deficiency impairs T4→T3 conversion. Repletion in deficient patients reasonable. Routine supplementation unvalidated.

Ashwagandha (KSM-66)

Normalize TSH and T4 via HPA modulation

B−

One RCT (Sharma 2018) showed TSH and T4 improvement in SCH. Promising but limited data. Cortisol effect may be mediating factor.

Magnesium

Reduce thyroid autoimmunity via anti-inflammatory effect

C+

Low magnesium is associated with higher TPO-Ab. Repletion sensible. Causality unproven.

Vitamin D

Reduce autoimmunity, modulate Treg/Th17 balance

B

Inverse association between vitamin D and TPO-Ab is robust. RCT data mixed but biological plausibility strong. Repletion in deficient PMOS patients is justified.

B12

“Energy and thyroid support”

D

No direct thyroid mechanism. Often added to formulas as a “feel better” ingredient. Relevant only in documented deficiency.

Desiccated Thyroid (NDT)

Full T4 + T3 replacement from porcine source

B−

Contains T3 + T4 in 4:1 ratio (not physiological 20:1). Reduces rT3 in some patients. Evidence inferior to levothyroxine for most patients but legitimate for T3 non-converters. Not a supplement — a prescription medication.

Bladderwrack / Kelp

“Natural iodine” for thyroid

D−

Uncontrolled iodine delivery. Risk of triggering Wolff-Chaikoff effect. Contraindicated in Hashimoto’s. No therapeutic role.

Tyrosine (L-Tyrosine)

Thyroid hormone precursor support

D

Thyroid hormone synthesis is not rate-limited by tyrosine in replete individuals. Theoretical rationale only.

Guggul (Commiphora mukul)

Increase T3 via guggulsterone activity

C

Animal data intriguing. Human RCT data sparse and mixed. Cannot recommend in PMOS currently.

Selenium: The One Thyroid Supplement With Genuine Evidence

Selenium deserves its own section because it is the single most evidence-supported thyroid supplement in the clinical literature, and it happens to be directly relevant to the PMOS population. Selenium is an essential component of the selenoprotein family, which includes glutathione peroxidases, thioredoxin reductases, and — critically — the deiodinase enzymes responsible for T4-to-T3 conversion.

Ventura et al. (2017) conducted a double-blind RCT of 200 mcg/day selenomethionine in 68 Hashimoto’s patients, demonstrating a significant reduction in TPO-Ab (from 1289 ± 212 to 643 ± 165 IU/mL, p < 0.001) and improved thyroid ultrasound echogenicity.¹³ A Cochrane-adjacent systematic review by Wichman et al. (2016) of four RCTs found consistent TPO-Ab reduction with selenomethionine at 200 mcg/day.¹⁴

The mechanism is immunomodulatory: selenium reduces reactive oxygen species in thyroid tissue, which is particularly significant in autoimmune thyroid disease where H₂O₂-mediated oxidative damage drives the inflammatory cascade. In PMOS patients with documented Hashimoto’s thyroiditis, selenium supplementation at 200 mcg/day has a legitimate clinical rationale and a reasonable evidence base.

Important caveat: Selenium toxicity (selenosis) occurs above 400 mcg/day and is a real clinical concern. Supplementation above 200 mcg/day is not supported by additional benefit and increases risk. Food sources: Brazil nuts, tuna, and sardines are adequate for selenium-replete individuals and should be considered first. Routine supplementation in selenium-replete populations without autoimmune thyroid disease is not justified by the evidence.

Iodine: The Supplement Most Likely to Harm Your PMOS Patient

I will say this plainly: high-dose iodine supplementation, particularly the multi-milligram doses marketed in certain “thyroid support” and “iodine loading” protocols, is contraindicated in patients with Hashimoto’s thyroiditis and should be approached with extreme caution in PMOS patients generally.

The Wolff-Chaikoff effect, the transient suppression of thyroid hormone synthesis in response to excess iodine, is a physiological protective mechanism. In individuals with underlying thyroid autoimmunity, this effect may not be transient. Excess iodine increases thyroid peroxidase activity and hydrogen peroxide generation, increasing oxidative damage and stimulating inflammatory cascades in autoimmune thyroid tissue.¹⁵

Leung et al. (2012) demonstrated that iodine excess is associated with increased TPO-Ab titers in susceptible populations.¹⁶ Teng et al.’s landmark study of iodine sufficiency vs. excess in Chinese populations showed higher rates of hypothyroidism and autoimmune thyroiditis in the iodine-excess cohort.¹⁷

Clinical bottom line: If your PMOS patient has Hashimoto’s thyroiditis, which, based on prevalence data, approximately 1 in 4 does, and she is taking a thyroid support formula with high-dose iodine, that supplement is actively working against her. This is not a theoretical risk.

Myo-Inositol + Selenium: The PMOS-Specific Thyroid Story

This combination has attracted genuine research interest, and it lands at the precise intersection of the thyroid axis and the insulin-inositol axis, which is why it is uniquely relevant to PMOS. Nordio and Pajalich (2013) published an RCT in which myo-inositol (600 mg) + selenium (83 mcg) twice daily reduced TSH from a mean of 5.4 to 3.3 mIU/L in women with subclinical hypothyroidism over six months.¹⁸

The proposed mechanism involves inositol’s role as a second messenger in TSH receptor signaling. Inositol triphosphate (IP3) is a downstream effector in the TSH receptor pathway, and inositol insufficiency (which is common in PMOS due to impaired renal reabsorption secondary to insulin resistance) may impair thyroid cell responsiveness.¹⁹ This is mechanistically elegant and clinically plausible. It is also worth noting that this is the same inositol that works on ovarian follicle FSH receptor signaling, the ovarian paradox made famous in the PCOS literature.

A follow-up RCT by Benvenga et al. (2017) confirmed these findings in a larger cohort.²⁰ This is a supplement combination with a legitimate mechanism and replicable RCT data — and it happens to be doubly relevant in PMOS patients given inositol’s established role in insulin sensitization.

Ashwagandha: Promising But Not There Yet

Ashwagandha (Withania somnifera, KSM-66 extract) has emerged as a popular thyroid support ingredient, largely on the basis of a single 2018 double-blind RCT by Sharma et al. published in the Journal of Alternative and Complementary Medicine. That study of 50 subjects with subclinical hypothyroidism found that 600 mg/day KSM-66 significantly improved TSH (reduced from mean 6.0 to 4.9 mIU/L), total T3, and total T4 compared to placebo over 8 weeks.²¹

This is a real, peer-reviewed RCT. It is not fabricated data. But one RCT of 50 subjects is a preliminary signal, not a clinical mandate. The mechanism is likely mediated through HPA axis modulation ashwagandha’s well-documented cortisol-lowering effect may be reducing HPA-axis interference with thyroid hormone synthesis. In PMOS patients with documented HPA dysregulation (high cortisol, elevated DHEA-S), this mechanism has additive logic. But we need larger, longer, better-controlled trials before making definitive recommendations.

Vitamin D: Immune Modulation With Real Thyroid Relevance

Vitamin D deficiency, which is prevalent in PMOS at rates of 67–85% depending on population and definition¹ has a well-documented inverse association with thyroid autoimmunity. The vitamin D receptor (VDR) is expressed on thyroid cells and on T and B lymphocytes. Vitamin D modulates Treg/Th17 balance, promoting regulatory T-cell activity that suppresses autoimmune inflammation.²²

Wang et al. (2015) found that each 10 ng/mL decrease in serum 25(OH)D was associated with a 1.5-fold increase in odds of TPO-Ab positivity.²³ Randomized trial data on vitamin D repletion and TPO-Ab reduction is mixed; some trials show benefit, some do not, and the heterogeneity reflects differences in dosing, baseline vitamin D levels, and study duration. However, given the independent metabolic rationale for vitamin D repletion in PMOS (insulin sensitization, cardiovascular risk reduction, anti-inflammatory effects), repleting vitamin D deficiency in PMOS patients is clinically justified regardless of the thyroid data.

What the Thyroid Advocacy Community Gets Right And Where It Overreaches

I want to be fair here, because the thyroid patient advocacy community and the clinicians who support it have pushed back against a genuine failure of standard endocrinology: the dismissal of symptomatic patients with “normal” TSH. This pushback has legitimacy.

The patient who is told her TSH is 3.8, and everything is fine, while she gains weight, loses hair, feels cognitively impaired, and cannot regulate her temperature that patient is not being treated adequately by a reflex to the reference range. The reference range of 0.4–4.0 mIU/L was derived from a population that included undiagnosed thyroid disease. Garber et al. acknowledged this in the 2012 ATA/AACE guidelines.²⁴ The debate about whether the upper limit of “normal” TSH should be 2.5 or 3.0 in certain populations is a legitimate scientific discussion.

Where Thyroid Advocacy Is Right

▸ The TSH reference range may be too broad for symptomatic patients or those with autoimmunity.

▸ T4-to-T3 conversion impairment is a real clinical entity in a subset of patients.

▸ Hashimoto’s thyroiditis is underdiagnosed; TPO-Ab testing should be routine in PMOS.

▸ The relationship between subclinical hypothyroidism and metabolic dysfunction is real and clinically relevant.

▸ Patient-reported symptoms matter and should not be dismissed when TSH is “normal.”

Where Thyroid Advocacy Overreaches

▸ Routine free T3 and reverse T3 measurement as PMOS screening is not evidence-based.

▸ High-dose iodine supplementation is not supported and may be harmful in Hashimoto’s.

▸ NDT (desiccated thyroid) is not superior to levothyroxine for most patients — the trials do not support this.

▸ The claim that “most thyroid disease is missed” overstates population prevalence data.

▸ Supplement protocols promising to “heal the thyroid naturally” that bypass physician assessment can delay appropriate treatment.

▸ T3-based therapies carry cardiovascular risk if dosed aggressively and should not be driven by patient demand alone.

A Practical Clinical Framework for Thyroid Assessment in PMOS

This is what I do in my practice. It is grounded in the evidence above and reflects the specific clinical context of the PMOS patient, not the general population.

Step 1: Baseline Workup Every PMOS Patient

▸ TSH (serum)

▸ Free T4

▸ Anti-TPO antibodies

▸ Anti-thyroglobulin antibodies (if anti-TPO negative but clinical suspicion)

▸ 25-OH Vitamin D (relevant to both thyroid autoimmunity and PMOS metabolics)

▸ Selenium level if considering supplementation in selenium-replete population

Step 2: Risk Stratification

▸ TSH normal + TPO-Ab negative: Annual recheck, no intervention beyond lifestyle

▸ TSH normal + TPO-Ab positive: Monitor every 6 months; consider selenium 200 mcg/day; vitamin D repletion; avoid high-dose iodine

▸ TSH 4.0–7.0 (SCH) + TPO-Ab positive in PMOS patient: Consider levothyroxine — clinical context overrides the “watchful waiting” default given additive metabolic burden

▸ TSH > 7.0 or overt hypothyroidism: Treat. Non-negotiable.

▸ Euthyroid on levothyroxine + persistent symptoms: Evaluate for DIO2 polymorphism; consider free T3 measurement; discuss T4/T3 combination therapy selectively

Step 3: Supplement Guidance for Thyroid in PMOS

▸ Selenium 200 mcg/day selenomethionine: Recommend in Hashimoto’s-positive PMOS patients — good evidence, low risk

▸ Myo-inositol 600 mg + selenium 83 mcg twice daily: Consider in SCH with PMOS — dual mechanism, two supporting RCTs

▸ Vitamin D: Replete to 40–60 ng/mL in all PMOS patients regardless of thyroid status

▸ Zinc: Replete if deficient; routine supplementation not indicated

▸ Ashwagandha KSM-66: May consider in PMOS patients with documented HPA dysregulation and SCH — acknowledge limited evidence

▸ High-dose iodine, kelp, bladderwrack: Avoid. Potential harm in autoimmune thyroid disease.

The Bottom Line

The thyroid is not the central driver of PMOS. Insulin resistance holds that position and always has. But the thyroid is a meaningful contributing axis, particularly through the autoimmune pathway, and thyroid dysfunction in a PMOS patient creates a compounding clinical problem that we cannot afford to miss or to manage poorly.

The supplement market for thyroid support ranges from genuinely evidence-based (selenium, myo-inositol + selenium, vitamin D) to actively harmful (high-dose iodine in Hashimoto’s patients). The thyroid advocacy community is right to push back against reflexive dismissal of symptomatic patients with borderline TSH. It overreaches when it promotes expensive multi-panel testing, reverse T3 as a routine metric, and NDT as universally superior to levothyroxine.

Our job as physicians, particularly as physicians managing PMOS, is to hold the line between those two failure modes: under-diagnosis and under-treatment on one side, over-testing and supplement-industry-driven over-treatment on the other. The evidence gives us enough to stand on. We do not need to lean on more than it offers.

Next in the series: the insulin-IGF-1 axis, the engine room of PMOS, where the metabolic story truly begins.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. If you want to support hormone balance more consistently, you can learn more about Inositol Plus here: Inositol Plus

References

1. Janssen OE, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150(3):363–369.

2. Sinha U, et al. Thyroid autoimmunity and PCOS: a systematic review and meta-analysis. Hum Reprod. 2013;28(8):2161–2168.

3. Danilovich N, et al. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology. 2000;141:4295–4308.

4. Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med. 1994;121(4):247–251.

5. Maratou E, et al. Thyroid hormone receptors in glucose transport regulation. Nat Rev Endocrinol. 2009;5:17–23.

6. Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96(2):269–281.

7. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults. Thyroid. 2012;22(12):1200–1235. (ATA/AACE).

8. Alexander EK, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum period. Thyroid. 2017;27(3):315–389.

9. Pearce SH, et al. 2013 ETA Guideline: Management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215–228.

10. Stott DJ, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism (TRUST trial). N Engl J Med. 2017;376(26):2534–2544.

11. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571–2579.

12. Idrees T, et al. Free triiodothyronine measurement as a routine test: ATA position statement. Thyroid. 2023;33(3):319–324.

13. Ventura M, et al. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658.

14. Wichman J, et al. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. Thyroid. 2016;26(12):1681–1692.

15. Markou K, et al. Iodine-induced hypothyroidism. Thyroid. 2001;11(5):501–510.

16. Leung AM, Braverman LE. Consequences of excess iodine. Nat Rev Endocrinol. 2014;10:136–142.

17. Teng W, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354(26):2783–2793.

18. Nordio M, Pajalich R. Combined treatment with Myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism. Int J Endocrinol. 2013;2013:434581.

19. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931–936.

20. Benvenga S, et al. Usefulness of l-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism. J Clin Endocrinol Metab. 2001;86:3428–3432.

21. Sharma AK, et al. Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. J Altern Complement Med. 2018;24(3):243–248.

22. Simsek Y, et al. Effects of vitamin D supplementation on thyroid autoimmunity. J Investig Med. 2016;64(3):711–714.

23. Wang J, et al. Vitamin D status and thyroid autoimmunity in a nationwide study. Clin Endocrinol (Oxf). 2015;82(3):388–394.

24. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(Suppl 2):1–207.

June 8, 2026 • Based on 15 articles retrieved from PubMed • Prepared by Dr. Herm Weiss, ObGyn & CEO, Provation Life

EXECUTIVE SUMMARY — TOP 5 FINDINGS THIS WEEK

1. HIIT beats regular-intensity exercise for androgen and insulin resistance reduction in PCOS — a 12-week RCT shows significantly greater FAI, HOMA-IR, and LH/FSH improvements with high-intensity protocols.

2. Apple cider vinegar added to metformin resolves metabolic syndrome in 74.5% of PCOS patients vs. 40.4% in controls — a well-designed 94-patient RCT. Effect sizes are clinically meaningful.

3. Berberine + progesterone significantly reduces testosterone, CRP, TNF-alpha, and IL-6 in PCOS — retrospective but biologically compelling, pointing toward combination nutraceutical protocols.

4. PCOS nomenclature under formal challenge: editorial calls for renaming to ‘Polyendocrine Metabolic Ovarian Syndrome’ (PEMOS). Implications for ICD codes, insurance coverage, and patient identity are substantial.

5. Gestational outcomes vary significantly across PCOS phenotypes — hyperandrogenic phenotypes (A, B, C) carry highest natural-pregnancy risk; Phenotype D emerges as higher risk in ART, challenging one-size-fits-all counseling.

TOP 3 STUDIES — FULL ANALYSIS

Apple Cider Vinegar as Adjunctive Therapy in PCOS + MetS (RCT)

Najafi A et al. | Scientific Reports 2026 | PMID 42215584 | doi:10.1038/s41598-026-55087-7

● STRONG

Study Design:

12-week double-blind RCT (n=94). Women meeting Rotterdam PCOS + NCEP ATP III MetS criteria + HOMA-IR >2.5. Randomized to ACV capsules 1500 mg/day vs. placebo, both on metformin 1500 mg/day.

Key Results:

• MetS resolution: 74.5% (ACV) vs. 40.4% (control), p=0.001

• Significant reductions in HOMA-IR, modified Ferriman-Gallwey score, improvements in FSFI and mPCOSQ quality of life

• Serum testosterone reduced in ACV group

Clinical Implications:

Strong enough to inform clinical counseling. ACV supplementation is low-cost and low-risk with RCT-level support as an adjunct in PCOS+MetS. ACV 1500 mg/day capsules may be more tolerable than liquid. Monitor for GI side effects.

HIIT vs. Regular-Intensity Training on Free Androgen Index in PCOS (RCT)

Celik GE, Ibanoglu MC et al. | BMC Endocrine Disorders 2026 | PMID 42231254 | doi:10.1186/s12902-025-02096-8

● MODERATE

Study Design:

RCT, n=48 PCOS women, 12-week supervised exercise program. HIIT (n=24) vs. regular-intensity training (n=24). Age included as covariate due to baseline group differences.

Key Results:

• HIIT: significantly greater reduction in free androgen index (FAI) and HOMA-IR vs. RIT (p<0.05)

• BMI, LH/FSH ratio, and fasting insulin all more improved in HIIT group

• Bonferroni corrections and Cohen’s d effect sizes applied

Clinical Implications:

HIIT should be the preferred exercise prescription for PCOS patients. Support structured protocols (20-30 min, 3x/week) over continuous moderate-intensity training. Moderate rating due to small sample and short follow-up; direction of effect is consistent with prior literature.

Adjunctive Berberine + Luteal-Phase Progesterone vs. Progesterone Alone in PCOS

Gao L, Ju Y et al. | Frontiers in Endocrinology 2026 | PMID 42255444 | doi:10.3389/fendo.2026.1700331

● MODERATE

Study Design:

3-month retrospective case-control study. Berberine + luteal-phase progesterone vs. progesterone alone. Clinical records reviewed for anthropometric, hormonal, metabolic, and inflammatory outcomes.

Key Results:

• Berberine group: significant reductions in BMI, WHR, total testosterone, fasting insulin, HOMA-IR

• Inflammatory markers CRP, TNF-alpha, IL-6 reduced only in berberine group

• LH/FSH ratio significantly lower in berberine group after adjustment

Clinical Implications:

Berberine’s multi-pathway action (insulin-sensitizing + anti-inflammatory + androgen-lowering) makes it a compelling candidate for combination protocols. The testosterone + CRP + IL-6 trifecta is particularly relevant for Provation Life formulation discussions. Retrospective design limits causality — RCTs needed.

WATCH LIST — EMERGING TRENDS

1. Nutraceutical Combination Protocols Gaining Traction

Three separate papers this week (berberine, ACV, nutrition bibliometric review) point to a maturing evidence base. The next frontier: combination berberine + inositol + ACV protocols in multi-arm RCTs.

2. PCOS Nomenclature Revolution (PEMOS)

The PEMOS renaming push is gaining momentum. Watch for ESHRE/ASRM response in 2026-2027 guidelines. First-mover brands in ‘metabolic women’s health’ framing will benefit.

3. Phenotype-Specific Care Becoming Imperative

Two independent papers highlight phenotype A-D stratification as clinically critical for gestational outcomes. Phenotype-specific algorithms expected in updated guidelines within 2-3 years.

4. AI/LLMs in PCOS Clinical Decision Support

LLMs outperformed ObGyns (76% vs. 50%) in adolescent PCOS diagnosis vignettes. AI-assisted clinical decision tools in ObGyn are moving from theoretical to viable.

Full literature review with all 15 study analyses, detailed ratings, and clinical implications available as a downloadable Word document.

Leave a comment

Provation Life • PCOS Intelligence Series • June 8, 2026
Prepared by Dr. Herm Weiss, ObGyn Physician & CEO • All citations sourced from PubMed

By Dr. Herman Weiss, MD, MBA, FACOG · ProvationLife™ · Free to all subscribers · Series overview

The morning the announcement came through that Polycystic Ovarian Syndrome was being formally reframed as Polyendocrine Metabolic Ovarian Syndrome, my phone did not stop. Patients who had been fighting with pharmacists over metformin prescriptions. Women who had been told by other physicians that their PCOS was “getting better” as they approached perimenopause. Colleagues who had been quietly using insulin-first frameworks for years are finally seeing the field catch up.

I called it. I’ve been calling it for the better part of two decades in clinical practice. And I suspect many of you reading this called it too.

But here’s what I said then and what I’ll say again now: the name change is not the destination. It’s the starting line. Because naming a condition Polyendocrine Metabolic without then delivering on the clinical depth that name implies is just branding. The word polyendocrine is not a descriptor. It is a diagnostic mandate. It obligates us to understand, measure, and treat every endocrine axis implicated in this disease — not just the one that shows up on a standard panel, not just the one we happened to train on, and not just the one the supplement market has decided to capitalize on this month.

That is what this series is.

The ovary is not the villain in PMOS. It never was. The ovary is the last organ standing when everything upstream has failed it. It is the readout of a systemic metabolic and endocrine collapse. Our job has always been to read further upstream than the ultrasound.

— Dr. Herman Weiss, MD, MBA, FACOG

WHAT THIS SERIES IS — AND WHAT IT ISN’T

This is not a PMOS 101 series. If you are looking for a beginner’s guide to polycystic ovary symptoms and lifestyle tips, there are hundreds of those online, and most of them say more or less the same thing. This is not that.

This is a physician-level, evidence-grounded, intellectually honest deep dive into the endocrine architecture of PMOS. Each installment covers one of the seven major hormonal axes implicated in this disease. Each installment does three things: it maps the basic science with the precision it deserves; it translates that science into specific, actionable clinical practice; and it provides an honest, referenced review of the pharmacological and supplement landscape, telling you what the evidence actually supports, what it does not support, and in some cases what is actively contraindicated in this population despite being heavily marketed.

The series is written for clinicians, advanced practitioners, and for the increasingly scientifically sophisticated patients who have spent years researching their own condition and deserve to be given the real information. It is also written for anyone who has ever sat in an exam room with a woman who has been dismissed, undertreated, or given a supplement stack with no mechanistic grounding and wondered: What does she actually need to know?

Every claim is referenced. Every supplement recommendation is graded. Every pharmaceutical recommendation is grounded in the current evidence hierarchy. I will tell you when the evidence is strong, when it is preliminary, and when the wellness market has outrun the science by three or four decades. I will not soften findings in either direction.

THE SEVEN-PART ROADMAP

Here is where we are going. Seven installments. Seven endocrine axes. One complete clinical framework.

What You Will Learn

1. Insulin-IGF-1 Axis

The engine room of PMOS. Why hyperinsulinemia drives every downstream feature of this disease. How to measure it correctly. What actually works — from metformin to myo-inositol to GLP-1 agonists.

2. Thyroid Axis

Why Hashimoto’s thyroiditis appears in 1 in 4 PMOS patients. The T3 controversy and where it crosses the line from clinical nuance to supplement industry exploitation. What selenium, iodine, and Vitamin D actually do.

3. HPA Axis

Cortisol, DHEA-S, and the adrenal androgen phenotype. The “adrenal fatigue” diagnosis that doesn’t exist — and the HPA dysregulation that does. Why sleep is endocrine medicine. What ashwagandha can and cannot do.

4. HPO Axis

The GnRH pulse frequency story. Why the LH:FSH ratio is both useful and misunderstood. The AMH-hypothalamus connection that is rewriting PMOS pathophysiology. Letrozole vs. clomiphene: what the NEJM said and why it changed practice.

5. Androgen Axis

Why total testosterone is an inadequate measure. SHBG as a metabolic biomarker. The 5α-reductase story and why DHT is the tissue villain. Hirsutism, AGA, acne — clinical scoring, treatment hierarchy, and the progestin selection problem nobody talks about enough.

6. Supporting Cast

Prolactin: the confounder, the comorbidity, and the PEG precipitation test that prevents unnecessary MRI. Growth hormone in PMOS. Vitamin D as a steroid hormone. The T3/reverse T3 story in chronic metabolic stress. Vitex agnus-castus: the one supplement with a credible prolactin mechanism.

7. Metabolic Endocrine Axis

Adipokines, leptin resistance, adiponectin, the gut-hormone interface. The GLP-1 revolution and what it means for PMOS specifically. MASLD in PMOS. The cardiovascular risk data we should be quoting at every encounter. The complete series synthesis: one patient, seven axes, one coherent clinical logic.

A CLOSER LOOK AT WHAT’S COMING

Here is a preview of each installment, the clinical questions each one will answer, and why they matter.

PART ONE · The Insulin-IGF-1 Axis: The Engine Room

This is the most important installment in the series because it addresses the most important pathophysiological truth in PMOS: insulin resistance is not a comorbidity. It is not a feature. It is the central generative architecture from which every other endocrine and reproductive dysfunction in this disease cascades. Understanding why requires understanding a molecular paradox — one that took decades of research to characterize and that fundamentally explains why this condition has been so persistently mismanaged.

▸ Why can a woman with a fasting glucose of 88 still be producing massive androgen excess through hyperinsulinemia?

▸ What is the serine kinase defect that simultaneously drives insulin resistance AND upregulates androgen synthesis — from the same molecular lesion?

▸ What does HOMA-IR actually measure and why is it not enough?

▸ Why is myo-inositol deficiency in PMOS not an accident — it is mechanistically predicted by the disease itself?

▸ Berberine, NAC, alpha-lipoic acid, inositol, metformin: what does each one actually do, and which has the evidence to justify the price tag?

PART TWO · The Thyroid Axis: Comorbidity, Amplifier, Diagnostic Trap

One in four PMOS patients has Hashimoto’s thyroiditis. That is not an anecdote. It is a meta-analyzed prevalence figure with odds ratios ranging from 2 to 4 depending on the population studied. And yet routine PMOS workups frequently omit anti-TPO antibodies. Part Two will change how you order and interpret thyroid labs in every PMOS patient you see — and deliver the most honest review of the thyroid supplement market you will find anywhere.

▸ Why does hypothyroidism lower SHBG, worsen hyperandrogenism, and deepen anovulation — even when the TSH is technically “normal”?

▸ The T3/reverse T3 debate: where legitimate clinical nuance ends and supplement industry exploitation begins

▸ Selenium: the one thyroid supplement with genuine RCT evidence — and the exact dose and formulation that matters

▸ High-dose iodine in a patient with Hashimoto’s: why this is not a harmless supplement but an active contraindication

▸ The myo-inositol + selenium combination: why it works on the thyroid and the ovary simultaneously

PART THREE · The HPA Axis: Stress, Cortisol, and the Adrenal PMOS Phenotype

The HPA axis chapter is the one that requires the most intellectual discipline, because the wellness industry has built an entire universe around cortisol dysregulation that is simultaneously partially correct and substantively distorted. “Adrenal fatigue” does not exist as a medical diagnosis. HPA axis dysregulation very much does. Part Three will teach you to tell the difference clinically, biochemically, and pharmacologically.

▸ What does adrenal androgen hyperresponsiveness look like on a lab panel, and which 20–35% of PMOS patients have it as their primary driver?

▸ The 11β-HSD1 enzyme in visceral fat: why serum cortisol can be normal while tissue cortisol is pathologically elevated

▸ Non-classical congenital adrenal hyperplasia: the diagnosis hiding in 1–2% of PMOS presentations that is entirely treatable and routinely missed

▸ Sleep apnea in PMOS: the undiagnosed condition that is simultaneously wrecking insulin sensitivity, cortisol rhythm, GH pulsatility, and reproductive function

▸ Ashwagandha KSM-66, phosphatidylserine, magnesium: what the randomized trial evidence actually say

PART FOUR · The HPO Axis: The Architecture of Anovulation

Part Four arrives at the axis everyone thinks of first when they hear the word “ovary” — and will immediately reframe it. The HPO axis in PMOS is not the source of the disease. It is the anatomical site where the disease becomes clinically visible. Understanding the GnRH pulse frequency story, the AMH-hypothalamus feedback loop, and why the progesterone brake is chronically disengaged is the foundation of rational fertility treatment in this condition.

▸ Why do the follicles arrest at 4–9 mm? What are they waiting for that they will never receive in an uncorrected PMOS environment?

▸ The 2023 Nature-lineage discovery: how elevated AMH from the arrested follicle pool feeds back to the hypothalamus and drives GnRH hypersecretion — making the ovary a co-driver of its own dysfunction

▸ Letrozole vs. clomiphene: the PPCOS II NEJM trial, the live birth rate difference, and why the mechanism explains the result

▸ The perimenopausal PMOS patient who is told she’s improving: why this is one of the most dangerous misunderstandings in women’s health

▸ Why AMH measurement has largely supplanted antral follicle count, and how to use it as a therapeutic monitoring tool

PART FIVE · The Androgen Axis: Where the Hormonal Excess Meets the Patient

This is the installment that most directly addresses what the patient sees and experiences every day. Hirsutism. Acne. Hair thinning. The features that drive women to seek diagnosis in the first place, that carry the greatest psychological burden, and that are most frequently addressed with cosmetic interventions while the metabolic driver continues running unchecked. Part Five will give you the tools to measure androgen status correctly, treat it mechanistically, and counsel your patients on a supplement market that ranges from evidence-based to dangerous.

▸ Why a woman with a “normal” total testosterone can have clinically severe hyperandrogenism — and what SHBG reveals that total testosterone does not

▸ The 5α-reductase paradox: why the same enzyme that drives facial hair growth causes scalp hair loss, and why DHT is the tissue villain serum testosterone can never fully expose

▸ Androgenic alopecia in PMOS: why the treatment window closes permanently, why we miss it systematically, and the four-pillar management framework that actually addresses the cause

▸ The progestin selection problem: why prescribing levonorgestrel-based contraception in a hyperandrogenic PMOS patient is a clinical mismatch

▸ Spearmint tea: a casual wellness remedy or a compound with documented androgen receptor binding activity and two RCTs? The honest answer is more interesting than either extreme.

PART SIX · The Supporting Cast: Prolactin, Growth Hormone, Vitamin D, and the Secondary Axes

Part Six covers the hormones that do not headline the PMOS story but that account for a disproportionate share of the cases that do not respond as expected to standard management. Prolactin is the most common endocrine confounder of the HPO axis — and is routinely measured incorrectly, with results that trigger unnecessary MRI workups in women whose prolactin is physiologically normal. Vitamin D is a steroid hormone whose receptor is expressed in the pancreas, the ovary, the thyroid, the adrenal gland, and the immune system simultaneously. Missing either changes the clinical trajectory.

▸ The pre-analytical protocol for prolactin measurement that your laboratory requisition form does not include — and why it prevents unnecessary pituitary imaging

▸ Macroprolactinemia: the biologically inactive immune complex that immunoassay cannot distinguish from pathological hyperprolactinemia without one simple laboratory step

▸ Why Vitamin D deficiency in PMOS is not explained by sun exposure alone — and why repleting it without magnesium co-administration may produce a blunted response

▸ The T3/reverse T3 story in caloric restriction and metabolic stress: when is it clinically meaningful, when is it a wellness industry narrative, and how do you tell the difference?

▸ Vitex agnus-castus: the mechanistic case for its dopamine D2 agonist activity, the eight RCTs that support it, and the precise clinical phenotype where it belongs

PART SEVEN · The Metabolic Endocrine Axis: Adipokines, Gut Hormones, and the Frontier

The final installment closes the series with the endocrine biology of adipose tissue itself — and with the pharmacological revolution it has generated. Adipose tissue in PMOS is not a passive fat depot. It is a dysfunctional endocrine organ secreting an altered cytokine and hormone profile that perpetuates insulin resistance, suppresses the HPO axis, and accelerates cardiovascular risk simultaneously. And the drugs targeting this system — GLP-1 receptor agonists — represent the most significant therapeutic advance in PMOS since metformin was introduced. Part Seven will tell you exactly what the evidence supports, what it does not, and how to synthesize seven installments of endocrine architecture into a single coherent clinical approach for every PMOS patient you see.

▸ Why adiponectin is the adipokine that predicts T2DM progression better than fasting glucose in PMOS cohorts — and what actually raises it

▸ The GLP-1 deficit in PMOS: why women with this condition produce less incretin response to meals, what that means for the postprandial insulin cycle, and why GLP-1 agonists are not just weight loss drugs in this population

▸ Semaglutide vs. metformin head-to-head in PMOS: the 2023 RCT data, the live-birth rate difference, the lean mass loss problem, and what the evidence actually says about sequencing

▸ MASLD in PMOS: prevalence, the transaminase screening failure, and why semaglutide is now the most evidence-supported pharmacological intervention for hepatic steatohepatitis in this population

▸ The complete synthesis: one master clinical table across all seven axes axis, primary driver, key labs, first-line pharmacotherapy, first-line supplement the clinical framework that takes everything in this series and makes it immediately usable

WHO THIS IS FOR

This series is written for:

Physicians and advanced practice clinicians managing PMOS in any specialty — OB/GYN, endocrinology, internal medicine, family medicine, reproductive endocrinology. The mechanisms are universal. The clinical applications are immediate.

Registered dietitians, health coaches, and allied health professionals who work with PMOS patients and want a mechanistic foundation for the nutritional and supplement recommendations they make. If you are going to recommend inositol or berberine or selenium, you should understand exactly why at the molecular level.

The well-researched patient who has spent years in forums, Facebook groups, and medical databases trying to understand why the standard “just lose weight and take the pill” advice has never fully addressed her disease. You deserve the same information your physicians have access to — and in some cases, more of it than they were given in training.

Anyone who has ever looked at a PMOS management plan that stops at cycle regulation and fertility and wondered: what about the cardiovascular risk? What about the insulin resistance that will still be there at 60? What about the endometrium? What about the patient in the perimenopausal transition who is being told she is getting better when she is entering her highest-risk metabolic decade?

A NOTE ON THE SUPPLEMENT REVIEWS

Each installment in this series includes a structured review of the supplement and nutraceutical landscape relevant to that axis. I want to be clear about the editorial standard I am holding myself to in these reviews, because it is different from what you will find in most wellness content and in most physician content:

I will not dismiss what the evidence supports because it comes from a supplement bottle rather than a pharmaceutical manufacturer. Myo-inositol has multiple randomized controlled trials showing clinical equivalence to metformin in specific endpoints. Selenium has a Cochrane-adjacent systematic review supporting its use in Hashimoto’s thyroiditis. These are not anecdotes. They are data, and they deserve to be treated as data.

I will not endorse what the evidence does not support because a product is popular, well-marketed, or intuitively appealing. High-dose iodine in a Hashimoto’s patient is contraindicated. DHEA supplementation in a hyperandrogenic PMOS patient is predictably harmful endocrine pharmacology. “Adrenal fatigue” protocols are not supported by the medical literature regardless of how passionately their advocates present them.

Every supplement will receive an evidence grade (A through D) with explicit rationale. The grade is based on the quality, quantity, and replicability of human clinical data — not on mechanistic plausibility alone, not on marketing materials, and not on patient testimonials.

The supplement market targeting PMOS is worth billions of dollars annually. Some of that money goes toward products with genuine clinical rationale. Much of it does not. Our patients deserve to know which is which.

THE PERSONAL DIMENSION

I have been practicing obstetrics and gynecology for 25 years. I have been managing PMOS with an insulin-first metabolic framework for most of that time — long before the name change made that framework official. And in those 25 years, I have watched this disease accumulate its consequences in women who were not given the tools to understand what was happening in their own bodies.

The woman who was told at 24 that she just needed to lose weight and come back when she wanted to get pregnant. The woman at 38 who arrived with a fatty liver, pre-diabetes, and androgenic alopecia that had been progressing for a decade while she was prescribed different formulations of the pill. The woman at 52 who was told her PCOS was “getting better” as her cycles regularized in perimenopause — and who six years later had a cardiovascular event that a metabolic risk profile from her thirties could have predicted.

These are not cautionary tales I invented. They are clinical realities I have witnessed repeatedly over a career in women’s medicine. And they are preventable — not entirely, not in every case, but overwhelmingly — when we bring the full endocrine architecture of this disease to bear on management from the moment of diagnosis.

PMOS is finally named correctly. The word polyendocrine is finally in the title. Now the clinical practice has to earn that title. This series is my contribution to that project.

The name change is not the destination. It’s the obligation. Naming this disease polyendocrine metabolic means we are now accountable to practicing it that way.

— Dr. Herman Weiss, MD, MBA, FACOG

HOW TO READ THIS SERIES

Each installment is designed to stand alone. If you come to this series at Part Four, you will not be lost. But the series is also designed as a cumulative architecture: each installment builds on the mechanisms established in the previous ones, and by the time you reach Part Seven, the clinical synthesis will be visible in a way it cannot be from any single installment alone.

Each installment will follow a consistent structure: the foundational biology, the clinical implications, the laboratory assessment framework, and the supplement/pharmacological review. The tone throughout will be what I hope characterizes everything I write and say on this platform: informed, direct, and honest about uncertainty. I will not pretend to know more than the evidence supports. I will not retreat from what the evidence clearly shows because it is inconvenient for a popular narrative.

Premium subscribers will receive each installment in full as both a Substack article and a formatted clinical reference document, printable, annotated, and organized for direct use in practice or for sharing with patients.

The PMOS Endocrine Deep Dive Series — Release Schedule

Part 1: The Insulin-IGF-1 Axis — The Engine Room

Part 2: The Thyroid Axis — Comorbidity, Amplifier, Diagnostic Trap

Part 3: The HPA Axis — Cortisol, DHEA-S, and the Adrenal PMOS Phenotype

Part 4: The HPO Axis — The Architecture of Anovulation

Part 5: The Androgen Axis — Where the Hormonal Excess Meets the Patient

Part 6: The Supporting Cast — Prolactin, Growth Hormone, Vitamin D, and the Secondary Axes

Part 7: The Metabolic Endocrine Axis — Adipokines, Gut Hormones, and the Complete Series Synthesis

All parts are available now for Premium subscribers.

Share this introduction with anyone who has been told their PCOS is “just a reproductive issue.” It is not. It never was.

Let’s get to work.

— Dr. Herman Weiss, MD, MBA, FACOG

Founder and CEO, ProvationLife™ · Host, The Metabolic Fix

If this resonates, share it. The woman who has been told her PCOS isn’t that serious needs to read this. The physician who has never ordered an anti-TPO antibody in a PCOS patient needs to read this. The dietitian who has been recommending high-dose iodine for thyroid support in PMOS patients needs to read this. The series is free to share. · @hweissmd

ProvationLife™ · The Metabolic Fix · @hweissmd · PMOS Endocrine Series — Introduction

She sat across from me, 46 years old, sharp, self-aware, and visibly frustrated. She’d spent decades understanding her body — the insulin swings, the hair changes, the way her energy crashed in a predictable rhythm she’d learned to manage through sheer discipline and trial and error. She’d built a life around this condition.

And then a physician told her: “You don’t need to worry about PCOS anymore. You’re past your childbearing years.”

I put my hand on my forehead.

Not out of frustration with her. Out of grief for how many women have heard some version of that sentence. How many have been handed a permission slip to stop paying attention to something that never stopped mattering.

PCOS — now being reclassified in the medical literature as PMOS: Polyendocrine Metabolic Ovarian Syndrome — was never a fertility condition wearing a hormonal costume. It was always a whole-life metabolic disorder that happened to show up first in the reproductive years because that’s when the symptoms were loud enough to get a diagnosis.

The ovaries were just the first organ brave enough to raise its hand.

What the Reclassification of PCOS to PMOS Actually Means

The May 2026 Lancet reclassification to PMOS is not a bureaucratic rename. It is a correction of a 30-year clinical mistake — the mistake of framing this condition through the narrow lens of reproduction.

PMOS is a polyendocrine disorder. That means it doesn’t live in one system. It spans the ovaries, the adrenal axis, the pancreas, the gut, the liver, and the brain. The metabolic dysfunction at its core — insulin resistance, chronic low-grade inflammation, dysregulated androgens — does not retire when the period stops.

If anything, the perimenopausal transition amplifies it.

Here is what clinicians should have been saying for decades:

“Your diagnosis today is a metabolic roadmap for the rest of your life. The choices you make in your 20s, 30s, and 40s will determine what your 50s, 60s, and 70s look like.”

Most women never heard that sentence. This post is for them.

The Early Warning Signs No One Connects to PMOS

The tragedy of PMOS is that its earliest signals are almost universally dismissed, minimized, or attributed to lifestyle — as if lifestyle and biology exist in separate rooms.

Markers to watch for, beginning in adolescence:

• Irregular cycles from the start — not just “normal teen irregularity,” but persistent, unpredictable cycles beyond 2 years post-menarche

• Acanthosis nigricans — darkened, velvety skin at the neck, underarms, or groin — one of the earliest visible signs of insulin resistance

• Acne that doesn’t respond to standard treatment, particularly along the jawline and chin

• Elevated fasting insulin (not just fasting glucose — insulin rises first, often years before glucose moves)

• Elevated triglycerides with low HDL — the classic dyslipidemia pattern of insulin resistance, visible in teenage bloodwork

• Unexplained fatigue, especially post-carbohydrate

• Difficulty with weight regulation disproportionate to caloric intake

• Family history of T2DM, early cardiovascular disease, or metabolic syndrome — PMOS is heritable; a mother or aunt with “bad blood sugar” may be the most important clue in the room

• Elevated LH:FSH ratio on early cycle bloodwork

• Androgens trending high — even within “normal” lab ranges, trajectory matters

None of these in isolation makes a diagnosis. But a clinician trained to see PMOS as a metabolic syndrome will recognize the constellation — and act early, when action changes outcomes most.

Why the Perimenopausal Years Are the Danger Zone

Here is the biology that my patient’s prior physician missed entirely:

Estrogen is metabolically protective. It improves insulin sensitivity. It modulates inflammation. It supports cardiovascular endothelium.

As estrogen declines through perimenopause, women with underlying PMOS lose that protection on top of the metabolic dysfunction they already carried. The result is a compounding risk that standard screening frameworks — designed for average-risk women — systematically underestimate.

Women with PMOS entering perimenopause face elevated risk for:

• Type 2 diabetes (2–4x higher lifetime risk)

• Cardiovascular disease — earlier onset, more aggressive progression

• Non-alcoholic fatty liver disease

• Sleep apnea (vastly underdiagnosed in women)

• Endometrial hyperplasia due to unopposed estrogen from anovulation

• Cognitive changes — emerging research links insulin resistance to accelerated neurological aging

This is not a list to frighten you. It is a list to orient you. Because every single item on it is modifiable — if you start early enough, and if you have a clinical team that understands what they’re dealing with.

The Diagnosis Should Have Been a Starting Line, Not a Label

When I see a 19-year-old with PMOS, I do not think: fertility patient.

I think: here is a woman who, if we intervene thoughtfully right now, may never develop T2DM. May never have a cardiac event at 58. May never sit across from a physician at 70 and hear that her “metabolic syndrome” came out of nowhere.

The PMOS diagnosis is one of the most powerful preventive medicine opportunities in all of women’s health. It is a biological signal, years or decades before damage accumulates, that the metabolic machinery needs support.

A 23-year-old diagnosed with PMOS who understands what she is managing — and has the clinical guidance to act on it — has a fundamentally different trajectory than one who is told to “lose weight, take the pill, and come back when you want to get pregnant.”

That difference is what we build at ProvationLife. That difference is the conversation I’m trying to create.

What follows is the clinical action framework I walk through with my own patients — the lifestyle interventions with the strongest evidence base, the supplement and nutritional strategies that actually move the needle, and the specific lab panels I recommend by life stage. This is the roadmap your PMOS diagnosis should have come with.

The PMOS Life-Stage Intervention Framework

(For members — the evidence-based protocol, by decade)

Read more

I remember exactly where I was when I saw it.

The announcement was official. Polycystic Ovarian Syndrome, the name that has defined, and I would argue confined, millions of women for nearly a century, was being reframed as Polyendocrine Metabolic Ovarian Syndrome. PMOS.

I called it. I’ve been calling it for years.

And immediately, immediately, my phone exploded.

First: Take Your Credit. I Mean It.

Before I say anything else, I want to address the wave of posts and “told you so’s” that flooded every medical social media platform within hours of the announcement. The physicians, researchers, dietitians, and yes, even the patients who have been screaming into the void for decades that this was never just about the ovaries, take your credit. You earned it.

Who cares who planted the flag first? What matters is that we are finally, collectively, talking about this the right way. And when the medical establishment moves, even slowly, even grudgingly, in the right direction, we celebrate it. Because our patients deserve that celebration more than anyone.

But then we get back to work. Because the name change is only the beginning.

Why PCOS Was Always the Wrong Name

Here is what I have said in my office, in lectures, on this newsletter, and in peer-reviewed literature. The ovary is not the villain. The ovary is the victim.

For 85 years, we named this condition after one of its most visible but least causative features, polycystic-appearing ovaries, and in doing so, we set in motion an entire generation of clinical misdirection. We sent women to gynecologists when they needed endocrinologists. We focused on the cysts when we should have been tracking insulin. We treated a metabolic inferno with a reproductive garden hose.

The Rotterdam criteria, as useful as they have been, essentially enshrined this confusion into diagnostic gospel. You could meet PCOS criteria with two of three features. Irregular cycles, hyperandrogenism, or polycystic ovaries on ultrasound. Insulin resistance? Metabolic dysfunction? Not even in the criteria. Not required. Not formally assessed.

We built an entire diagnostic architecture on a foundation that missed the point.

What PMOS Actually Means and Why It Matters Clinically

The new framing, Polyendocrine Metabolic Ovarian Syndrome, changes the story in three critical ways:

1. The endocrine axis comes first. We are now explicitly acknowledging that this is a disorder of hormonal dysregulation that spans multiple endocrine systems — not just gonadal function. The HPO axis, the adrenal contribution, thyroid interplay, and critically, the insulin-IGF-1 signaling axis. These are not peripheral features. They are the engine of this disease.

2. Metabolism is structural, not optional. By embedding “metabolic” into the name itself, we can no longer treat insulin resistance as a comorbidity or a coincidence. It is part of the core diagnosis. This is not a footnote. This is the title of the paper.

3. The ovarian manifestation is downstream. The ovaries are responding to a systemic hormonal and metabolic environment that is fundamentally disordered. The cysts, the anovulation, and the androgen excess at the follicular level are outputs. They are the smoke. The fire is metabolic.

This is not semantics. This is a clinical paradigm shift, and it has real consequences for every woman sitting in a waiting room right now with a diagnosis that has confused her for years.

The Texts and Calls Started the Day of the Announcement

I am not exaggerating when I tell you that the morning after the announcement went live, my phone did not stop.

One text in particular has stayed with me. A patient, a woman I’ve been managing for three years, sent me a message that said simply: “Does this mean I wasn’t crazy?”

She wasn’t crazy. She was right. And she had been told, implicitly and sometimes explicitly, that the drugs she needed were “diabetes drugs,” that her metabolic concerns were secondary, that the primary issue was reproductive and manageable with the pill.

She’d had to fight with her pharmacist, genuinely fight, argue, explain that yes, she has a prescription for metformin, and no, she does not have diabetes. Her doctor prescribed it for other reasons. She had to justify a treatment decision made by a board-certified physician to someone who was reading off a drug indication list that hadn’t caught up with the clinical science.

That is what happens when the name is wrong. The name informs the reimbursement. The reimbursement informs the pharmacy. The pharmacy informs the patient. And the patient, standing at the counter, has to defend her own diagnosis.

PMOS fixes this. Not completely. Not overnight. But it starts fixing it.

The Comment That Made Me Furious

One thing I cannot let pass without direct address: I had a patient come in who had been told by another physician, a physician, that perimenopausal women don’t need to worry about PCOS anymore.

I want to sit with that for a moment.

The logic, presumably, is that if PCOS is fundamentally a reproductive disorder, then once the reproductive window is closing, the condition resolves or becomes irrelevant. Out of ovulatory concern, out of mind.

This is not just wrong. This is dangerous.

Because here is what actually happens to women with PCOS, now PMOS, as they move through perimenopause: their metabolic risk accelerates. The hyperinsulinemia doesn’t disappear when estrogen declines; it compounds. The cardiovascular risk profile, already elevated in PCOS, gets an additional push from the hormonal transition. The visceral adiposity that has been building for decades doesn’t stop building. Non-alcoholic fatty liver disease, type 2 diabetes, and hypertension. These are not conditions that respect the menopause boundary.

Telling a woman with PMOS that she can stop worrying about perimenopause is like telling someone with a genetic lipid disorder that their cholesterol stops mattering at retirement. The condition doesn’t end. The risk doesn’t end. The need for monitoring and metabolic management doesn’t end.

PCOS, PMOS, is a lifelong metabolic condition with reproductive manifestations. Not a reproductive condition that occasionally has metabolic features.

What This Means Going Forward

I will be honest with you. Part of me exhaled when the announcement came through. Not because I needed the validation, though I will accept it, but because this is what liberation looks like when you’ve been fighting an upstream current for years.

Other physicians, researchers, and endocrinologists are now doing the heavy lifting to realign the field. The institutional machinery of medicine, the guidelines committees, the board certifications, the CME modules, and the pharmacy databases will slowly, inevitably follow. And that machinery matters, because it is what reaches the patients who will never find a Substack like this one.

But for those of you reading this right now, whether you are a clinician, a researcher, or a woman sitting with a diagnosis that has never fully made sense to you — hear this clearly:

You were not wrong. The name was wrong.

The ovaries didn’t start this. They were just the part we could see on the ultrasound.

Now we have a name that finally tells the truth. And with the right name, we can finally build the right treatment.

Dr. Herman Weiss, MD, MBA, FACOG is a board-certified OB/GYN with 25 years of clinical experience and the CEO and Founder of ProvationLife™, a physician-led women’s metabolic health company. Follow him @hweissmd on LinkedIn, Instagram, and Substack. Listen to The Metabolic Fix wherever you get your podcasts.

If this resonated with you, share it with a woman who has been told her PCOS “isn’t that serious.” It is. And now, finally, the name says so.

P.S. If you want a deeper, step-by-step approach to managing PMOS, you can explore the master class here: PMOS Master Class

Founder & CEO, ProvationLife™ | Host, The Metabolic Fix | Board-Certified OB/GYN

25 Years Clinical Practice in Women’s Metabolic Health

Introduction

Something shifted in my exam room this week.

Women who have been my patients for years — women who have been living with PCOS for a decade or more — are coming in differently. They’ve read the Lancet article. They’ve seen the discussion online. They know that a serious proposal to rename their condition has been gaining scientific momentum, and they want to understand what it means for them.

The new name is PMOS: Polycystic Metabolic-Ovarian Syndrome. The addition of a single word — Metabolic — may seem like academic housekeeping. It is not. It is a paradigm correction that has been needed for thirty years, and the questions my patients are asking in response to it reveal exactly how much damage the old framing caused.

Below I’ve organized the five most common questions I’m now fielding in clinical practice around this name change. But I’m not stopping at the questions. For each one, I’m giving you the metabolic intervention that actually follows from the answer — because the purpose of renaming this condition is not semantic satisfaction. It is clinical action.

If you have PCOS — PMOS — and from this point forward I will use both terms interchangeably — this is the reframe your care has been waiting for.

PART ONE

The Five Questions

01 THE DIAGNOSIS QUESTION

“Does this mean my diagnosis is wrong?”

The first thing I hear when a patient learns about PMOS is some version of panic. Years of living with PCOS — the labs, the medications, the grief — and now I’m telling her the name has changed. The look on her face says: did someone get this wrong?

Your diagnosis was never wrong. PCOS was always real. What changed is our understanding of what was driving it — and that changes everything about how we treat it.

Polycystic Metabolic-Ovarian Syndrome. That’s what PMOS stands for. The Metabolic is the new word, and it is the most important word that has ever been inserted into this diagnosis. Because here is what 25 years of clinical practice has taught me: the cysts were never the disease. They were the symptom of a disease we were describing backwards.

The old name — Polycystic Ovary Syndrome — pointed the finger at the ovary. So generations of women were told their ovaries were the problem. The irregular cycles, the androgen excess, the infertility — all ovarian pathology. The metabolic dysfunction underneath it? Background noise. Weight management advice. Lifestyle recommendations buried on page three of the visit summary.

PMOS does not change what happened to you. It changes what we do next. And what we do next is treat the root — which is metabolic.

“The cysts were never the disease. They were a downstream signal of a metabolic system that had been dysregulated, often for years, before a single follicle became visible on ultrasound.”

— Herman Weiss, MD, MBA, FACOG

02 THE WEIGHT QUESTION

“Why has no one ever told me that weight loss is supposed to be this hard?”

This question does not come with curiosity. It comes with years of accumulated shame. The calorie counting. The diets. The workouts. The doctor who said ‘just lose five percent of your body weight’ like it was a matter of willpower. I hear this and I feel the weight of what medicine failed to explain.

It is harder. Measurably, biochemically, mechanistically harder. And you were told it wasn’t, which is one of the most damaging things we have done to women with this condition.

Here is the mechanism. PMOS is, at its core, a hyperinsulinemic state. Insulin is elevated — often significantly elevated — even in women whose fasting glucose looks perfectly normal. And insulin is the master fat-storage hormone. When insulin is chronically elevated, your adipose tissue receives a continuous biochemical signal to store, not release, energy. You are working against your own hormonal environment every time you try to create a caloric deficit.

Add to this: elevated androgens suppress adiponectin, an anti-inflammatory adipokine that promotes fat oxidation. Leptin resistance — common in PMOS — blunts satiety signaling so hunger is amplified. And cortisol dysregulation, which is endemic in this condition, preferentially deposits visceral fat regardless of total caloric intake.

You were not failing. You were fighting a biochemical tide while being told the water was calm. PMOS names that tide. And naming it means we can finally work with it instead of pretending it doesn’t exist.

“When insulin is chronically elevated, your body receives a continuous signal to store energy, not release it. Willpower cannot override a hormonal instruction written in the language of your own metabolism.”

— Herman Weiss, MD, MBA, FACOG

03 THE FERTILITY QUESTION

“Does PMOS change anything about my ability to get pregnant?”

This one lands differently depending on where a woman is in her journey. For some it’s urgent — she’s been trying for two years. For others it’s future-facing, still theoretical. But it is always present, always weighed.

The biology of anovulation in this condition has not changed. What has changed is our ability to address the root cause rather than just the downstream symptom.

In PMOS, the most common driver of anovulation is hyperinsulinemia. Elevated insulin stimulates ovarian theca cells to produce excess androgens, which disrupts follicular maturation and prevents ovulation. We have been treating this with ovulation induction agents — clomiphene, letrozole — which work on the symptom. PMOS now frames insulin as the primary target.

What this means practically: metabolic optimization should come before, not after, ovulation induction. Insulin sensitization — whether through diet, exercise, inositol, metformin, or some combination — can restore ovulatory function in a meaningful percentage of women before we ever write an ovulation induction prescription.

The PMOS framework does not eliminate the need for reproductive intervention. It changes the sequence. And in that sequence, many women may find they need far less intervention than they expected.

“Metabolic optimization is not the consolation prize before fertility treatment. In PMOS, it is often the fertility treatment — and it is the one we have been systematically deprioritizing.”

— Herman Weiss, MD, MBA, FACOG

04 THE PERIMENOPAUSE QUESTION

“I am in my mid-forties — is this the same thing returning?”

This question is being asked by a growing cohort of women diagnosed in their twenties, managed symptomatically for two decades, now watching symptoms return with new intensity — anxiety, brain fog, weight that won’t move, unpredictable cycles. They’re right to wonder if this is connected.

It is connected. And the connection is metabolic.

Perimenopause and PMOS both involve hormonal flux but converge on a shared metabolic substrate. As estrogen declines in perimenopause, insulin sensitivity decreases — a direct, well-documented effect of estrogen withdrawal on peripheral glucose disposal. For a woman who has been living with subclinical insulin resistance for twenty years, this additional metabolic stress can unmask or amplify symptoms that had been partially controlled.

The brain fog, the mood instability, the sleep disruption, the visceral weight gain — these are not purely estrogenic symptoms. They are metabolic symptoms. And in the woman with longstanding PMOS entering perimenopause, the two systems are dysregulating simultaneously.

This matters because treatment cannot be purely hormonal. Adding estrogen may help. But if the underlying insulin resistance is not addressed, the metabolic cascade continues underneath the hormonal intervention. We are managing two overlapping metabolic transitions. Both must be treated.

“When a woman with PMOS enters perimenopause, two metabolic systems begin to destabilize simultaneously. The approach that treats only one of them will leave the other unaddressed — and she will feel it.”

— Herman Weiss, MD, MBA, FACOG

05 THE MEDICATION QUESTION

“I have been on the pill for twelve years to manage my PCOS. Was that actually treating anything?”

I take a breath before answering this one, because the honest answer is complicated. The oral contraceptive pill is one of the most prescribed interventions in the history of PCOS management. PMOS reframes what treatment actually means.

The pill managed symptoms. It did not treat the underlying condition. And for many women, that distinction has been blurred for a decade or more.

Oral contraceptives suppress ovarian androgen production and provide cycle regularity. Those are real clinical benefits. But here is what the pill cannot do: it cannot improve insulin sensitivity. In fact, certain formulations can worsen it. It cannot address the gut microbiome dysregulation that drives the estrobolome disruption common in PMOS. It cannot reduce chronic systemic inflammation.

So for twelve years, the symptom was managed and the disease progressed. The PMOS framework asks us to return to that foundational question: what is the metabolic state of this patient, and what would it take to actually change it?

That is not an accusation against the physicians who prescribed the pill. It is an honest reckoning with what we defined as treatment — and what we should have been asking all along.

“The pill regulated the cycle. It did not regulate the metabolism. For millions of women, those twelve years of management were twelve years of downstream symptom suppression while the root cause ran uncontested.”

— Herman Weiss, MD, MBA, FACOG

PART TWO

The Five Recommendations

The name change is not the intervention. This is.

Read more

1. What is PMOS, and is it actually different from PCOS?
   For women who were diagnosed with PCOS years ago, what does this name change really mean?

   Yes — and the distinction matters more than you might think. PMOS stands for Polycystic Metabolic-Ovarian Syndrome. It’s not just a rebranding exercise. It’s a scientific correction that’s been decades overdue. The old name, PCOS — Polycystic Ovary Syndrome — told women this was a problem with their ovaries and their cysts. But here’s the clinical reality: the ovaries are not the source of the problem. They’re a downstream target. The real driver is a complex interplay of insulin resistance, metabolic dysregulation, androgen excess, and chronic low-grade inflammation. The ovaries respond to that environment — they don’t create it. For women who were diagnosed with PCOS years ago, this name change means your diagnosis finally reflects what’s actually happening in your body. It means your weight struggles, your brain fog, your fatigue, your cardiovascular risk — these aren’t side effects. They’re central features of the same underlying condition. It means you weren’t imagining things when “it’s just a hormonal issue” never felt like the whole story. As a physician, I’ve spent 25 years watching women leave appointments feeling blamed and confused. PMOS is the beginning of an honest conversation.
   
   

2. Why did it take medicine so long to rename this condition?
   If so many women felt misunderstood by the term PCOS, what was the delay?

   Medicine moves slowly when money and inertia are aligned. PCOS as a term has been embedded in ICD codes, insurance billing, pharmaceutical trials, research grants, and medical education for over 80 years. Changing a name isn’t just a semantic decision — it requires consensus across specialties, regulatory bodies, and institutions that don’t always communicate well with each other. But I’ll be direct about the other part of the answer: women’s health has historically been underfunded, understudied, and underrepresented in research. Conditions that predominantly affect women — PCOS, endometriosis, fibroids, perimenopause — have been systematically deprioritized in medical literature for generations. That’s not opinion; that’s documented funding disparity. The good news is that the metabolic science has now reached a tipping point. The explosion of research around insulin resistance, the microbiome, mitochondrial function, and the gut-hormone axis has made the old framing impossible to defend. The name PMOS is beginning to appear in the academic literature, and I believe it will become the standard within this decade. For patients who felt dismissed for years? Your frustration was valid. The science caught up to your experience — not the other way around.
   
   

3. Can a woman have PMOS even if her ultrasound shows no ovarian cysts?
   What should women know if they have symptoms like irregular cycles, acne, weight gain, or hair changes, but their doctor says the ultrasound is “normal”?

   Absolutely. And this is one of the most consequential misunderstandings in women’s health today. Under the Rotterdam Criteria — which is still the most widely used diagnostic framework — you only need two of three findings to be diagnosed: irregular cycles, elevated androgens, or polycystic ovarian morphology on ultrasound. That means a “normal” ultrasound does not rule out this condition. Full stop. The name “polycystic” has caused enormous harm here. Women come in with irregular cycles, acne, hirsutism, insulin resistance, and weight gain — textbook PMOS — and they’re told they’re fine because the ultrasound didn’t show the classic “string of pearls.” That’s a diagnostic failure, not a clean bill of health. What I tell women in my practice: if you have two or more of the following — irregular periods, unexplained weight gain especially around the midsection, acne or oily skin that doesn’t respond normally to treatment, excess facial or body hair, hair thinning on the scalp, or a first-degree relative with PCOS or type 2 diabetes — you deserve a full hormonal and metabolic workup. That means fasting insulin, HOMA-IR, total and free testosterone, DHEA-S, SHBG, fasting glucose, HbA1c, and a full lipid panel. Not just an ultrasound. Your symptoms are data. Don’t let a single normal test convince you otherwise
   
   

4. Why does PMOS make weight loss so much harder?
   What is happening hormonally or metabolically that makes the usual advice to “eat less and move more” feel so frustrating?

   Because “eat less and move more” is advice built for a normally functioning metabolic system. PMOS is, at its core, a metabolic condition — and the metabolic machinery is broken in specific, measurable ways. Here’s what’s actually happening. First: insulin resistance. When cells don’t respond properly to insulin, glucose can’t be efficiently cleared from the bloodstream. The pancreas compensates by producing more insulin. Chronically elevated insulin is a powerful fat-storage signal, particularly for visceral adipose tissue. You’re not overeating your way to weight gain — you’re insulin-resistant, and your body is doing exactly what elevated insulin tells it to do. Second: hyperandrogenism. Elevated androgens — testosterone, DHEA-S — shift fat distribution toward the abdomen and interfere with adipose tissue metabolism. They also amplify insulin resistance. It’s a cycle. Third: disrupted hunger signaling. Women with PMOS frequently have leptin resistance and altered ghrelin patterns, which means the hormonal signals that should tell your brain “I’m full” or “I’m not hungry anymore” are misfiring. This is not a willpower problem. This is a signaling problem. Fourth: the gut microbiome. Emerging research — and I find this compelling — shows that dysbiosis, meaning an imbalanced gut microbial community, impairs estrogen metabolism through the estrobolome, drives systemic inflammation, and worsens insulin sensitivity. Your gut is not peripheral to PMOS. It may be central to it. When I hear a woman say she’s eating 1,400 calories, exercising five days a week, and still gaining weight — I don’t question her effort. I look for the metabolic blockade.
   
   

5. Is there one best diet for PMOS, or does that question miss the point?
   How should women think about keto, low GI, Mediterranean, intermittent fasting, and other popular approaches?

   The question doesn’t miss the point — but the framing of “best diet” usually does. Here’s my clinical perspective: the primary therapeutic target in PMOS is insulin resistance. Any dietary approach that consistently lowers fasting insulin, reduces postprandial glucose spikes, and supports a healthy gut microbiome is going to be beneficial. The specific protocol is less important than whether it achieves those metabolic goals and whether the woman can sustain it. With that said: the evidence for low-glycemic and ketogenic approaches is particularly strong in PMOS. Carbohydrate restriction directly reduces the insulin load, which is the most efficient lever we have for reversing insulin resistance. In my clinical experience and in the published literature, women with PMOS who reduce refined carbohydrates — even without aggressive caloric restriction — frequently see improvements in cycle regularity, androgen levels, and body composition within 8 to 12 weeks. The Mediterranean diet shows strong data for cardiovascular risk reduction and anti-inflammatory effects — both highly relevant in PMOS. Intermittent fasting can improve insulin sensitivity and metabolic flexibility, though women need to be thoughtful about how fasting protocols affect cortisol and HPA axis function. What I tell my patients: we need to find your personal metabolic response, not the statistically average one. That’s where tools like continuous glucose monitoring become genuinely useful — not for diabetics, but for metabolically vulnerable women who want to understand how their specific body responds to specific foods. That’s precision nutrition. That’s the future of managing PMOS.
   
   

6. What does PMOS look like after 40?
   For women with regular cycles who suddenly feel anxious, foggy, tired, or different in their bodies, how do PMOS, perimenopause, and ovarian aging overlap?

   This is one of the most underrecognized clinical situations I see, and it’s one I care deeply about. Perimenopause typically begins in a woman’s early-to-mid 40s and is characterized by fluctuating — and eventually declining — estrogen and progesterone. But here’s what’s underappreciated: women with underlying PMOS enter perimenopause with a metabolic system that’s already under strain. The hormonal volatility of perimenopause doesn’t just cause hot flashes and mood changes — it further destabilizes insulin sensitivity, amplifies inflammation, and accelerates the cardiovascular and metabolic risks that PMOS already confers. The symptom overlap is real and clinically challenging. Anxiety, brain fog, fatigue, weight gain around the abdomen, sleep disruption, low libido — these can all be features of PMOS, perimenopause, or both simultaneously. And there’s a third variable: thyroid dysfunction, which is more common in women with PMOS and increases in prevalence in the perimenopausal decade. All three can look nearly identical on a symptom checklist. My approach: any woman over 40 presenting with this symptom constellation needs a comprehensive hormonal panel — FSH, LH, estradiol, progesterone timed to cycle phase if she’s still cycling, testosterone, SHBG, insulin, and thyroid including reverse T3. You need the full picture before you can meaningfully intervene. What I don’t want is for a woman to be told, “You’re just perimenopausal,” when she’s actually experiencing an acceleration of metabolic disease that’s been brewing for years and is now entirely treatable.
   
   

7. What should mothers tell their daughters about PMOS?
   If a younger woman has irregular periods, acne, unwanted hair growth, or unexplained weight changes, when should she push for a deeper evaluation?

   Tell her that her symptoms are real, her body is giving her information, and she deserves a physician who takes that information seriously. PMOS has a strong hereditary component. If a mother has PCOS or PMOS, her daughter has a significantly elevated risk. That means early identification isn’t just possible — it’s a clinical and ethical obligation. The signs to watch for in adolescent and young adult women: periods that are consistently irregular beyond the first two years post-menarche; acne that is persistent, severe, or cystic and doesn’t respond well to standard treatment; hirsutism — unwanted hair growth on the face, chin, chest, or lower abdomen; unexplained weight gain especially in the abdominal area; and skin changes like acanthosis nigricans, the dark, velvety patches in skin folds that signal insulin resistance. The challenge in adolescents is that irregular cycles in the first year or two after first period are developmentally normal. But beyond that window, irregular cycles need investigation — not just a prescription for oral contraceptives. The pill will regulate the cycle, but it doesn’t treat the underlying insulin resistance. I’ve seen women spend their entire 20s on oral contraceptives for “irregular periods” and only discover their PMOS diagnosis at 30 when they’re struggling to conceive. Push for a fasting insulin level. Push for total and free testosterone. Push for a metabolic panel. And if the first physician dismisses the concern, find another physician. A PMOS diagnosis at 17 with proper metabolic intervention is a fundamentally different trajectory than a PMOS diagnosis at 35. The earlier we intervene, the more we can change the long-term story.
   
   

8. Does being on the pill treat PMOS, or can it hide what is really going on?
   Many women were put on birth control as teenagers to “regulate” their cycles. What did that help, and what might it have missed?

   The pill manages symptoms. It does not treat the underlying condition. And for a long time, our field conflated those two things — to the significant detriment of a generation of women. Here’s what oral contraceptives genuinely do in PMOS: they suppress endogenous androgens, which reduces acne and hirsutism. They regulate the withdrawal bleeding that women experience as a “period,” which protects against endometrial hyperplasia from unopposed estrogen. For women who need contraception, they serve a dual purpose. These are real clinical benefits. Here’s what they don’t do: they don’t reverse insulin resistance. They don’t reduce hyperinsulinemia. Some formulations actually worsen insulin sensitivity, depending on the progestin component. They don’t address the gut microbiome. They don’t modify long-term cardiovascular or metabolic risk. And they suppress ovarian function in a way that makes accurate hormonal assessment nearly impossible while on them. The problem I see repeatedly: a 16-year-old comes in with irregular periods and acne. She’s put on the pill. The acne clears. The periods “regulate.” She feels better. No one revisits the underlying diagnosis. She stays on the pill for 10 to 15 years. Then she comes off at 28 or 30 wanting to conceive — and the PMOS, never addressed, has been compounding in the metabolic background the entire time. I want to be clear: I’m not anti-pill. I prescribe it regularly. But I prescribe it as symptom management while we concurrently address the metabolic root. It should be part of a treatment plan, not a substitute for one.
   
   

9. What does an evidence-based PMOS treatment plan look like today?
   From diagnosis forward, what should women expect in terms of testing, lifestyle changes, medications, follow-up, and long-term monitoring?

   A properly constructed PMOS treatment plan is metabolic medicine — not just hormone management. Here’s how I approach it. Diagnosis and baseline: A full metabolic and hormonal panel is non-negotiable. Fasting insulin and glucose with HOMA-IR calculation. Total and free testosterone, DHEA-S, SHBG, LH, FSH. Complete lipid panel with LDL particle size if available. HbA1c. Thyroid panel including TSH and free T3. A pelvic ultrasound for baseline ovarian morphology. And in the right clinical context, a gut microbiome assessment — the data here is growing and I believe this will become standard of care. Lifestyle: This is first-line therapy, not a footnote. A low-glycemic or ketogenic nutritional approach for insulin resistance. Resistance training — not just cardio — because skeletal muscle is the primary site of insulin-mediated glucose disposal and building it is one of the most powerful interventions we have. Sleep hygiene, because sleep deprivation directly worsens insulin sensitivity and elevates cortisol. Stress management, because chronic HPA axis activation drives cortisol-mediated insulin resistance. This isn’t soft medicine — it’s mechanistically grounded intervention. Supplementation with evidence base: Myo-inositol and D-chiro-inositol in a 40:1 ratio — this is the strongest supplement data we have in PMOS, with meaningful effects on insulin sensitivity and ovulatory function. N-acetyl cysteine. Magnesium. Omega-3 fatty acids for anti-inflammatory effect. In selected patients, a targeted probiotic formulation to support the estrobolome. Medications when indicated
   
   

10. When should GLP-1 medications like semaglutide be considered for PMOS?
    Who may be a good candidate, who should avoid them, and what should women understand before asking their doctor?

    GLP-1 receptor agonists represent one of the most significant advances in metabolic medicine of the past decade, and their relevance to PMOS is substantial. But they are powerful tools, and precision matters. Who is a reasonable candidate: Women with PMOS who have documented insulin resistance and a BMI above 27 with metabolic comorbidities — or above 30 without — who have made a sincere effort at lifestyle modification and are not achieving adequate metabolic control. Women with PMOS-related infertility where excess weight is a significant contributing factor may also benefit, though this requires careful coordination with reproductive endocrinology. Women who have prediabetes or early type 2 diabetes in the setting of PMOS are strong candidates. Beyond weight loss — and this is important — GLP-1 agonists directly improve insulin sensitivity, reduce hepatic glucose output, decrease systemic inflammation, and may have beneficial effects on ovarian androgen production. The mechanism isn’t simply caloric restriction. These drugs are working on the same metabolic pathways that are dysregulated in PMOS. Who should be cautious or avoid: Women who are pregnant or planning pregnancy in the near term — current guidance recommends stopping semaglutide at least two months before attempting conception, and there is insufficient safety data in pregnancy. Women with a personal or family history of medullary thyroid carcinoma or MEN2. Women with a history of pancreatitis. Women with significant gastrointestinal conditions. What women should understand before asking their doctor: These medications require a proper clinical evaluation — not a telehealth prescription mill. The side effect profile, particularly nausea and GI symptoms, is real.

    Leave a comment

    Subscribe now

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

By Dr. Herman Weiss, MD, MBA, FACOG | The Metabolic Fix | May 2026

In my last post, I wrote about why the renaming of PCOS to PMOS — Polyendocrine Metabolic Ovarian Syndrome — is one of the most consequential reframings in women’s health in a generation.

Today I want to go deeper. Much deeper.

Because if you only understand that the name changed, you’ve missed the most important part. The name is not three random adjectives strung together. Those three words — Polyendocrine. Metabolic. Ovarian. — are three pillars of a biological architecture that has been collapsing on women for decades while we argued about the wallpaper.

Each pillar is distinct. Each has its own mechanisms, its own clinical consequences, its own opportunities for intervention. But here is what nobody teaches in medical school, what almost no patient is ever told, and what the old name made nearly impossible to communicate:

The three pillars don’t stand independently. They collapse into each other.

Understand the cascade, and you understand the disease. Understand the disease, and you can actually fix it.

Let’s build this from the ground up.

Pillar One: Polyendocrine — The Fire That Started Everything

The Hypothalamus Doesn’t Know It’s Misfiring

Every story about PMOS begins in the brain. Not in the ovaries. Not in the bloodstream. In the hypothalamus — specifically, in a small population of neurons called KNDy neurons (kisspeptin, neurokinin B, dynorphin) housed in the arcuate nucleus, deep in the basal hypothalamus.

These neurons are the GnRH pulse generator. Their job is to fire in a precise, rhythmic pattern — sending kisspeptin signals that drive the gonadotropin-releasing hormone (GnRH) neurons to release their pulses into the portal circulation. Those GnRH pulses travel to the anterior pituitary and orchestrate the exquisitely timed release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Timing is everything. A slow GnRH pulse frequency favors FSH secretion — the hormone that nurtures follicles, drives estrogen production, and enables ovulation. A fast GnRH pulse frequency favors LH secretion — the hormone that triggers ovulation and, in excess, drives androgen production from the ovarian theca cells.

In PMOS, the pulse generator is stuck on fast.

A neuroendocrine hallmark of the syndrome is persistently rapid GnRH pulsatility, which favors pituitary synthesis of LH over FSH and contributes to the increased LH concentrations and LH:FSH ratios that are typical of this disorder.

The result is a pituitary that is chronically over-producing LH and under-producing FSH. And that ratio imbalance — more LH, less FSH — is the opening move in a pathophysiological chess game that plays out across years and decades in the body of nearly every woman with PMOS.

Why Is the Pulse Generator Misfiring?

This is where PMOS gets fascinating — and where the architecture of the disease reveals itself as genuinely polygenic and multi-system.

Meta-analyses of large-scale genomic analyses and recent definitive studies confirm that PMOS has polygenic origins across neuroendocrine, metabolic, and reproductive pathways. This is not a single-gene disorder. It is a convergence of multiple biological vulnerabilities, amplified by each other.

Several inputs are now known to drive aberrant GnRH pulsatility:

Hyperandrogenism feeds back to the hypothalamus. Androgens — testosterone, androstenedione — act directly on GnRH neurons to increase their firing rate. This creates one of the most vicious feedback loops in all of endocrinology: faster GnRH pulses → more LH → more androgen production from theca cells → faster GnRH pulses. The system accelerates itself.

Anti-Müllerian Hormone (AMH) amplifies the loop. Serum AMH concentrations are elevated in women with PCOS, and a recent series of experiments provided compelling evidence that AMH can directly stimulate GnRH neuron activity and secretion. In women with PMOS, the accumulation of arrested small antral follicles produces excess AMH — and that excess AMH loops back to stimulate the same GnRH neurons that are already firing too fast. The disease amplifies its own neuroendocrine driver.

Insulin resistance completes the neuroendocrine triangle. An additional contributing factor to the hyperandrogenic state is hyperinsulinemia resulting from insulin resistance, which upregulates LH receptors and promotes androgen secretion at thecal cells. So the metabolic dysfunction — which we’ll explore in Pillar Two — doesn’t stay in the metabolic compartment. It reaches back up into the brain and makes the neuroendocrine dysregulation worse.

The Multi-Gland Problem

Here is why the word “polyendocrine” is doing real scientific work.

The HPO axis dysfunction described above would be enough to justify the prefix. But PMOS doesn’t stop at the hypothalamic-pituitary-ovarian axis. The adrenal glands are frequently co-involved — contributing their own excess androgens (DHEA-S, androstenedione) in what’s called adrenal hyperandrogenism, present in roughly 20-30% of women with PMOS. The pancreas is dysregulated — producing excess insulin in a futile attempt to overcome peripheral resistance. Adipose tissue is hormonally active — secreting adipokines that further dysregulate appetite, inflammation, and metabolic signaling. There are emerging signals about thyroid co-involvement and hypothalamic-pituitary-adrenal axis dysregulation under chronic stress.

This is not an ovarian problem. This is a multi-gland, multi-axis, neuroendocrine systems failure. The word “polyendocrine” doesn’t capture everything — it just captures the most important things.

What This Means Clinically

Understanding the polyendocrine pillar has direct, actionable implications for how we evaluate and treat:

A woman with PMOS who presents with irregular cycles, hair loss, acne, and anxiety is not presenting with a gynecological complaint. She is presenting with evidence of a neuroendocrine system that is dysregulated at the level of the hypothalamus, pituitary, adrenal glands, and ovaries simultaneously.

Measuring her androgens — total and free testosterone, DHEA-S, androstenedione — is not optional. Understanding her LH/FSH ratio is not optional. Considering her stress physiology, her cortisol pattern, her thyroid status is not optional. These are the clinical expressions of a polyendocrine system in distress.

And critically: the neuroendocrine dysregulation begins early. A recent study of daughters of women with PCOS, who are at high risk for developing PCOS, found that postmenarcheal adolescents exhibit high circulating LH and AMH concentrations, with a positive correlation between the two — compatible with a putative role of AMH in the neuroendocrine defects.

The fire started in the brain. In many women, it started in adolescence. And nobody told them.

Pillar Two: Metabolic — The Accelerant

The neuroendocrine dysregulation of Pillar One creates a hormonal environment that feeds directly into metabolic catastrophe. And then that metabolic catastrophe feeds back and makes the neuroendocrine dysregulation worse. This is the engine that drives PMOS from a hormonal disorder into a systemic, life-shortening disease.

Insulin Resistance: The Central Metabolic Defect

If hyperandrogenism is the signature of Pillar One, insulin resistance is the signature of Pillar Two — and it is arguably the most consequential feature of PMOS that the old name made invisible.

Insulin resistance and compensatory hyperinsulinaemia are present in 85% of affected individuals — including 75% of lean women with PMOS — amplifying androgen secretion and disrupting steroidogenesis, highlighting the metabolic-endocrine interplay.

Let that number sit with you. Seventy-five percent of lean women with PMOS have insulin resistance. Not overweight women. Lean women. Women whose doctors looked at them and said, “You look fine.” Women whose BMI was normal and who were sent home without metabolic evaluation because the name of their condition pointed toward their ovaries, not their pancreas.

The mechanism of insulin resistance in PMOS is unique and still not fully understood — but what is clear is that it is intrinsic to the disease, not secondary to weight gain. Women with PMOS have evidence of defects in the post-receptor insulin signaling pathway, specifically involving the PI3K/AKT/MAPK pathway, that are present regardless of adiposity. The ovaries, paradoxically, remain sensitive to insulin’s mitogenic and steroidogenic effects even when they are resistant to its metabolic effects — a selective resistance that drives hyperandrogenism directly.

The Hyperinsulinemia-Hyperandrogenism Loop

Here is where Pillars One and Two fully merge:

Excess insulin → direct stimulation of ovarian theca cells to produce more androgens → more androgens → faster GnRH pulsatility → more LH → more theca cell stimulation. The insulin resistance doesn’t just create metabolic disease. It turbocharges the androgen excess that was already driving the neuroendocrine dysregulation. This is not a complication of PMOS. This is the second engine of the disease itself.

At the same time, excess insulin suppresses the production of sex hormone-binding globulin (SHBG) in the liver — the protein that binds androgens and keeps them biologically inactive. As SHBG falls, free testosterone rises even if total testosterone is unchanged. This is why women with PMOS can have “normal” total testosterone levels and still experience severe androgen-driven symptoms. Free testosterone is what matters. And insulin — through SHBG suppression — is what frees it.

The Long Game: What Insulin Resistance Does to a Woman’s Life

The metabolic pillar is where PMOS stops being a condition of irregular periods and starts being a condition that determines whether a woman lives to see her grandchildren.

The likelihood of developing metabolic disorders is about three to seven times higher in women with PMOS than in women without it. Insulin resistance is common even in lean women with PMOS.

Diabetes onset was, on average, 10 years earlier among women with PCOS than in women without PCOS.

Ten years earlier. Read that again. A woman with PMOS who develops type 2 diabetes doesn’t develop it at 55. She develops it at 45 — at the peak of her career, when her children are teenagers, when she still believes she has decades of metabolic headroom. And because nobody screened her insulin at 25, nobody connected her irregular cycles to her insulin levels at 30, nobody explained the cascade she was already in — she had no opportunity to intervene.

The cardiovascular picture is equally sobering. Women with PMOS carry elevated levels of small, dense LDL particles — the atherogenic fraction — alongside reduced HDL and elevated triglycerides. Subclinical coronary atherosclerosis has been detected in adolescents with PMOS. Endothelial dysfunction is measurable early. And metabolic dysfunction leads to a risk for cardiovascular disease that increases with aging in women with PMOS — with the severity of insulin resistance associated with the amount of abdominal obesity, even in lean women.

The silent metabolic damage begins before the diagnosis is made. It continues during the years of diagnostic delay. It compounds through every year that the treatment plan focuses only on cycles and fertility rather than fasting insulin, lipids, liver function, and vascular health.

Non-Alcoholic Fatty Liver Disease: The Invisible Complication

NAFLD in PMOS is chronically underrecognized, underscreened, and underreported — and it is a direct metabolic consequence of the insulin resistance of Pillar Two.

Hyperinsulinemia drives hepatic de novo lipogenesis — the liver converts excess glucose into fat. Visceral adiposity, even in lean women with PMOS, generates a chronic flux of free fatty acids to the liver. The result is hepatic steatosis, which can progress to steatohepatitis (NASH), fibrosis, and cirrhosis. Women with PMOS have a dramatically elevated prevalence of NAFLD relative to age- and BMI-matched controls.

When was the last time a gynecologist ordered a hepatic function panel and an abdominal ultrasound on a 28-year-old with irregular cycles?

That is a rhetorical question. And its answer is an indictment.

Inflammation: The Thread Running Through Everything

Lean and obese patients with PCOS both have chronic inflammation mediating the long-term cardiometabolic complications and comorbidities observed — including dyslipidemia, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease.

Chronic low-grade inflammation is not a side effect of PMOS. It is woven into its pathophysiology. Elevated inflammatory cytokines — IL-6, TNF-α, CRP — are consistently measurable in women with PMOS regardless of BMI, and they participate directly in worsening insulin resistance, amplifying androgen production, and damaging the vascular endothelium. The gut microbiome — specifically the estrobolome, which we’ll address in a future piece — is a key regulator of this inflammatory state, and its dysbiosis in PMOS is increasingly well-documented.

Inflammation also explains the psychological burden. Women with PMOS have significantly elevated rates of anxiety and depression — not just as a psychological response to a chronic illness, but as a direct neurobiological consequence of the inflammatory cytokines and hormonal dysregulation that are remodeling their brain chemistry in real time.

What This Means Clinically

The metabolic evaluation of a woman with PMOS is not optional. It is not a nice-to-have. It is the clinical assessment that determines her 20-year trajectory.

Every woman with PMOS should receive at minimum: fasting insulin and glucose (and ideally a 2-hour oral glucose tolerance test), a full lipid panel with attention to triglycerides and HDL, hepatic function tests, high-sensitivity CRP, and serious conversation about cardiovascular risk beginning in her 20s.

This is what “metabolic medicine” looks like in practice. And it was nearly impossible to justify ordering when the name of the disease said “ovarian syndrome.”

PMOS makes it mandatory.

Pillar Three: Ovarian — The Consequence Made Visible

The neuroendocrine fire of Pillar One, accelerated by the metabolic dysfunction of Pillar Two, lands in the ovaries with full force. Pillar Three is where the damage becomes visible — in the follicles, in the cycles, in the fertility, and in the long-term gynecological health of women who go undiagnosed for years.

Folliculogenesis Arrest: When Development Stalls

Normal ovarian physiology depends on a precise sequence. Each month, a cohort of primordial follicles is recruited. Under FSH stimulation, one follicle emerges as dominant — growing from a 2mm antral follicle to a 20mm preovulatory follicle, producing rising estradiol, triggering the LH surge, and releasing a mature oocyte. The remaining follicles undergo atresia.

In PMOS, this sequence is disrupted at multiple points simultaneously.

Enhanced androgen production from ovarian theca cells occurs due to increased LH levels, and decreased FSH leads to folliculogenesis arrest, accumulating small antral follicles and ultimately increasing AMH levels.

The elevated LH stimulates theca cells to produce excess androgens. The deficient FSH fails to provide adequate granulosa cell stimulation for follicular maturation. Heightened luteinizing hormone, insulin resistance, and obesity stimulate theca cell androgen production, while granulosa cell dysfunction impairs aromatization of androgens to estrogens.

The result: follicles don’t die — they arrest. They stall at the small antral stage, accumulating in the ovarian cortex. The ovary fills with developmentally suspended follicles — the “polycystic” morphology that gave the old name its anatomical anchor. But here is the critical insight that the old name obscured: the cysts didn’t cause the disease. They are the footprint of it. The follicular arrest is the downstream consequence of the neuroendocrine and metabolic dysregulation that came first.

Many women with PMOS — including those with insulin resistance, hyperandrogenism, irregular cycles, and full metabolic risk profiles — never develop the characteristic ovarian morphology on ultrasound. The absence of “cysts” is not the absence of disease. It never was. The name just made everyone think it was.

AMH: The Ovarian Marker That Explains Everything

Anti-Müllerian hormone has emerged as one of the most illuminating biomarkers in PMOS — and its story elegantly closes the loop between all three pillars.

AMH is produced exclusively by the granulosa cells of small antral follicles. In a normal ovary with a normal follicular cohort, AMH levels reflect the ovarian reserve. In PMOS, with its accumulation of arrested small antral follicles, AMH levels are dramatically elevated — often two to three times higher than age-matched controls.

But AMH doesn’t just sit there as a passive marker. As we saw in Pillar One, elevated AMH loops back to the hypothalamus — directly stimulating GnRH neuron activity and contributing to the neuroendocrine dysregulation that initiated the cascade. The ovary, through its excess AMH production, becomes a participant in perpetuating its own dysfunction.

A 2023 retrospective cohort study found that serum AMH levels were significantly higher in women with insulin resistance, with positive correlations noted between AMH, insulin resistance measures, fasting insulin, androgens, and LH/FSH ratio — suggesting that elevated AMH may be linked to increased insulin resistance.

The ovary is not a victim in PMOS. It is an active contributor to the endocrine chaos. And its primary messenger — AMH — is the signal that ties everything together.

Anovulation and Its Consequences: Beyond Infertility

The folliculogenesis arrest of Pillar Three means that many women with PMOS ovulate infrequently or not at all — a state called oligoanovulation. The clinical expression is irregular or absent menstrual cycles. And while the immediate concern for most patients is fertility, the consequences of chronic anovulation extend far beyond reproductive capacity.

Progesterone deficiency. Every ovulation produces a corpus luteum. The corpus luteum produces progesterone. No ovulation means no corpus luteum means no progesterone in the luteal phase. Sustained progesterone deficiency, with unopposed estrogen, creates chronic endometrial proliferation — a direct pathway to endometrial hyperplasia and, without intervention, endometrial cancer. The endometrial cancer risk in women with PMOS is three to four times that of the general population. This is not a fertility concern. This is an oncological concern.

Bone density. Progesterone and estrogen both play roles in bone mineral density maintenance. Chronic anovulation — particularly in lean women with PMOS — creates a hormonal environment that impairs bone formation and increases fracture risk over time.

Pregnancy complications. For women with PMOS who do conceive — spontaneously or with assistance — the background metabolic and endocrine dysregulation increases the risks of gestational diabetes, pre-eclampsia, preterm birth, and large-for-gestational-age infants. The ovarian pillar doesn’t end when pregnancy begins.

The Androgen Signature on the Skin and Scalp

The androgen excess that is simultaneously a driver and a consequence of the three-pillar cascade expresses itself visibly in ways that are often dismissed, minimized, or attributed to stress or aging:

Hirsutism — terminal hair growth in androgen-sensitive areas. Acne — particularly jawline, neck, and back, in patterns different from adolescent acne. Androgenic alopecia — progressive temporal and crown hair loss that is devastating to self-image and is frequently misdiagnosed or untreated. Seborrhea. Acanthosis nigricans — the dark, velvety hyperpigmentation at the neck, armpits, and groin that is a visible marker of insulin resistance.

These are not cosmetic complaints. They are clinical signs of the full PMOS cascade, written on the surface of the body for any clinician who has been taught to read them.

What This Means Clinically

The ovarian evaluation of PMOS requires a fundamental reframe. Ultrasound is a useful tool — but it is neither necessary nor sufficient for diagnosis, and the presence or absence of polycystic ovarian morphology should never be the gating criterion for taking a woman’s symptoms seriously.

The ovarian pillar is best understood as a readout — an anatomical and functional expression of the neuroendocrine and metabolic dysfunction that preceded it. Treating the ovarian manifestations in isolation — inducing ovulation without addressing insulin resistance, prescribing the pill without addressing androgen excess mechanisms, managing irregular cycles without monitoring endometrial health — is treating the symptom while ignoring the fire.

The Architecture: How the Pillars Fall Into Each Other

This is the cascade that every clinician needs to understand — and every woman with PMOS deserves to be taught:

The hypothalamus fires too fast → GnRH pulses accelerate → LH rises, FSH falls. Elevated LH drives theca cells to overproduce androgens. Deficient FSH fails to support follicular maturation.

Excess androgens feed back to the hypothalamus → GnRH fires faster → the neuroendocrine loop tightens.

Insulin resistance develops (driven by intrinsic metabolic defects, amplified by the androgenic environment) → Hyperinsulinemia develops → Insulin directly stimulates theca cells to produce more androgen → SHBG falls → Free testosterone rises → More hyperandrogenism → Faster GnRH pulsatility.

Elevated AMH from arrested follicles loops back to hypothalamic GnRH neurons → Further accelerates the pulse frequency → Further raises LH → Further suppresses FSH → Further impairs follicular maturation → More follicular arrest → More AMH.

Chronic inflammation, generated by insulin resistance, visceral adiposity, and gut dysbiosis, amplifies every step of the cascade — worsening insulin resistance, worsening androgen production, damaging the endothelium, dysregulating appetite hormones, remodeling brain chemistry.

The ovary — saturated with excess LH, excess androgens, deficient FSH, excess insulin, and elevated AMH — arrests its follicles, fails to ovulate, fails to produce progesterone, and becomes a source of further androgenic and AMH-mediated amplification.

This is not a circle. It is a spiral. And without intervention — real, comprehensive, metabolically and endocrinologically informed intervention — it tightens with every passing year.

Why This Architecture Is a Clinical Opportunity

I don’t tell this story to frighten anyone. I tell it because understanding the cascade means understanding where to interrupt it.

The good news — and there is very good news — is that each pillar has addressable mechanisms. The neuroendocrine dysregulation can be modulated by approaches that reduce androgen excess and normalize GnRH pulsatility. The metabolic dysfunction responds to insulin sensitization — through nutritional intervention, targeted nutraceuticals (inositols, chromium, cinnamon, folate, zinc), lifestyle modification, and where appropriate, pharmaceutical support. The ovarian consequences improve when the upstream dysfunction is addressed — not through hormonal suppression alone, but through metabolic restoration that removes the androgenic drive from theca cells and restores FSH-mediated follicular maturation.

The three-pillar architecture of PMOS is not a counsel of despair. It is a map. And maps are what physicians use to navigate toward health.

The Naming Catches Up to the Science

Polyendocrine: recognizes that the condition is underpinned by multiple interacting hormonal disturbances, including insulin, androgens, and neuroendocrine hormones, rather than being an isolated ovarian disorder. Metabolic: acknowledges the inherent metabolic features such as insulin resistance, obesity, and increased risks for type 2 diabetes and cardiovascular disease. Ovarian: retains the connection to ovarian dysfunction, including ovulatory disturbances and infertility, which remain defining features of the syndrome.

One name. Three pillars. Decades of science finally compressed into five syllables that tell the truth about what is happening in 170 million women’s bodies worldwide.

This is why the name change matters. Not because names are magic. But because this name, for the first time, gives every clinician, every patient, every researcher, and every policymaker the same accurate map.

Now we have to use it.

Coming next: The Gut-Hormone Axis in PMOS — How the Estrobolome Connects Intestinal Bacteria to Androgen Excess, Insulin Resistance, and Folliculogenesis. The microbiome isn’t a side story. It may be the missing chapter.

Dr. Herman Weiss, MD, MBA, FACOG, is a board-certified OB/GYN with 25 years of clinical experience and the CEO/Founder of ProvationLife™, a physician-led women’s metabolic health company. Follow @hweissmd for daily clinical insights on women’s metabolic health.

Key Sources:

• Teede HJ et al. The Lancet, May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8

• Rojas J et al. “PCOS, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth.” Int J Reprod Med. 2014. PMC4334071

• Moore AM et al. “Neuroendocrine mechanisms responsible for elevated GnRH and LH pulses in PCOS.” J Neuroendocrinol. 2025.

• Rudnicka E et al. “Decoding androgen excess in PCOS.” World J Diabetes. 2025. PMC12278101

• Shi Y, Zhao H. “Abnormal GnRH pulsatility in PCOS: recent insights.” Front Endocrinol. 2021. PMC7365617

• Frontiers in Endocrinology: “Central Regulation of PCOS: Abnormal Neuronal-Reproductive-Metabolic Circuits.” 2021. PMC

• Chen ZJ et al. “Progression of glucose intolerance and cardiometabolic risk factors over a decade in women with PCOS.” PLOS ONE. 2019. PMC6814217

• Xu Y, Qiao J. “Association of Insulin Resistance and Elevated Androgen Levels with PCOS.” J Endocrinol Res. 2022. PMC8959968

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

By Dr. Herman Weiss, MD, MBA, FACOG

Today, published in The Lancet and presented simultaneously at the European Congress of Endocrinology in Prague, a landmark global consensus paper made official what many of us in women’s metabolic health have been saying for years: the name “polycystic ovary syndrome” is wrong. It has always been wrong. And now — after 11 years, 22,000 voices from 56 leading academic, clinical, and patient organizations across the globe — the medical world has finally caught up.

PCOS is dead. Long live PMOS.

Polyendocrine Metabolic Ovarian Syndrome. That’s the new name. One letter changed in the acronym. An enormous paradigm shifted in medicine.

I want to take you inside why this matters — not just as a news item, but as one of the most consequential reframings in women’s health in a generation. Because how we name a disease determines how we see it, how we treat it, who studies it, who funds it, and ultimately, how well our patients do.

First, Some History: Why PCOS Was Always the Wrong Name

The term “polycystic ovary syndrome” was coined in the 1930s by Stein and Leventhal, based on the observation of enlarged, cyst-containing ovaries in women with menstrual irregularities and excess androgens. At the time, naming it for the most visually prominent finding — the ovaries — was understandable. It was the era before sophisticated hormonal assays, before metabolic phenotyping, before we understood insulin’s role in androgen excess. We named what we could see.

The problem? The name stuck. For nearly 90 years, medicine anchored one of the most common endocrine disorders in women to a finding that is neither universal nor central to the disease.

Here is what the name PCOS implied to every clinician, every patient, every researcher, every insurance underwriter, and every NIH grant reviewer who encountered it:

• It’s an ovarian problem.

• It involves cysts.

• It belongs to gynecology.

• It’s primarily about reproduction.

Every single one of those implications is wrong — or at minimum, profoundly incomplete.

What the Name Got Wrong (Clinically and Mechanistically)

Let’s be precise about the pathophysiology, because the new name, PMOS — Polyendocrine Metabolic Ovarian Syndrome — earns each of its words.

Polyendocrine.

This is not a single-hormone disorder. PMOS involves dysregulation across multiple endocrine axes simultaneously: hypothalamic-pituitary-ovarian axis dysfunction, hyperandrogenism, insulin resistance with compensatory hyperinsulinemia, altered GnRH pulsatility, disrupted LH/FSH ratios, cortisol dysregulation under stress, and emerging evidence of thyroid co-involvement. The word “polycystic” captured none of this. The word “polyendocrine” captures all of it.

Metabolic.

This is perhaps the most important word added. Insulin resistance is present in 70–80% of women with PMOS, regardless of body weight. The metabolic consequences — type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, hypertension, and elevated cardiovascular risk — are not complications of PMOS. They are features of it. They were hiding in plain sight behind an ovary-focused name that directed clinicians toward reproductive medicine and away from metabolic medicine.

Ovarian.

The ovaries remain in the name, appropriately. Ovarian dysfunction — disrupted folliculogenesis, arrested follicular development, androgen hypersecretion from theca cells — is a real and central component of this syndrome. But notice the shift: the ovaries are one part of a larger picture, not the headline.

What This Name Change Means for Patients

1. Fewer Missed Diagnoses

The single most common complaint I hear from women with PMOS is some version of this: “I went to three doctors before anyone took me seriously.” Or: “My ultrasound was normal, so they said I didn’t have PCOS.” This happened because the name trained clinicians to look for the wrong thing. PMOS recenters the diagnostic lens on the endocrine and metabolic features that are actually universal. This alone could accelerate diagnosis for millions of women who currently wait an average of 2 years to receive a correct diagnosis.

2. Reduced Stigma

The original name carried a brutal double burden. First, it anchored the disorder in reproduction — framing every woman with PMOS primarily through the lens of her fertility. Second, because the metabolic features drive weight gain and the condition disproportionately affects heavier women, “PCOS” became entangled with weight stigma and self-blame. Women were told: “Just lose weight and it will go away.” The name gave that dismissal intellectual cover. PMOS doesn’t. PMOS says: this is a polyendocrine disorder. The metabolic dysfunction came first.

3. Broader, More Holistic Treatment

When gynecology “owned” PCOS, the therapeutic toolkit was reproductive: oral contraceptives, clomiphene, metformin as an afterthought. PMOS, by naming the endocrine and metabolic nature of the disease, invites endocrinology, cardiology, hepatology, and metabolic medicine to the table as equal partners. It creates the clinical permission — and eventually the guideline mandate — for comprehensive metabolic screening: fasting insulin and glucose, lipid panels, hepatic function, blood pressure, sleep apnea evaluation, and psychological health assessment. These are the interventions that protect women with PMOS from their most serious long-term risks.

What This Name Change Means for Research

A disease’s name is not just a label. It is a filing system for the entire apparatus of medical science. It determines which journals publish the research, which subspecialties generate the investigators, which NIH study sections review the grants, and which ICD codes are used for billing and epidemiological tracking.

PMOS changes the filing system. Consider:

• Grant funding: NIH study sections for endocrinology and metabolism have significantly larger budgets and broader scope than reproductive medicine sections. PMOS now has a credible claim on those resources — and on cardiovascular disease, diabetes, and metabolic syndrome research portfolios.

• Industry investment: GLP-1 receptor agonists, SGLT-2 inhibitors, and novel insulin sensitizers are among the most commercially active drug classes in medicine right now. PMOS, explicitly named as a metabolic syndrome, positions itself as a legitimate indication for these agents — opening a pipeline the old PCOS framing kept partially closed.

• International disease classification: The Lancet paper makes explicit that ICD codes and disease classification systems will be updated. This is monumental. ICD codes drive insurance coverage, hospital coding, and population-level epidemiology. A reclassification from a gynecological code toward an endocrine/metabolic code reshapes decades of data and aligns future collection with biological reality.

• Clinical trials: The populations enrolled in trials are defined by diagnosis codes and inclusion criteria. Broadening the framing of PMOS will expand trial eligibility, improve phenotypic characterization, and produce data that is more actionable across the full metabolic spectrum.

What This Name Change Means for Education

Medical education is downstream of nomenclature. When the textbook chapter is titled “Polycystic Ovary Syndrome” and filed under gynecology, medical students learn to look for it in OB/GYN rotations, not on internal medicine wards. Primary care physicians learn it as something to refer out, not manage longitudinally.

PMOS repositions this disease as a core competency of metabolic medicine — something every internist, every family physician, every endocrinologist, every cardiologist, and yes, every OB/GYN should be trained to recognize and manage. The curricular implications ripple through medical schools, residency programs, CME, and board examination content.

There is also the patient education dimension. Women with PMOS have historically received deeply fragmented information — some from their gynecologist about fertility, some from their PCP about weight, some from the internet about “natural cures.” A coherent name — one that accurately describes the condition — is the beginning of coherent health literacy.

What This Means for Women’s Metabolic Health — and ProvationLife

At ProvationLife, we built our entire clinical philosophy on exactly this premise: that women’s metabolic health disorders are polyendocrine, gut-mediated, inflammation-driven, systemic conditions that require an integrated, multisystem approach. We called it before the Lancet did.

The PMOS renaming is intellectual validation — and a commercial inflection point. Here’s what I see coming:

• The patient population just got larger on paper. Women who never identified with “ovarian” or “cysts” but do identify with insulin resistance, metabolic dysfunction, and hormonal chaos will now recognize themselves in the diagnosis. Prevalence estimates — currently at 1 in 8 women globally, 170+ million people — may rise.

• The supplement, nutrition, and lifestyle market will follow. Products and programs targeting PMOS metabolic features — gut microbiome optimization (the estrobolome!), insulin sensitization, androgen modulation, anti-inflammatory nutrition — now have a more scientifically credible umbrella under which to operate.

• Payers and health systems will need to adapt. As clinical guidelines are updated to reflect PMOS’s metabolic scope, insurance coverage for metabolic screening, CGM use, and GLP-1 therapies in this population will face pressure to expand.

• The mainstream media conversation accelerates. The reframing of one of the most common women’s health conditions as a metabolic syndrome — not a reproductive one — aligns exactly with the broader cultural conversation about women’s health and the failures of a system that has historically reduced women to their reproductive organs.

The Dissenting Voice: Why This Isn’t Universally Celebrated

Science requires intellectual honesty, and I want to acknowledge the legitimate criticism. PCOS Challenge — one of the most prominent patient advocacy organizations — issued a statement today expressing concern that the renaming process, while well-intentioned, did not establish the evidentiary standard required to prove that the name itself caused the documented harms, or that a new name will correct them.

They are not wrong about this. A name change is necessary but not sufficient. The hard work of structural reform — in medical education, in reimbursement, in research funding, in guideline development — remains.

But I would argue: you cannot have the institutional reform without the name change. The name is the frame. Get the frame right first.

The Bottom Line: What Took So Long?

Fourteen years. More than 22,000 stakeholders. Modified Delphi methods. Nominal group technique workshops. International surveys across six continents. A paper in The Lancet.

Why did it take this long to rename a disease that has been incorrectly named since the 1930s? The answer tells you everything you need to know about medicine’s relationship with women’s health. When a condition is filed under “women’s reproductive problems,” it exists in a second-tier research and policy environment — underfunded relative to its prevalence, under-represented in trial design, and underestimated in its systemic impact.

The name PCOS wasn’t just inaccurate. It was a permission structure for neglect.

PMOS is a correction. It is medicine acknowledging, in its most formal possible language — a global consensus paper in The Lancet — that it got the framing wrong, and that the women who suffered delayed diagnoses, fragmented care, dismissed symptoms, and misunderstood metabolic risk deserved better.

They still do. But at least now, the name tells the truth.

Dr. Herman Weiss, MD, MBA, FACOG

Board-certified OB/GYN • 25 years of clinical experience • CEO/Founder, ProvationLife™

@hweissmd | The Metabolic Fix | ProvationLife.com

Sources

• Teede HJ et al. “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.” The Lancet, May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8

• University of Colorado Anschutz Medical Campus press release, May 12, 2026

• PCOS Challenge: The National PCOS Association statement, May 12, 2026

• eClinicalMedicine / The Lancet: “Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming,” 2025

• STAT News: “PCOS is now called PMOS. The renaming process lasted a decade,” May 12, 2026

• Live Science: “Goodbye PCOS: Polycystic ovary syndrome is getting a new name,” May 12, 2026

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

What To Do When Your Labs Come Back “Normal” But You Still Feel Awful

The exact protocol I use once I have a HOMA-IR result in hand — thresholds, interventions, the treatment decision framework, and the conversation most physicians never have.

By Dr. Herman Weiss, MD, MBA, FACOG — Board-Certified OB/GYN · 25 Years Clinical Practice

hweissmd · The Metabolic Fix · Paid Subscriber Article · May 2026

If you’ve read Part 1, you now know two things: that fasting insulin is the test that actually catches insulin resistance in PCOS, and that HOMA-IR is the metric that tells you how serious it is.

What you may not know is what to do with that number once you have it.

That’s what this article is. Not general advice about eating better and exercising more. The actual protocol — differentiated by phenotype, calibrated to your specific HOMA-IR result, and written the way I explain it to patients in my own clinic.

I’m going to walk you through four things: what each HOMA-IR threshold actually means clinically, which intervention belongs at which threshold, how I think through the metformin versus inositol versus GLP-1 decision, and what the right dietary architecture looks like for the insulin-resistant PCOS phenotype.

Read this carefully. Print it out if it helps. Bring it to your next appointment.

Subscribe now

Read more

By Dr. Herman Weiss, MD, MBA, FACOG — Board-Certified OB/GYN · 25 Years Clinical Practice

hweissmd · The Metabolic Fix · Free Article · May 2026

She sat across from me in the exam room, 34 years old, exhausted, frustrated, and completely convinced she was losing her mind.

She’d been told for eight years that everything looked “fine.” Her blood sugar was normal. Her A1c was normal. Her thyroid was fine. And yet she couldn’t lose weight no matter what she did, her periods were a disaster, and she felt like she was fighting her own body every single day.

I ran one test her previous physicians hadn’t ordered.

Her fasting insulin was 34 μIU/mL. Her HOMA-IR — a measure of insulin resistance — was 7.8. For context, we start getting concerned above 2.5. She had been metabolically dysregulated for almost a decade. And not one physician had caught it, because not one physician had run the right test.

This is not a rare story in my practice. It is an almost daily one.

The test your OB/GYN almost certainly didn’t order

When a woman comes in with suspected PCOS, the standard metabolic workup most physicians run looks something like this: fasting glucose, HbA1c, maybe a lipid panel. These are useful tests. They’re just not the right tests for catching insulin resistance early in a young woman with PCOS.

Here’s the problem. Fasting glucose and HbA1c are markers of glucose dysregulation — they tell you what your blood sugar is doing. But insulin resistance, the metabolic engine driving most PCOS, is a disorder of insulin — not glucose. And insulin can be dangerously elevated for years before blood sugar ever moves out of the normal range. [1]

By the time your fasting glucose is elevated, you have often already spent years — sometimes a decade — in a state of compensatory hyperinsulinemia. Your pancreas has been working overtime, pumping out excess insulin to keep blood sugar in check, and the entire time, your ovaries have been responding to that insulin by overproducing androgens. Which means irregular periods. Which means acne. Which means the weight that won’t move regardless of what you eat.

The glucose test is measuring the aftermath. It’s not measuring the cause.

What the research says

A 2025 review in Reproductive and Developmental Medicine confirmed that insulin resistance is the predominant metabolic abnormality in PCOS, present in 60–80% of patients — and critically, that IR exists across all PCOS phenotypes, including lean women with normal BMI. [2] The glucose-centric approach to diagnosis misses most of them.

What HOMA-IR actually measures — and why it changes everything

HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It sounds complicated. The calculation is not.

You take a fasting glucose result (in mmol/L) and a fasting insulin result (in μIU/mL), multiply them together, and divide by 22.5. The number you get tells you how hard your body is working to manage its own insulin — and how well it’s succeeding. [3]

In clinical practice, I use these general thresholds:

Below 1.5 — Optimal insulin sensitivity

1.5 to 2.5 — Normal range, monitor over time

2.5 to 3.5 — Early insulin resistance, act now

Above 3.5 — Significant insulin resistance, metabolic intervention needed

The woman I described at the opening had a HOMA-IR of 7.8. That is not borderline. That is a metabolic emergency that had been sitting undetected for almost a decade because everyone was looking at her blood sugar and calling it normal.

“We’ve been measuring the wrong thing in women for 30 years. That’s not a gap in the science — it’s a gap in the standard of care. And it’s correctable.”

Why PCOS insulin resistance is particularly insidious

Insulin resistance in PCOS isn’t just a metabolic inconvenience. It is the engine of the condition. Here is the cycle, as simply as I can put it: excess insulin signals the ovarian theca cells to overproduce androgens. Those androgens disrupt follicular development, prevent normal ovulation, and drive the irregular cycles that bring most women to the clinic. Meanwhile, the insulin-androgen environment promotes visceral fat accumulation, which worsens insulin resistance further, which produces more androgens. [4]

Round and round it goes. And the longer it runs unchecked, the harder it is to interrupt.

This matters enormously for what comes next in a woman’s life. More than half of women with PCOS will develop type 2 diabetes by age 40. [5] The metabolic burden compounds as estrogen levels decline in perimenopause — a transition that tends to accelerate insulin resistance further and amplify cardiovascular risk. The women who enter perimenopause with unaddressed insulin resistance are at significantly higher risk for adverse outcomes. [6]

This is not a conversation we can defer. The window matters.

The lean PCOS reality

One of the most important points I want to make: insulin resistance is not a condition that only affects overweight women. Approximately 30% of PCOS cases occur in women with normal BMI. Many of these women are told they “don’t look like” they have PCOS or that their weight isn’t a problem — and their metabolic dysfunction goes completely unmeasured. HOMA-IR is the test that finds them.

What’s actually happening in your ovaries right now

I want to make this concrete, because I think most women with PCOS have been given a diagnosis without an explanation. So let me give you the explanation.

Your ovaries are not broken. They are responding correctly to an incorrect hormonal environment. When insulin is chronically elevated, the theca cells lining your ovarian follicles receive a signal to make more androgens — primarily testosterone. Those elevated androgens stall the normal growth and maturation of the follicle. The egg gets stuck. The follicle doesn’t rupture. You don’t ovulate. That stalled follicle becomes the “cyst” we see on ultrasound — which is really just an arrested follicle, not a true cyst at all. [4]

Fix the insulin environment, and you fundamentally change what your ovaries are doing. That’s why addressing insulin resistance — not just managing symptoms with birth control pills — is the root-cause approach.

But you cannot fix what you have not measured. And right now, a significant percentage of women with PCOS have never had their fasting insulin tested.

This week: what to do before your next appointment

You don’t have to wait for the medical system to catch up. Here is what I want you to do.

1. Request fasting insulin with your next blood draw. Not just fasting glucose. Not just HbA1c. Specifically ask for “fasting insulin.” It is a standard lab test available at virtually every laboratory. It may require you to explicitly request it, because it is not part of the standard PCOS panel most physicians use. Ask anyway.

2. Calculate your own HOMA-IR. Once you have your fasting glucose (in mmol/L) and fasting insulin (in μIU/mL), use this formula: (fasting glucose × fasting insulin) ÷ 22.5. If you are in the US and your glucose is in mg/dL, divide it by 18 first to convert to mmol/L. A result above 2.5 is clinically significant.

3. Ask for AMH while you’re at it. Anti-Müllerian hormone is no longer just a fertility marker. Recent research has established it as a biomarker of PCOS disease activity — and emerging evidence suggests it plays a role as a neuroactive hormone in PCOS pathogenesis. [1] If you haven’t had it tested, add it to the list.

4. Know your number before you make any treatment decisions. Whether you’re considering metformin, GLP-1 therapy, inositol supplementation, or a dietary approach, your HOMA-IR result will fundamentally shape which intervention is most likely to work for you. These are not interchangeable. The correct path depends on what your insulin is actually doing.

5. If your physician won’t order it, ask why. You are entitled to an explanation. “Your glucose is normal” is not an explanation for why fasting insulin testing is inappropriate in a woman with PCOS symptoms. If you are not getting satisfactory answers, seek a second opinion from a physician with specific PCOS metabolic expertise.

Coming in Part 2 — for paid subscribers

Knowing your HOMA-IR number is the first step. Knowing what to do with it is the second — and it’s where most women (and many physicians) get lost.

Part 2 of The IR Files is for paid subscribers. It covers exactly what I do in the clinic once I have a HOMA-IR result in hand: which interventions I recommend at which thresholds, how I think about the metformin versus inositol versus GLP-1 decision, what the right dietary architecture looks like for the insulin-resistant PCOS phenotype versus the lean phenotype, and the conversation I have with patients about what the next 5 years looks like if we address this now versus if we don’t.

It is the protocol behind the diagnosis. And it is the piece that most women with PCOS have never been given.

→ Subscribe to access Part 2: What To Do When Your Labs Come Back “Normal” But You Still Feel Awful

PCOS is the most common endocrine disorder in women of reproductive age. Up to 70% of affected women remain undiagnosed. And of those who are diagnosed, a substantial percentage have never had their insulin resistance properly measured.

That is not a coincidence. It is a systems failure. And naming it clearly is the first step toward fixing it.

If this post changed how you understand your own labs — or prompted you to finally ask for a test you should have had years ago — share it. The woman in your life who needs to read this probably isn’t going to find it unless you send it to her.

— Dr. Herman Weiss, MD, MBA, FACOG

CEO & Founder, ProvationLife™ | Host, The Metabolic Fix

References

[1] Dokras A et al. “Polycystic ovary syndrome in 2025 — insights and innovations.” Fertility & Sterility. Published online September 22, 2025. PMID: 40992713.

[2] Liu R et al. “Research progress on insulin resistance in polycystic ovary syndrome.” Reprod Dev Med. 2025;9(2):119–128. doi:10.1097/RD9.0000000000000131.

[3] Matthews DR et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma insulin and glucose concentrations in man.” Diabetologia. 1985;28(7):412–419. doi:10.1007/BF00280883.

[4] StatPearls. “Polycystic Ovarian Syndrome.” Updated July 7, 2025. National Library of Medicine. ncbi.nlm.nih.gov/books/NBK459251/

[5] Office on Women’s Health. “Polycystic Ovary Syndrome.” womenshealth.gov. Reviewed 2023.

[6] Dokras A et al. “PCOS as a cardiovascular disease risk-enhancing factor.” Fertility & Sterility. September 2025. PMID: 40992713.

This article is for educational purposes. It does not constitute medical advice. Please consult a qualified physician before making any changes to your care.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

hweissmd Substack  ·  The Metabolic Fix  ·  May 2026

I’ve been in clinical practice for 25 years. I’ve watched the PCOS conversation evolve — slowly, frustratingly slowly — from “just lose weight and your periods will regulate” to something far more nuanced, far more systemic, and far more urgent.

The last 12 months have been different. The research is finally catching up to what many of us have been seeing in our exam rooms for years. And some of it is changing how I diagnose, how I treat, and — honestly — how I talk to my patients about their long-term health.

Here’s what’s new, what’s proven, and what you should actually do about it.

1. PCOS Is Now Officially a Cardiovascular Risk Factor

This isn’t a footnote. This is a headline.

A landmark review published in Fertility & Sterility in September 2025, out of the University of Pennsylvania, confirmed what the cardiometabolic data has been pointing toward for years: PCOS confers elevated risk of heart attack and stroke even during the reproductive years. Not later. Now. [1]

The authors are explicit — PCOS should be classified as a cardiovascular disease risk-enhancing condition. Think about what that means in practice. We’re talking about the same category as chronic kidney disease and inflammatory arthritis. Yet most of my patients with PCOS have never had a lipid panel ordered by the physician who diagnosed them.

That needs to change.

The same paper highlights something I find genuinely fascinating: anti-Müllerian hormone (AMH) is no longer just a fertility marker. It’s emerging as a neuroactive hormone that may play a role in the brain-ovary signaling that drives PCOS itself. [1] We’ve been using AMH to count antral follicles for years. That framing is getting a lot more complicated — and a lot more interesting.

2. The Diagnostic Criteria Have Been Updated — And Simplified

The 2023 International Evidence-Based Guideline is now being widely implemented, and there are two things I want every clinician — and every patient who has felt dismissed — to know.

First: if a patient has both irregular cycles and hyperandrogenism, the diagnosis can be made clinically. No ultrasound required. No AMH required. Two cardinal features, case made. [2, 3]

Second: for adult women who don’t have both features, AMH can now serve as a direct alternative to transvaginal ultrasound for assessing polycystic ovarian morphology. That means a primary care physician can diagnose PCOS without specialized imaging — which removes a real access barrier for patients in underserved communities. [2]

The adolescent rules are deliberately more conservative. In teenagers, both hyperandrogenism and ovulatory dysfunction must be present. Ultrasound and AMH are not recommended in this group because too many normal adolescents would be over-diagnosed. [3] I appreciate the rigor there — we don’t want to label a 16-year-old with a condition that will follow her through her health record for life if we’re not sure.

The bottom line: diagnosing PCOS just got cleaner. Use the updated algorithm.

3. The Gut-Hormone Axis Is Real — And It’s Actionable

I’ve been talking about the gut microbiome in the context of women’s reproductive health for a while now, and I know it can sound like a stretch to some colleagues. It doesn’t sound like a stretch anymore.

A 2025 systematic review in Frontiers in Microbiologysynthesized both human and animal research on the gut microbiome in PCOS, and the picture is consistent. [4]Multiple independent studies are converging on one finding: women with PCOS have significantly reduced levels of Akkermansia muciniphila — a keystone gut bacterium that supports intestinal barrier integrity, regulates inflammation, and is directly tied to insulin sensitivity. [5]

Why does this matter for PCOS? Because the insulin-androgen cycle is the engine of the condition. Hyperinsulinemia drives excess androgen production by the ovarian theca cells. Anything that worsens insulin resistance — including gut dysbiosis — fans that flame.

There’s also a GLP-1 connection here. Gut-derived glucagon-like peptide-1 (GLP-1) stimulates insulin secretion from pancreatic beta-cells, suppresses glucagon, and slows gastric emptying. [6] When the gut microbiome is disrupted, GLP-1 production is impaired — which may be one of the reasons metabolic dysfunction clusters so reliably with the PCOS phenotype.

Probiotics and fermented foods aren’t alternative medicine in this context. They’re a mechanistically grounded intervention. I’m recommending them to my patients now.

4. GLP-1 Receptor Agonists in PCOS: The Evidence Is Getting Stronger

I get asked about semaglutide and liraglutide in PCOS constantly right now. The honest answer used to be: “promising, but the trials are small.” That answer is becoming less satisfying — because the trial data is maturing.

A November 2025 randomized controlled trial out of Huazhong University enrolled 60 overweight and obese women with PCOS and randomized them to metformin alone, liraglutide alone, or combination therapy for 12 weeks. [7] All three groups showed significant improvements in body weight, blood glucose, lipid profiles, and the LH/FSH ratio. The combination arm showed the most comprehensive metabolic and hormonal improvements.

What I find especially compelling is the parallel animal experiment in the same study, which showed that the combination of metformin plus liraglutide produced the most significant beneficial changes in gut microbiota composition. The metabolic and microbiome benefits appear to compound. [7]

This is consistent with an earlier network meta-analysis of 23 studies involving 951 women, which found that liraglutide monotherapy was superior to both orlistat and metformin for weight loss and waist circumference reduction in women with PCOS. [8]

Before initiating GLP-1 therapy in PCOS patients, screen for contraindications: history of pancreatitis, diabetic retinopathy, thyroid cancer. Plan for 6–12 months of monitoring. And have a real conversation with your patient about expectations — this isn’t a cure, it’s a metabolic lever. [8]

5. Inositols: Still First-Line, Now Better Understood

The 40:1 myo-inositol to D-chiro-inositol ratio has been a cornerstone of my PCOS supplement recommendations for years. Recent mechanistic work reinforces why this specific ratio matters.

In healthy ovarian follicles, myo-inositol is the dominant form — it’s essential for FSH signal transduction. Insulin drives the conversion of myo-inositol to D-chiro-inositol through an enzyme called epimerase. In insulin-resistant states — which describes most of my PCOS patients — this conversion goes haywire. You get excess D-chiro-inositol and a depletion of myo-inositol at the follicular level, which impairs egg quality and disrupts normal ovarian signaling. [4]

Supplementing at the 40:1 ratio restores physiologic follicular concentrations, improves oocyte quality, and consistently reduces androgen levels — without the GI side effects of metformin or the risks of other pharmaceutical insulin sensitizers.

Standard dosing I use: 4g myo-inositol + 100mg D-chiro-inositol daily, split into two doses. Most generic “PCOS supplements” on the market do not use this ratio. Read the label.

6. PCOS Is Systemic — And We Need to Treat It That Way

The most recent mechanistic research has confirmed what the clinical picture has always suggested: PCOS is not a disease of the ovary. It’s a systemic syndrome. [9]

Low-grade chronic inflammation, non-alcoholic fatty liver disease, oxidative stress, epigenetic dysregulation — these are not complications of PCOS. They’re features of it. Emerging therapeutic targets include advanced glycation end products (AGEs), sex hormone-binding globulin (SHBG), and microRNAs. None of these are in clinical protocols yet, but they represent the next wave. [9]

The implication for how we practice right now: no single intervention is enough. A woman who takes metformin but eats a highly processed diet, doesn’t sleep, and has an unaddressed gut dysbiosis is not being fully treated. The phenotype is heterogeneous. The treatment has to be too.

THIS WEEK’S ACTION PLAN

Evidence-based steps you can implement immediately.

IF YOU HAVE PCOS:

1. Get your AMH level checked — Not just for fertility. AMH is now a recognized marker of PCOS disease activity and neuroendocrine function. Ask your OB/GYN to include it in your workup.

2. Request a cardiovascular baseline — Fasting lipid panel, fasting glucose, fasting insulin (to calculate HOMA-IR), and blood pressure. PCOS is a cardiovascular risk enhancer. This conversation should be happening at diagnosis, not 20 years later.

3. Add one fermented food daily — Plain kefir, kimchi, or sauerkraut to begin rebuilding Akkermansia muciniphila and short-chain fatty acid production. Lowest-risk, most evidence-supported microbiome intervention available right now.

4. Check your inositol ratio — If you’re taking an inositol supplement, verify it’s 40:1 myo-inositol to D-chiro-inositol. Most off-the-shelf PCOS supplements aren’t formulated correctly. Standard dose: 4g myo-inositol + 100mg D-chiro-inositol daily, two divided doses.

5. Ask about GLP-1 eligibility — If you are overweight (BMI ≥27) with PCOS and haven’t responded adequately to lifestyle changes and/or metformin, ask your physician specifically about GLP-1 receptor agonist therapy. The evidence supports it.

IF YOU’RE A CLINICIAN:

6. Implement the updated 2023 diagnostic algorithm — Irregular cycles + hyperandrogenism = diagnosis. You don’t need the ultrasound. Simplify your workflow and reduce time to diagnosis.

7. Put PCOS on the cardiovascular risk radar — Document it, counsel it, add it to the problem list. It changes the monitoring calculus for the long term.

8. Order HOMA-IR — Fasting insulin remains underutilized. A HOMA-IR >2.5 identifies the insulin-resistant phenotype most likely to benefit from metformin, inositols, and GLP-1 therapy. Add it to your standard PCOS panel.

9. Consider GLP-1 + metformin combination — The November 2025 RCT supports this approach as superior for weight, lipids, and LH/FSH normalization in overweight PCOS women. The data is there.

10. Bring the gut into your lifestyle counseling — The microbiome data is strong enough now to include probiotic and fiber recommendations in your PCOS lifestyle guidance. Lactobacillus and Bifidobacterium species, plus prebiotic fibers (inulin, FOS), are where the evidence currently sits.

The bottom line is this: PCOS is converging on a systems-biology understanding that the best clinicians have intuitively held for years. The gut, the brain, the ovary, the heart — they are connected. The research is finally proving what we suspected.

We don’t have to wait for a new drug. The tools to meaningfully change outcomes for women with PCOS — diagnostically, metabolically, reproductively — exist today. The question is whether we’re using them.

I’m going to keep pushing until the standard of care catches up to the science.

— Dr. Herman Weiss, MD, MBA, FACOG CEO & Founder, ProvationLife™  |  Host, The Metabolic Fix

REFERENCES

[1]  Dokras A et al. "Polycystic ovary syndrome in 2025 — insights and innovations." Fertility & Sterility. Published online September 22, 2025. PubMed PMID: 40992713.

[2]  Teede HJ et al. "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463.

[3]  StatPearls. "Polycystic Ovarian Syndrome." Updated July 2025. National Library of Medicine. ncbi.nlm.nih.gov/books/NBK459251/

[4]  Hanna A et al. "Systematic review of gut microbiota composition, metabolic alterations, and the effects of treatments on PCOS and gut microbiota across human and animal studies." Front Microbiol. 2025;16:1549499. doi:10.3389/fmicb.2025.1549499.

[5]  Liu Y et al. "Gut microbiota: an emerging target connecting polycystic ovarian syndrome and insulin resistance." Front Cell Infect Microbiol. 2025;15:1508893. doi:10.3389/fcimb.2025.1508893.

[6]  Research Progress of Gut Microbiota and Its Metabolites in PCOS. Front Endocrinol. 2025;16:1700191. doi:10.3389/fendo.2025.1700191.

[7]  Long XF et al. "Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats." Front Endocrinol. Published November 26, 2025. doi:10.3389/fendo.2025.1599879.

[8]  Ghazi N et al. "Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome." Biomedicines. 2022;10:1989. doi:10.3390/biomedicines10081989. PMC9405922.

[9]  "The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome." Front Endocrinol. 2025. PMC12883396.

Dr. Herman Weiss, MD, MBA, FACOG  |  ProvationLife™  |  May 2026

Dr. Herm Weiss  ·  hweissmd  ·  The Metabolic Fix

Let me be honest about why I’m doing this.

I spent 25 years in clinical OB/GYN watching the same patterns repeat themselves. Women coming in with PCOS who’d been told to “just lose weight.” Perimenopausal women being handed antidepressants when what they actually had was a hormone story nobody had taken the time to read. Patients who were doing everything right and still not getting better, because the system was optimized for throughput, not answers.

I started writing. Then I started talking. The Metabolic Fix is the result — a place where I can say the things I didn’t always have time to say in a 15-minute appointment. And this AMA is a chance for you to push back on me, stump me, or just ask what you’ve always wanted to ask your gynecologist but felt like you couldn’t.

So. Let’s go.

ON PCOS — WHAT MEDICINE GETS WRONG

Q

Why does it take so long to get a PCOS diagnosis? It happened to me at 31 after a decade of being told I was “just irregular.”

Because the diagnostic criteria are genuinely contested among endocrinologists, and because gynecologists — myself included — were trained in an era when PCOS was still primarily understood as an ovarian problem rather than a metabolic one. We were looking for the wrong things, in the wrong order, with the wrong urgency.

The Rotterdam criteria — which most of us still use — require only two of three features: irregular cycles, elevated androgens, or polycystic ovary morphology on ultrasound. The metabolic component, the insulin resistance that is present in 70–80% of cases, is not in the diagnostic criteria at all. So we diagnosed the surface and missed the engine.

Ten years is not unusual. I’ve heard worse. And I say that with genuine regret, not as a deflection.

Q

My doctor told me metformin is the gold standard for PCOS insulin resistance. Is that still true?

Metformin is a useful drug and I’ve prescribed a lot of it. But “gold standard” is doing a lot of work there.

The evidence for myo-inositol — particularly at the 40:1 ratio with D-chiro-inositol — is now comparable to metformin for insulin sensitization in PCOS, with a significantly better tolerability profile. More than 30 randomized controlled trials. First published in the New England Journal of Medicine in 1999. And yet I still encounter patients whose physicians have never mentioned it.

Berberine is another one. AMPK activation, comparable glycemic outcomes to metformin in multiple trials, studied specifically in PCOS. Not a supplement fad — a mechanism.

Metformin has its place. It is not the only place.

Q

Everyone online is telling me a different diet for PCOS — keto, low GI, Mediterranean, carnivore. Who’s right?

They’re all partly right and all partly missing the point.

What the research actually shows is that reducing insulin burden matters more than the specific dietary label you adopt. Keto does it by eliminating carbohydrates. Low GI does it by slowing glucose absorption. Mediterranean does it through fiber and fat quality. Carnivore does it by removing processed food entirely. The mechanism is the same. The packaging is different.

The question I ask patients is simpler: what can you sustain when you’re tired, traveling, or at someone’s birthday party? Because that’s when it has to work. A perfect protocol you abandon in month two is outperformed by an imperfect one you keep doing in month twelve.

My honest framework: eat real food, prioritize protein at every meal, make fiber non-negotiable, and stop eating in a way that requires a spreadsheet. The rest is details.

“We diagnosed the surface and missed the engine. The insulin resistance that drives 80% of PCOS wasn’t even in the diagnostic criteria.”

ON PERIMENOPAUSE — THE CONVERSATION NOBODY IS HAVING

Q

I’m 44, my cycles are fine, but I feel like a different person — anxious, brain fog, not sleeping. My doctor ran labs and said everything is “normal.” What is going on?

Welcome to perimenopause. It starts, on average, in the mid-40s — sometimes earlier — and it starts before your labs show anything obviously abnormal. Because the first hormonal shift is not a drop in estrogen. It’s a drop in progesterone. And progesterone is the hormone that calms the nervous system, supports sleep architecture, and keeps anxiety from taking the wheel.

A standard FSH and estradiol panel, drawn on a random cycle day, will often look completely normal at this stage. Which is technically accurate and clinically useless. The biology is transitioning. The labs haven’t caught up.

When a 44-year-old woman tells me she’s anxious in a way she’s never been before, not sleeping through the night, and feels like her brain is running on half its usual capacity — I am not ordering more labs. I am having a conversation about perimenopause. Because that is what she is describing.

Q

Should I be on hormone therapy? I’m scared of the breast cancer risk.

I understand why you’re scared. The 2002 Women’s Health Initiative study generated headlines that scared an entire generation of women off hormone therapy — and scared an entire generation of physicians off prescribing it. That fear persists even though the WHI findings have been substantially reanalyzed, recontextualized, and in many respects walked back in the literature.

The current data, particularly for women who initiate hormone therapy before age 60 or within ten years of menopause onset, shows a risk profile that is far more nuanced — and for many women, far more favorable — than the original headlines suggested. The risks are real. They are also individualized, time-sensitive, and need to be weighed against the documented risks of untreated menopause: cardiovascular disease, bone loss, cognitive decline, and a measurably lower quality of life.

This is a conversation, not a protocol. Any physician who tells you HRT is categorically safe or categorically dangerous without knowing your individual history isn’t giving you medicine. They’re giving you a policy.

Q

I have PCOS and I’m now in perimenopause. It feels like my body is fighting itself on two fronts. Am I right?

You’re right that it feels that way. You’re partly wrong about what’s actually happening — and I mean that in the most encouraging way I can.

PCOS and perimenopause share an underlying biology: insulin resistance, chronic low-grade inflammation, and hormonal dysregulation. They’re not two separate battles. They’re the same terrain, shifting. And the metabolic work you’ve done over years of managing PCOS — understanding insulin, understanding inflammation, paying attention to what you eat and how you sleep — is not wasted. It is a head start.

Here’s something that surprises most patients: the androgen excess that defined your PCOS experience often mellows in perimenopause, because estrogen decline changes the hormonal ratio. Acne can improve. Hirsutism can ease. The picture shifts. Not always, and not cleanly — but it shifts.

The women who navigate this transition hardest are the ones who’ve never had to pay attention to their metabolism before. You have been paying attention for years. That is worth something.

Q

Why did you start a company? Isn’t that a strange move for an OB/GYN?

It looked strange from the outside. From the inside it felt like the only logical next step.

Clinical medicine at its best is an extraordinary privilege. You are present for some of the most significant moments in a person’s life. But the system it operates in has become increasingly hostile to the kind of care I wanted to deliver — time, depth, the space to actually explain the mechanism behind what I was prescribing. A 15-minute appointment slot is not sufficient for a woman with PCOS who has spent a decade being dismissed. It is not sufficient for a perimenopausal woman who needs to understand what is happening to her body and why.

ProvationLife is my attempt to build the infrastructure that medicine didn’t give me. Education at scale. Evidence-based tools. Products formulated by someone who has read the actual literature and spent 25 years watching patients respond — or not — to what’s available. I’m not anti-medicine. I’m frustrated by its limitations in the spaces where women need it most.

I still see many patients and am actually trying to live a double life.

Q

What’s The Metabolic Fix actually going to cover? Why a podcast?

The podcast covers what I wish every woman with a hormonal or metabolic condition had been told from the beginning: the mechanisms, not just the symptoms. Why insulin resistance drives androgen excess in PCOS. Why estrogen’s departure in perimenopause is also the departure of its anti-inflammatory function. Why the gut microbiome is not a wellness concept but a peer-reviewed regulatory system with direct effects on hormones.

Why a podcast? Because the fifteen-minute appointment isn’t enough, and a Substack post — including this one — has a ceiling. Audio lets me think out loud. It lets me be a physician and a person simultaneously, which is harder to do in writing than you’d think. And it reaches women who are driving, or walking, or lying awake at 3am wondering why their body has stopped making sense. That’s my audience. That’s who I’m talking to.

That’s the pre-loaded version. Now it’s your turn.

Leave your questions in the comments — on PCOS, perimenopause, supplements, hormones, the podcast, the company, or whatever else you’ve been carrying around that nobody has given you a straight answer on. I’ll be working through them over the next week, and the best ones will become future episodes of The Metabolic Fix.

No question is too basic. No question is too clinical. The whole point is that you should have been told this already.

— Herm

Leave a comment

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

A patient in her 50s comes in for “recurrent UTIs.” Another mentions discomfort with intimacy, almost as an aside. A third has persistent vaginal irritation that’s been treated repeatedly as infection—with little success.

Different complaints. Same underlying physiology.

This is genitourinary syndrome of menopause (GSM)—a chronic, progressive condition that affects a substantial proportion of women, yet remains underdiagnosed, under-discussed, and often mismanaged.

What GSM Actually Is (and Isn’t)

The term GSM was introduced in 2014 by American College of Obstetricians and Gynecologists to replace the narrower concept of “vulvovaginal atrophy.” The goal was to reflect reality more accurately: this is not just a vaginal issue.

It’s a multisystem hypoestrogenic syndrome affecting:

• Vulvovaginal tissue

• Lower urinary tract

• Sexual function

Typical symptoms include:

• Vaginal dryness, burning, irritation

• Dyspareunia and decreased lubrication

• Urinary urgency, dysuria

• Recurrent urinary tract infections

Prevalence estimates range widely—from ~27% to over 80% of postmenopausal women—depending on how actively you ask and how symptoms are defined (Crandall et al., JAMA 2023; Faubion et al., Mayo Clin Proc 2017).

The key point: this is common, persistent, and not self-limited.

The Physiology Is Straightforward. The Clinical Impact Is Not.

At its core, GSM is driven by declining estrogen (and to some extent androgen) levels.

That hormonal shift leads to:

• Thinning of the vaginal epithelium

• Loss of elasticity and rugae

• Reduced blood flow and lubrication

• Increased vaginal pH (>4.5)

Over time, these changes alter the microbiome, weaken mucosal defenses, and contribute to urinary symptoms and recurrent infections (NAMS 2020; AAFP 2020).

This is not cosmetic. It’s structural and functional.

And unlike vasomotor symptoms, GSM does not improve with time. It progresses.

Why We Miss It

Two reasons, consistently:

1. Patients don’t volunteer symptoms
There’s embarrassment, normalization (“this is just aging”), or lack of awareness that treatment exists.

2. Clinicians don’t consistently screen
Unless you ask directly, you won’t hear it.

A simple shift in practice changes detection rates dramatically:

• “Any vaginal dryness or discomfort?”

• “Any pain with intercourse?”

• “Any urinary urgency or recurrent infections?”

These questions should be as routine as asking about hot flashes.

Diagnosis: Clinical, Not Complicated

GSM is a clinical diagnosis.

On exam, you may see:

• Pale, thin epithelium

• Loss of vaginal rugae

• Introital narrowing

• Increased fragility

No biopsy is required unless something atypical is present (Kaufman et al., J Urol 2025).

What matters most is connecting symptoms to physiology.

Treatment: Practical, Stepwise, and Highly Effective

Management should be individualized, but there is a clear evidence-based framework.

1. Start Simple (and Don’t Skip This)

For mild symptoms:

• Vaginal moisturizers: 1–3× per week (not just before intercourse)

• Lubricants: as needed

Some data suggest these can approach the efficacy of hormonal therapies in mild cases (Danan et al., Ann Intern Med 2024).

Clinical pearl: Many patients underuse these or use them incorrectly. Education alone improves outcomes.

2. Escalate When Needed: Local Hormonal Therapy

When symptoms persist, low-dose vaginal estrogen is the gold standard.

Forms include:

• Estradiol tablets (10 mcg)

• Creams

• Vaginal rings

Expected outcomes:

• ~60–80% improvement in dryness and dyspareunia

• Improved tissue integrity and pH normalization

Importantly:

• Minimal systemic absorption

• No progestogen required for endometrial protection at low doses

(NAMS 2020; AUA/SUFU/AUGS 2025)

3. Alternatives Worth Knowing

For patients who prefer non-estrogen options or need alternatives:

• Vaginal DHEA (prasterone 6.5 mg daily)

• Ospemifene (oral SERM, 60 mg daily)

Both show meaningful improvements (roughly 30–80% depending on endpoint) in dyspareunia and dryness (Crandall et al., JAMA 2023).

4. Adjunctive Tools That Add Real Value

• Pelvic floor physical therapy → especially with pain or muscle dysfunction

• Vaginal hyaluronic acid → emerging evidence for symptom relief

• Dilator therapy → underutilized but effective in select patients

Laser and energy-based therapies?
The evidence is still insufficient to recommend routine use.

Special Populations: Where Nuance Matters

Women with a history of breast cancer

Data on vaginal estrogen safety remain limited.

Management should include:

• Shared decision-making

• Coordination with oncology

• Emphasis on nonhormonal therapies first

(Crean-Tate et al., AJOG 2020)

Older adults

The American Geriatrics Society recommends:

• Avoid systemic estrogen

• Favor local therapies (vaginal estrogen, DHEA) and nonhormonal options

(Beers Criteria update, 2025)

What Actually Moves the Needle in Practice

If there’s one takeaway, it’s this:

Recognition drives treatment. Treatment drives quality of life.

Actionable shifts you can implement immediately:

• Add GSM screening to every menopausal visit

• Normalize the conversation (“This is common and treatable”)

• Start with education before escalation

• Use local estrogen earlier when appropriate

• Follow up—this is a chronic condition, not a one-time fix

The Bigger Picture

GSM sits at the intersection of endocrinology, urology, sexual health, and quality of life.

And yet, it often gets reduced to a footnote.

It shouldn’t be.

Because when treated effectively, the impact is immediate, meaningful, and often transformative for patients.

References

1. American College of Obstetricians and Gynecologists Practice Bulletin No. 213, 2019

2. Faubion SS et al. Mayo Clinic Proceedings. 2017

3. Crandall CJ et al. JAMA. 2023

4. North American Menopause Society (NAMS). 2020 Position Statement

5. Kaufman MR et al. Journal of Urology. 2025 (AUA/SUFU/AUGS Guideline)

6. Danan ER et al. Annals of Internal Medicine. 2024

7. Crean-Tate KK et al. American Journal of Obstetrics and Gynecology. 2020

8. Ringel NE et al. American Family Physician. 2020

9. Steinman MA. American Geriatrics Society Beers Criteria Update, 2025